Development and Evaluation of Paclitaxel-Loaded Liposomal Formulations for Targeted Drug Delivery to Breast Cancer by Kannan, Vinayagam
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
12-2010
Development and Evaluation of Paclitaxel-Loaded
Liposomal Formulations for Targeted Drug
Delivery to Breast Cancer
Vinayagam Kannan
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Pharmaceutics and Drug Design Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Kannan, Vinayagam , "Development and Evaluation of Paclitaxel-Loaded Liposomal Formulations for Targeted Drug Delivery to
Breast Cancer" (2010). Theses and Dissertations (ETD). Paper 135. http://dx.doi.org/10.21007/etd.cghs.2010.0158.
Development and Evaluation of Paclitaxel-Loaded Liposomal
Formulations for Targeted Drug Delivery to Breast Cancer
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Pharmaceutical Sciences
Research Advisor
George C. Wood, Ph.D.
Committee
Hassan Almoazen, Ph.D. Mostafa Waleed Gaber, Ph.D. James R. Johnson, Ph.D. Ram I. Mahato, Ph.D.
Thaddeus A. Wilson, Ph.D.
DOI
10.21007/etd.cghs.2010.0158
Comments
One year patent embargo expired December 2011
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/135
 
 
DEVELOPMENT AND EVALUATION OF PACLITAXEL-LOADED 
LIPOSOMAL FORMULATIONS FOR TARGETED DRUG DELIVERY TO 
BREAST CANCER 
 
 
 
 
 
 
 
 
A Dissertation 
Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Vinayagam Kannan 
December 2010 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2010 by Vinayagam Kannan 
All rights reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
ACKNOWLEDGEMENTS 
 
 
It is an immense pleasure to thank all the people who helped me in this dissertation 
work. I express my sincere gratitude to my advisor Dr. George C. Wood for his 
professional guidance, generous encouragement, and unconditional support all through 
this work. I thank Dr. Laura A. Thoma for providing me an opportunity to join the 
Parenteral Medications Laboratories (PML) and for her unwavering commitment to 
support this research work. I am grateful to my faculty committee members Dr. Hassan 
Almoazen, Dr. Mostafa Waleed Gaber, Dr. James R. Johnson, Dr. Ram I. Mahato, and 
Dr. Thaddeus A. Wilson for their advice, support, and help at various stages of this work. 
 
I extend my sincere gratitude to other members of the PML group (past and present). 
Especially, I am thankful to Dr. Murali K. Divi, Dr. Hari R. Desu for their help, support, 
and suggestions in this work. I thank Dr. Robert J. Nolly, Dr. Himanshu Bhattacharjee, 
Dr. Vivian Loveless, Barry Braganza, Frank P. Horton, Pavan Balabathula, Gwen 
Stornes, Anthony C. Samsa, Elizabeth D. Barker, and Jennifer L. Hart for their support at 
various stages. I enjoyed scientific and technical discussions with all the members of the 
PML group. I am also grateful to the members of Dr. Mostafa Waleed Gaber group, Dr. 
Ram I. Mahato group, Dr. James R. Johnson group, and Dr. Tiffany N. Seagroves group 
and the faculty and staff of the Department of Comparative Medicine for their help and 
support. 
 
I am thankful to The University of Tennessee Health Science Center and the PML for 
the facilities, equipment, and financial support. I thank all the faculty and staff of the 
Department of Pharmaceutical Sciences for their support. I am also thankful to the 
Parenteral Drug Association (PDA) for providing pre-doctoral fellowship.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
ABSTRACT 
 
 
The objective of this work was to develop and evaluate paclitaxel-loaded liposomal 
formulations for targeted drug delivery to breast cancer. The liposomal formulation was 
optimized to maximize drug loading and physical stability. Cholesterol and saturated 
lipid content showed a negative influence on paclitaxel loading. Short-term stability 
studies showed that optimum drug-lipid ratio is necessary for adequate physical stability. 
Biodistribution studies in mouse xenografts bearing MDA-MB-231 breast cancer using 
near infrared fluorescence imaging showed that the accumulation of tumor vasculature 
targeted long-circulating liposomes (LCL) in the tumor was significantly less than non-
targeted LCL at 48 h. The accumulation of these liposomes in the peritoneal cavity was 
higher suggesting that they were cleared rapidly by the reticuloendothelial system. The 
antitumor efficacy of paclitaxel-loaded tumor vasculature targeted LCL was compared 
with paclitaxel-loaded tumor cell targeted LCL. The antitumor efficacy was comparable 
for tumor vasculature targeted LCL, non-targeted LCL, and paclitaxel solution 
formulation with tumor volumes of ~ 60-70% of the control treatment on 39 days post 
tumor inoculation. In contrast, tumor cell targeted LCL showed a significantly higher 
antitumor efficacy compared to all other treatments with tumor volumes of ~ 30% of the 
control treatment. To improve the long-term stability, these liposomes were lyophilized. 
The leakage and vesicle size increase during lyophilization was minimized by using 
lyoprotectant sucrose in the formulation. Feasibility of developing gas-filled liposomes 
for ultrasound mediated drug delivery was evaluated using freeze drying gas entrapment 
method for the preparation. The in vitro measurements of echogenicity showed that these 
paclitaxel-loaded tumor vasculature targeted gas-filled liposomes were acoustically active 
and can be disintegrated by high intensity ultrasound pulses. 
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1 
CHAPTER 1. INTRODUCTION 
 
 
1.1. STATEMENT OF THE PROBLEM 
 
 
1.1.1. Breast Cancer and Treatment Choices 
 
Cancer is the disease characterized by a rapid and abnormal proliferation of cells. 
Cancer cells originate from normal cells through a series of genetic changes leading to 
progressive conversion to cancer cells [1]. Cancer is a dreadful disease and is the second 
leading cause of death in United States [2, 3]. About 1.5 million new cases of cancer and 
more than half-a-million deaths have been estimated in the United States for the year 
2009 [4]. Solid tumors account for more than 85 percent of all the cases reported with 
cancer [5, 6]. Breast cancer is the most commonly diagnosed form of solid tumors and is 
the second leading cause of death in western women. About 20-30% women with breast 
cancers develop metastatic breast cancers. Breast cancer research has increased 
dramatically during the last 2 decades, resulting in an extraordinary progress in our 
understanding of the disease, and in more efficient, and less toxic treatment options. The 
treatment choices for breast cancer can be categorized into local or systemic therapy. 
Surgery, radiation therapy, hyperthermia, and photodynamic therapy are examples of 
localized therapy. Surgery is the treatment of choice for breast cancer which involves 
lumpectomy, partial mastectomy or quadrantectomy, and mastectomy. Radiation therapy 
is an adjuvant therapy in which high energy radiation is used to kill cancer cells 
remaining in the breast, chest wall, underarm area after the surgery. Local therapy is 
beneficial for non-metastatic forms of breast cancers whereas systemic therapy is 
required for metastatic forms of breast cancers.  Systemic therapy by means of 
chemotherapy, hormonal therapy, immunotherapy or targeted therapy, and gene therapy 
involves administration of the respective therapeutic agent by the oral or parenteral route.  
 
 
1.1.2. Chemotherapy 
 
Chemotherapy is the use of drugs to kill cancer cells. It can be used as adjuvant 
therapy after surgery for patients with no evidence of metastasis. Adjuvant chemotherapy 
reduces the risk of recurrence of cancer. Chemotherapy can also be used as a neoadjuvant 
therapy to surgery wherein the drugs are administered before surgery to shrink the tumor 
so that it can be removed easily by surgery. Chemotherapy is the first line therapy for 
advanced breast cancer in which the cancer has already spread beyond the breast and 
underarm area at the time of diagnosis. In chemotherapy, the drug distributes throughout 
the body via blood stream to reach the cancer cells. This form of systemic therapy is very 
useful to kill breast cancer cells which have metastasized to distant organs. Apart from 
killing cancer cells, these drugs also kill normal cells and result in toxic effects. For 
chemotherapy to be effective, the drug should be delivered at the tumor sites at adequate 
concentrations [7]. Inadequate concentrations of the drug at the tumor microenvironment 
could result in regrowth of the tumor cells and development of resistance [5].  
2 
1.1.3. Paclitaxel: Mechanisms of Action 
 
Paclitaxel, one of the most effective drugs used in chemotherapy of breast cancer, is a 
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It 
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin 
dimers and stabilizes microtubules by preventing depolymerization. The stability results 
in inhibition of the normal dynamic reorganization of the microtubule network that is 
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel, like other 
antimicrotubule agents, activates the intrinsic mitochondrial apoptotic pathway. Loss of 
the mitochondrial membrane potential by opening of the permeability transition pore 
results in the release of proapoptotic factor cytochrome c, caspase cascade activation, and 
DNA fragmentation [10-12]. These effects are modulated by the members of Bcl-2 
family composed of proapoptotic proteins (Bax-like proteins and BH3-only proteins) and 
antiapoptotic proteins (Bcl-2-like proteins). Paclitaxel turns the balance of proapoptotic 
and antiapoptotic proteins towards apoptosis by translocation of Bax from cytosol to 
mitochondria and/or by phosphorylation mediated inhibition of Bcl-2 [13, 14].  
 
 
1.1.4. Drawbacks of Paclitaxel Therapy 
 
Paclitaxel is marketed as Taxol® and AbraxaneTM as an adjuvant in the treatment of 
node-positive breast cancer or second line treatment of breast cancer after failure of 
combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant 
chemotherapy. Due to poor solubility of paclitaxel, Taxol® was formulated with ethanol 
and Cremophor®EL. Although the product is diluted before use, the concentration of 
Cremophor®EL is high enough to cause serious hypersensitivity reactions on 
administration requiring pre-medication with corticosteroids and antihistamines [15]. 
AbraxaneTM, albumin-bound nanoparticle formulation of paclitaxel, addressed solvent 
related adverse effects of Taxol® and eliminated the need for premedication with 
corticosteroids. But, phase III clinical trials in metastatic breast cancer patients showed 
higher rates of sensory neuropathy compared to Taxol® treatment [16]. Apart from the 
toxicity associated with the formulation components, administration of free paclitaxel is 
also associated with systemic toxicities such as myelosuppression, and peripheral 
neuropathy [17]. So, it is imperative to deliver paclitaxel locally to the tumor sites to 
minimize systemic toxicity.  Hence, there is a need for an effective drug delivery system 
for chemotherapy with paclitaxel to produce cytotoxic concentrations of the drug at the 
tumor sites without affecting normal tissues.  
 
 
1.1.5. Barriers in Drug Delivery to Solid Tumors  
 
Since cancer cells require nutrition to grow and metastasize in to other organs, they 
form new vessels, from existing vessels, which are structurally and functionally 
abnormal. These newly formed vessels are leaky, tortuous, dilated, and saccular and have 
abnormal interconnections [6]. The variations in distribution of blood vessels in a solid 
tumor can range from well perfused periphery to seminecrotic to avascular or necrotic 
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regions at the core of the tumor. In addition, hydrostatic pressure generated by 
proliferating cancer cells within the tumor can compress the blood vessels and lymphatic 
vessels leading to impaired blood flow and lymphatic drainage. The high interstitial 
pressure in tumors compared to normal tissues results in a net convection flow in the 
tumor interstitium outwards from the core of the tumor. Conventional and modern 
therapeutic agents for solid tumors include molecules, particles, and cells. To reach 
cancer cells in a solid tumor, these agents must make their way to the blood vessels of a 
tumor, cross the vessel wall into the interstitium, and then transport through the 
interstitial matrix [5, 7]. The mechanisms of transport involve diffusion and/or 
convection depending upon the size, charge, and configuration of the agent [7].  
Transport of small molecules in the interstitial space is mainly by diffusion which is 
governed by diffusivity and the concentration gradient. The transport of larger molecules 
is by convection which depends on hydraulic conductivity and pressure difference [5, 
18]. The unique nature of solid tumors with high interstitial pressure, and  heterogeneity 
in vasculature pose a formidable barrier to delivery of therapeutic agents [19].  
 
 
1.1.6. Strategies for Effective Delivery of Paclitaxel to Solid Tumors 
 
An ideal drug delivery system should improve the therapeutic efficacy of paclitaxel 
overcoming the barriers to drug delivery and also minimize toxicity, and lower the total 
dose required for the therapy. Targeted drug delivery fulfils many of these desirable 
attributes,  improving efficacy of many existing drugs by altering pharmacokinetics and 
biodistribution [20]. Drug targeting can be broadly classified into passive targeting and 
active targeting. Passive targeting is the accumulation of therapeutic agent at the target 
site due physicochemical nature of the carrier or due to pathological factors of the target 
site. In contrast, active targeting involves the attachment of specific active ligands to the 
surface of the carrier so that it can recognize target receptors expressed on the surface of 
specific cell, tissue, or an organ. Tumor cells express many molecules on their surface 
which is not expressed by normal cells. Some receptors show higher expression in the 
tumor cells as compared to normal cells. So, solid tumors stands out as one disease that 
will get most of the benefits of targeted drug delivery [21]. Nanoscaled delivery systems 
are of particular interest in targeted drug delivery to solid tumors because of their ability 
to escape clearance by reticuloendothelial system (RES). The clearance of 
nanoparticulate systems by the RES increases with an increase in size. Nanoscaled 
systems approved or under clinical trial for use in drug delivery include liposomes, 
albumin based particles, PEGylated proteins, biodegradable polymer-drug composites, 
polymeric micelles, polymer-drug-conjugate based particles, dendrimers, and inorganic 
or solid particles [22]. 
 
 
1.1.7. Liposomes for Paclitaxel Delivery to Solid Tumors 
 
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and 
hydrophilic drugs [23]. The entrapped drug is protected from inactivation, and free drug 
is not available in the circulation which, in turn, minimizes systemic toxicity of the drug. 
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Therefore, preparation of liposomes of paclitaxel can alter the pharmacokinetic and 
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced 
efficacy of the treatment. In addition, flexibility in design of liposomes allows selective 
localization of these carriers by passive targeting due to enhanced penetration and 
retention (EPR) effect at the tumor sites, or by active targeting due to targeting ligands 
conjugated to the surface of the liposomes [24-27].  An ideal carrier for drug delivery 
must have a longer circulation time which can be achieved by reducing the size of 
liposomes and/or modifying the surface with poly(ethylene glycol) derivatives [28]. 
Targeting capability can be achieved by attaching specific ligands onto the surface of the 
liposomes. Thus, incorporation of paclitaxel in the bilayer of targeted long-circulating 
liposomes not only deliver the drug specifically to the tumor cells but also minimize 
systemic toxicity associated with free drug, by minimizing the exposure to normal 
tissues. The release of drug from these liposomes, at the target site, is determined by one 
or more of the following natural cytosolic mechanisms [23]. 
 
 Specific or non-specific adsorption on to the cell surface 
 Fusion with the cell membranes and subsequent release of the drug into the 
cytoplasm 
 Adsorption onto the cell surface resulting in destabilization of cell membrane 
components so that the released drug can enter via micropinocytosis 
 Direct or transfer protein mediated exchange of lipid components with cell 
membrane 
 Specific or non-specific endocytosis in which the endosomes deliver the drug 
into the lysosome or the endosomes undergo destabilization and release the 
drug in cytoplasm 
 
  
1.1.8. Stability of Liposomes 
 
The liposomal encapsulated drug tends to leak from the liposomes on storage of these 
vesicles in aqueous dispersions. In addition, the liposomes can fuse together and form 
larger liposomes and result in an increase in vesicle size distribution. The stability of 
liposomes can be improved by freezing, lyophilization, spray drying, and supercritical 
fluid technology [29-31]. Lyophilization stands out as a preferred method to improve 
long-term shelf life of liposomes especially those containing thermosensitive drugs [32]. 
By removing water from the liposomal dispersion by lyophilization, the structural and 
permeability properties can be retained [33]. However, the lyophilization process itself 
can induce physical changes such as loss of the encapsulated agent, and an increase in 
vesicle size [34]. Careful selection and optimization of the formulation and process is 
necessary to improve the shelf life of paclitaxel-loaded liposomes. 
 
 
1.1.9. Echogenic Liposomes 
 
Apart from targeting and controlled release, it may be an additional advantage to 
improve permeability at the tumor vasculature. Incorporation of gases in the bilayer of 
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liposomes makes them ultrasound active [35]. These echogenic liposomes have the 
potential for stress on activation by ultrasound and eventually release the contents at the 
target site. These liposomes can be visualized at the target site, and by changing the 
intensity of ultrasound, they can be disintegrated providing a means for controlling the 
drug release. Interestingly, the disintegration of gas-filled species by contrast enhanced 
ultrasound produces liquid jets that can produce small gaps in the vasculature and 
improve the permeability [36]. This phenomenon exhibited by microbubbles can be 
explored for targeted delivery using echogenic liposomes wherein the targeted liposomes 
maintain basal levels of the drug by virtue of cytosolic transport, and by altering intensity 
of ultrasound, high cytotoxic concentrations of the drug can be achieved at the target site. 
Thus, cavitation effect of ultrasound on the echogenic liposomes provides a control over 
drug release, and also enhances drug permeability by producing small gaps in the 
endothelial walls of vasculature [36-39]. 
 
 
1.2. REVIEW OF LITERATURE: FORMULATION DEVELOPMENT, AND 
DELIVERY ASPECTS OF LIPOSOMES IN CANCER CHEMOTHERAPY 
 
Liposomes are bilayered vesicles made of phospholipids. In 1964, Bangham and 
Horne  described that lecithin dispersions contained ‘spherulites’ composed of concentric 
lamellae by negative staining technique using electron microscope [40]. This liquid 
crystal phase structure of phospholipids in water or salt solutions was referred as ‘smectic 
mesophase’. These lipid systems were tested for the permeability of anions and cations 
through the membrane to describe their analogy to certain biological membranes [41, 42]. 
These artificial structures were colloquially referred as ‘Liposomes’ or ‘Bangasomes’ 
[43, 44].  Later, the term liposomes, derived from greek words ‘lipos’ meaning fat and 
‘somas’ meaning body, gained popularity in literature and was generally accepted. 
Liposomes were used initially as model membranes to characterize the behavior of cell 
membrane. Gregordias and coworkers explored the therapeutic potential of liposomes by 
developing Aspergillus niger aminoglucosidase entrapped liposomes as enzyme carriers 
in enzyme replacement therapy of glycogen storage diseases [45, 46]. These radio labeled 
liposomes were removed rapidly from plasma following intravenous administration to 
rats. About 56% of the total radioactivity was recovered in liver within 15 min of 
administration. These results showed that liposomes can be used as effective carriers for 
delivery of enzymes to liver and spleen.  Further, they developed liposomes containing 
invertase (β-D-fructofuranosidase) to follow the fate of enzyme activity rather than 
following radioactivity of labeled liposomes. These liposomes accumulated in liver and 
spleen within 6 hours of intravenous injection in rats. The invertase activity was 
maximum in the mitochondrial-lysosomal fraction of the liver suggesting that the 
liposomes can be used as potential carriers for delivering enzymes and drugs to liver and 
spleen [47, 48].  Then, they tested the applicability of liposomes in drug delivery by 
developing liposomes loaded with actinomycin D in the lipid bilayer or penicillin in the 
aqueous core of the liposomes [49]. The distribution of liposome entrapped, and non-
entrapped drug was studied by intravenous injection to rats. Though the elimination of 
liposomal entrapped drugs was slower than the free drugs, a considerable amount of the 
liposomal drug accumulated in lysosomes of liver and spleen. On reaching lysosomes, the 
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drug action requires disruption of liposomes by lysosomal lipases to release the drug.  As 
a further development, they evaluated the uptake of liposome entrapped agents in the 
tumor cells using radio labeled albumin entrapped liposomes [50]. The study involving 
three metastatic cancer patients showed that the radioactivity in the tumors was slightly 
higher to much higher than that of the corresponding normal tissues.  The improved 
localization was attributed to extensive vascularization in tumor and enhanced 
endocytotic activity of the tumor cells.  
 
From the time liposomes found their way in drug delivery, extensive research in the 
area lead to numerous advances to improve the formulation and to improve their 
efficiency as a carrier in drug delivery [28, 51-54].  The following sub-sections will 
briefly outline basic properties, and some of the advances in formulation development of 
liposomes with special emphasis in their application in chemotherapy of solid tumors.  
 
 
1.2.1. Composition of Liposomes 
  
Liposomes are composed of natural or synthetic phospholipids. Phospholipids have a 
head group and a tail group with two fatty acyl chains of varying lengths. The phosphate 
head group is attached to different functional groups which can determine the degree of 
hydration and charge of the liposomes [28]. The choline functional group offers some 
degree of hydration and confers a neutral charge. Ethanolamine contributes to a minimum 
degree of surface hydration while it is also a neutral in charge. On the other hand, serine 
and glycerin functional groups confer a negative charge with some surface hydration. 
Polyethyleneglycol (PEG) ethanolamine provides high degree of hydration and a steric 
effect with a negative charge. The properties of tail group fatty acyl chains determine 
fluidity, thickness, and order of membrane packing of the bilayer. The chain length can 
range from C14-C18. An increase in chain length increases the thickness, and gel to liquid 
crystalline transition temperature (Tm) of the bilayer. An increase in the level of 
saturation increases the rigidity and Tm, and reduces fluidity of the bilayer. Varying the 
degree of saturation and chain length of the two tail acyl chains can result in a decrease in 
the order of membrane packing and a lower Tm compared to lipids with two identical acyl 
chains [55]. 
 
 
1.2.1.1.  Effect of Fluidity of the Bilayer 
 
The lipid bilayers of liposome membranes exist in the well ordered gel phase at 
temperatures below their gel to liquid crystalline transition temperature (Tm). The Tm 
involves partial melting of acyl chains while the spherical liposomes remain intact. At 
temperatures above Tm, the lipids exist in a disordered fluid phase or liquid crystalline 
phase wherein the acyl chains become mobile within the hydrophobic region of the 
liposome while the anchoring of polar head groups prevent complete freedom of 
movement [28, 56]. At the temperatures corresponding to Tm of the phospholipids, 
maximum permeability or leakage is observed [57]. The phase behavior of liposomes 
determines their permeability, aggregation, ability to bind to serum proteins, and fusion 
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[28]. The phase behavior on the other hand, depends on the composition of the bilayer. 
By careful selection of chain length, saturation/unsaturation of fatty acyl chains of the 
lipids, the fluidity of the bilayer can be altered. 
 
Introduction of double bonds and shortening the chain length of phospholipids can 
increase the fluidity of the bilayer and thereby increase the permeability across the 
bilayer [55]. The permeability of glycerol and erythritol was evaluated in liposomes made 
of different phospholipids. The swelling rates of liposomes composed of 
(distearoyl)lecithin or (1-stearoyl-2-oleyl)lecithin or (dioleyl)lecithin or 
(dilinoleyl)lecithin showed that the permeability increased with an increase in number of 
double bonds. Similarly, liposomes made of (disteroyl)lecithin or (dipalimitoyl)lecithin 
or (dimyristoyl)lecithin showed a decrease in permeability with an increase in chain 
length as glycerol could not to penetrate the bilayer with increasing chain length.  
 
Thermal motion of fatty acyl chains result in molecular cavities. When cholesterol is 
added along with phospholipids, it occupies these cavities and therefore, does not 
increase area per molecule in mixed monolayers.  This observation was proved by the 
measurement of surface potential for palmitoyl lecithin-cholesterol mixtures which did 
not show a change in surface potential [58]. At high surface pressures cholesterol 
liquefied solid monolayers indicating that cholesterol imparts fluidity to the phospholipid 
monolayers. Ladbrooke et al showed that cholesterol controls fluidity of the hydrocarbon 
chains of phospholipids by disrupting the crystalline chain lattice of the gel phase, and by 
inhibiting the flexibility of chains in the dispersed liquid crystalline phase [59]. For lipids 
which would normally be above their Tm (T > Tm), there will be a limitation in flexibility 
and for those lipids which remain at gel state (T < Tm) have greater fluidity. 
 
Liposomes containing mixtures of phospholipids and cholesterol demonstrated a 
decrease in permeability with an increase in concentration of cholesterol [55]. Cholesterol 
reduced the permeability of glycerol in liposome structures made of egg-yolk lecithin or 
(1-palmitoyl-2-oleyl)-lecithin or (dioleyl) lecithin in a concentration dependant manner. 
The effect of cholesterol permeability was not limited to glycerol. A decreased chloride 
permeability, from liposomes made of egg-yolk lecithin and cholesterol compared to that 
pure lecithin, has been reported [60]. Valinomycin induced permeability of 86Rb+ was 
also reduced by inclusion of cholesterol in the liposome composition [61]. Demel et al 
explained that the permeability reducing property of cholesterol is related to planar sterol 
nucleus, an intact side chain, and a 3β-hydroxyl group based on their study with several 
natural and synthetic sterols on the permeability of glucose, glycerol, and  86Rb+ using 
egg lecithin liposomes [62]. The reduced permeability is due to increased packing and 
decreased mobility of the hydrocarbon chains [63]. 
 
Kirby et al demonstrated that the inclusion of cholesterol in the liposomes improves 
in vitro and in vivo stability of the liposomes using a fluorescent tracer 
carboxyfluorescein [64]. The liposomes rich in cholesterol (1:1 ratio of egg 
phosphatidylcholine (EPC) and cholesterol) were more stable following intravenous 
injection to mice compared to liposomes containing less or no cholesterol. A similar 
stability trend was observed in mouse whole blood, plasma or serum. The stabilizing 
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effect was similar in neutral, negative, and positive charged liposomes. The liposomes 
containing cholesterol were resistant to exchange of phospholipids with high density 
lipoproteins and thereby exhibited better in vivo stability. 
 
 
1.2.1.2.  Effect of Surface Charge of the Liposomes 
 
The liposomes have a charge based on the composition of head group of the 
phospholipids. These phospholipids can have neutral, positive, or negative charge. The 
surface charge of the liposomes determines their stability in dispersion, in vivo circulation 
time, ability to interact with target cells, and recognition by plasma proteins or opsonins. 
Neutral liposomes have lower tendency to be cleared by the RES but have poor stability 
in dispersion due to aggregation. Negative surface charge provides better colloidal 
stability, but these liposomes have higher non-specific uptake in vivo, and are easily 
recognized by macrophages. With permeability of the bilayer remaining constant 
between neutral and negatively charged liposomal formulations, negatively charged 
liposomes were cleared faster than the liposomes with neutral charge [65]. Liposomes 
with different surface charge were removed from circulation at different rates even 
though the total body clearance of encapsulated compound is similar [66]. Hepatic uptake 
of positive and negatively charged liposomes was greater than the liposomes of neutral 
charge [67]. Neutral liposomes gain negative charge in presence of blood plasma due to 
adsorption or binding plasma components whereas negatively charged liposomes remain 
unchanged [68]. Wilkins and myers suggested that surface charge of the particle could 
affect the steric arrangement of the adsorbed protein in a manner that is recognizable by 
the fixed macrophages of the RES [69].  
 
Phagocytosis of complement opsonized liposomes was strongly dependent on the 
charge of the liposomal lipids. The presence of acidic negatively charged lipids 
phosphatidylserine, phosphatidylinositol and dicetyl phosphate profoundly suppressed the 
uptake of the liposomes [70]. The drug penetration through the skin was greater from a 
gel formulation containing negatively charged liposomes compared to positively charged 
liposomes [71]. Histological studies showed that negatively charged liposomes diffused 
to the dermis and lower portions of hair follicles through the stratum corneum and the 
follicles much faster than the positively charged vesicles. Electrostatic interactions are 
one of the main forces affecting the association of liposomes with the charged cell 
surface. An increase in the concentration of negatively charged lipid phosphatidylserine 
(PS) in the lipid bilayer resulted in increased association of liposomes with human colon 
CX-1.1 cancer cells [72]. Heath and coworkers demonstrated that the uptake of 
methotrexate-γ-aspartate  from negatively charged liposomes was more efficient in five 
different cancer cell lines as compared to neutral liposomes [73].  
 
Positively charged liposomes, frequently used for condensation of DNA on the 
surface for gene delivery, also have shown higher clearance by the RES. The degree of 
interaction of liposomes with macrophages can be modulated by the positive charge on 
the liposomes [74]. The 99mTc marker entrapped in positively charged liposomes was 
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cleared five times faster than the lipid integral membrane marker, showing that the 
presence of positive charge affects in vivo stability of liposomes [75].  
 
In vitro cellular binding and uptake study using human ovarian carcinoma HeLa cell 
lines showed that endocytosis of positively charged liposomes was greater than 
negatively charged liposomes, and neutral liposomes [76]. Cationic liposomes have 
shown the tendency to preferentially accumulate the A-Mel-3 melanoma of the hamster 
in comparison to normal surrounding tissue [77]. Intravital microscopy revealed that the 
uptake of cationic liposomes in the solid tumor was due to their accumulation in 
angiogenic tumor vessels but neutral, and negatively charged liposomes showed non-
specific extravasation into parenchyma. Positively charged paclitaxel-loaded liposomes 
showed a significant regression of tumor and delayed metastasis due to antivascular 
targeting by virtue of positive charge [77, 78]. 
 
 
1.2.2. Size of Liposomes 
 
The size of the liposomes is one of the major factors determining their fate after 
intravenous injection [79]. Larger liposomes are cleared rapidly from the circulation 
following intravenous administration. These liposomes are taken up into Kupffer cells of 
liver and fixed macrophages of spleen [80]. Smaller liposomes of size less than 100 nm 
have the ability to pass through fenestrated endothelium, or regions of increased capillary 
permeability, and gain access to liver parenchymal cells. Liver and spleen are the major 
sites of localization for liposomes irrespective of their size. Harashima and Kiwada 
compiled the data from literature for pharmacokinetics of liposomes of different sizes and 
calculated the total body clearance [79]. Their analysis indicated that the clearance was 
proportional to the size of the liposomes. AmBisomeTM (Gilead Sciences, Inc., Foster 
City, CA), the marketed liposomal formulation of amphotericin B is formulated to the 
size specification of 45-80 nm to reduce RES uptake [28]. 
 
Liposomes of different size were treated with serum and their uptake was determined 
in perfused liver [81]. The results showed that opsonins bind to the liposomes depending 
upon the size, and they were taken up by the liver phagocytosis based on the extent of 
opsonization. The hepatic extraction of liposomes increased with an increase in liposome 
size (200, 400 and 800 nm). Allen and Everest studied the effect of liposome size and 
composition on pharmacokinetics of encapsulated [14C] labeled sucrose [82]. They used 
two liposomal compositions egg phosphatidylcholine-cholesterol, and sphingomyelin-
phosphatidylcholine with in vitro serum stability of 2.5 and 35 h respectively. Liposome 
entrapment increased the circulation time of sucrose in vivo with a higher circulation time 
for small unilamellar vesicles compared to multilamellar vesicles. The same trend of in 
vitro stability was observed in vivo. Senior et al showed with liposomes of similar 
composition, the trend is that increase in size results in rapid clearance [65]. The effect of 
size was prominent in determining the circulation half life of liposomes than the 
membrane permeability. 
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The kinetics of differential uptake of various types of liposomes by the liver Kupffer 
cells and parenchymal cells were evaluated by Rahman and coworkers [83]. Liposomes 
of different size were loaded with 59Fe-Desferal. The uptake in two cell types of liver was 
monitored at specific time points following intravenous injection to mice.  Fractionation 
of the liver into parenchymal and non-parenchymal cell fractions revealed that liposomes 
of size 60-80 nm were taken up by the parenchymal cells, while the larger multilamellar 
liposomes of size 500 nm were taken up by Kupffer cells. These results suggested that the 
size plays an important role in sorting liposomes to Kupffer cells or hepatocytes. 
 
The activation of complement system can also induce complement mediated 
clearance of liposomes [81]. When inactivated serum was used to omit the activity of 
opsonins, size dependant degradation in serum was observed which was consistent with 
size dependant complement activation. The uptake of these liposomes in inactivated 
serum by the liver was primarily due to complement activation. Abra et al quantified the 
relationship between in vivo disposition and dose size for liposomes of three different 
diameters (460, 160, 58 nm) in mice [84].  Saturation in liver with increasing lipid dose 
was seen with all three sizes together with increase in blood levels.  
 
 
1.2.3. Surface Modification of Liposomes 
 
The clearance of liposomes by RES depends on non-specific hydrophobic interactions 
of liposomes with RES cells, and specific opsonization reaction involving blood 
components. The liposomes cleared by RES accumulate into Kupffer cells of liver or 
fixed macrophages of spleen. This will be an advantage if the liposomes are targeted to 
the organs of RES. But, delivering the liposomes to non RES organs and tissues require 
approaches to overcome the short circulation time due to clearance by RES. In addition, 
repeated administration followed by accumulation of liposomes in the RES organs can 
impair the RES and result in consequences of altering the host defense mechanism.  
 
The rate of clearance of intravenously administered liposomes depends on several 
factors including surface charge. Even though, liposomal membranes are similar to cell 
membranes they are cleared rapidly by several mechanisms. But, analysis of composition 
of cell membranes revealed that the presence of large amounts of sialic acid residues on 
the cell membranes can impart negative charge to the surface and thereby improved 
stability. Allen et al. developed liposomes with lipid composition which mimics surface 
characteristics of erythrocytes by including ganglioside GM1 in the formulation [80, 85]. 
Biodistribution studies in mice showed that the liposomes containing ganglioside GM1 
have longer circulation time compared to conventional liposomes, and other negatively 
charged liposomes containing dipalmitoylphosphatidylglycerin (DPPG), and sulfatides. 
The blood/RES ratio for the ganglioside GM 1 containing liposomes increased in the 
presence of bilayer rigidifying lipid, sphingomyelin. The data demonstrated that surface 
sialic acid and bilayer viscosity worked synergistically increasing circulation time of 
liposomes. The authors also evaluated the effect of size on biodistribution of liposomes of 
various compositions in the presence and absence of ganglioside GM1. Circulation half-
lives increased with decreasing size down to liposomes extruded through 80 nm filters. 
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Further decrease in size resulted in an increased accumulation in liver possibly due to the 
ability of the smaller liposomes to penetrate liver sinusoids and gain access to 
hepatocytes. Gabizon and Papahadjopoulos [86] confirmed the improved circulation 
time, and reduced clearance of GM1 containing liposomes. Further, they demonstrated a 
25-fold increase in tumor uptake of the liposomal tracer in a J6456 lymphoma muscular 
tumor model in mice as compared to the free tracer. In another study, they showed that 
physicochemical features contributing to optimal retardation of liposome clearance 
include a hydrophilic carbohydrate moiety and a sterically hindered negatively-charged 
group [87]. Asialoganglioside (AGM1) was less effective in retarding clearance of 
liposomes than monosialoganglioside (GM1) indicating that there is a need for negative 
charge in addition to the carbohydrate group. The negatively charged lipids 
phosphatidylinositol phosphate (PIP) and trisialoganglioside (GT1) were less effective 
than phosphatidylinositol (PI) and GM1 in retarding clearance of liposomes. Increasing 
the molar fraction of negatively charged lipid resulted in an increased uptake in the liver. 
 
 Blume and Cevc [88] demonstrated that the steric surface protection offered by PEG 
chains slows down the adsorption of macromolecules from blood on to the vesicles, and 
thereby, suppresses the clearance of the liposomes by RES. In vivo evaluation in mice 
showed that the steric barriers prolonged the vesicle circulation time for up to 24 h. The 
authors claimed that the polymeric coating with PEG is non-immunogenic, and non-toxic 
as against the inclusion of natural glycolipids. Although glycolipids are non-
immunogenic, their use in artificial membranes at higher concentrations, not encountered 
in normal membranes, can trigger immunogenic reaction. In a similar direction, Klibanov 
et al demonstrated that coating the surface of the liposomes with PEG improves 
circulation time of the liposomes in blood minimizing the uptake by the RES [89]. In a 
biodistribution study in mice, the authors showed that the circulation half-life of PEG 
coated liposomes were 10-fold greater than conventional liposomes of same size. Coating 
the liposomes with PEG increases the hydrophilicity of the liposome surface and 
minimizes the hydrophobic interaction with RES. It also sterically prevents the binding of 
opsonins to the liposomes to overcome specific interaction with RES. Doxil®(Alza 
Corporation, now part of Johnson & Johnson, Inc., New Brunswick, NJ), the marketed 
liposomal formulation of doxorubicin is a PEGylated formulation to overcome clearance 
by the RES. 
 
Liposome grafted PEG can neutralize the surface charge of the liposomes and provide 
shielding from interaction with various opsonins. The effect of PEG in minimizing the 
clearance is dependent upon the charge of the liposomes and the chain length of the 
surface grafted PEG polymer [90]. The clearance of positively charged liposomes was 
minimized by incorporation of either phosphatidylethanolamine (PE) conjugated to 
PEG750 or PEG5000 whereas the clearance of negatively charged liposomes was 
minimized only by PE-PEG5000 but not PE-PEG750. The presence of negatively charged 
lipid phosphatidylserine (PS) on the membrane surface can form transient nucleation sites 
for binding plasma proteins which in turn increases the clearance. These nucleation sites 
may not be accessible when PEG-lipids are present at elevated levels where they adopt a 
highly compressed brush conformation. An increase in the concentration of 
distearoylphosphatidylethanolamine-PEG2000 (DSPE-PEG2000) showed a decrease in 
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clearance of these negatively charged liposomes with 15% providing almost complete 
shielding effect [91]. The combined effects of densely packed PEG and extension of the 
polymer barrier from the membrane surface provided steric inhibition of high affinity 
protein-membrane interactions.  
 
The presence of modified polyvinyl alcohol (PVA) on the surface of liposomes can 
affect the interaction of liposomes with serum proteins inhibiting the protein adsorption 
[92]. Flow cytometry and confocal laser scanning microscopy evaluation of interaction of 
liposomes containing DiI (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocianin 
perchlorate) with J774 cells revealed that there is a steric hindrance effect on the 
interaction [93]. The introduction of a PVA layer on the liposomal surface inhibited the 
interaction of the liposomal core and J774 cells in a similar fashion as with PEG-coated 
liposomes. The use of a mixture of PEG and PVA in the surface modification has been 
shown to prolong the residence time of the liposomes compared to those with PEG alone 
[94]. A decrease in the adsorbed amount of several opsonins and an increase in the 
adsorbed amount of dysopsonins were responsible for lower affinity of these liposomes to 
the liver and longer residence in the systemic circulation.  
  
 
1.2.4. Drug Loading in Liposomes 
 
The unique nature of the liposomes is that their ability to incorporate lipophilic drugs 
in the bilayer, and hydrophilic drugs in the aqueous core. The flexibility in the 
composition of bilayer allows modification of bilayer integrity and fluidity to prepare 
stable drug-loaded liposomes. It is also possible to load both lipophilic and hydrophilic 
drugs in the liposomes. Drug loading in the liposomes can be accomplished by passive 
loading and active loading and is reviewed by Mayer and coworkers [95]. Drug loading 
efficiency can vary with the nature of the drug, lipid composition, type of liposomes, size, 
drug-lipid ratio, and method of preparation. 
 
 
1.2.4.1.  Passive Loading 
 
For hydrophilic drugs, passive loading refers to the ability of the liposomes to capture 
certain aqueous volume along with dissolved drug in the core of liposomes during vesicle 
formation. The loading efficiency will vary with the type of liposomes as small 
unilamellar vesicles (SUV) have a lower trapped volume as compared to large 
unilamellar vesicles (LUV) and multilamellar vesicles (MLV). 
 
Methotrexate was loaded in the aqueous core of liposomes by passive loading to 
encapsulate the drug for delivery to liver cancer [96]. Due to small trapped volume, about 
18% of the drug was entrapped in liposomes. Large unilamellar liposomes prepared by 
extrusion procedure with 33% loading efficiency for methotrexate and cytosine 
arabinoside have been reported [97]. Szoka and Papahadjopoulos developed large 
unilamellar and oligolamellar liposomes with high trapped volumes by reversed phase 
evaporation technique to encapsulate up to 65% of aqueous phase [98]. They improved 
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the loading of cytosine arabinoside by inverted micelle formation within organic solvent 
followed by solvent removal to improve encapsulation.  
 
 
1.2.4.2.  Active Loading 
 
Active loading refers to entrapment of lipid soluble or water soluble drugs in the 
bilayer or aqueous core of liposomes respectively due to nature of the drug and lipids. 
Lipid soluble drugs are dissolved along with phospholipids during film formation step in 
the preparation of liposomes. The entrapment of these drugs is dependent on packing 
restrictions of the bilayer and can vary with lipid composition. On the other hand, 
amphiphilic drugs are often difficult to entrap in the liposomes because they easily 
permeate through the bilayer. The interaction between the drug and charged head group 
of the lipid components has been explored to improve loading efficiency. Electrostatic 
interaction and/or intercalation of doxorubicin with negatively charged PS or cardiolipin 
in the bilayer improved the drug loading efficiency as compared to neutral liposomes [99-
101].  
 
Amphiphilic cations can be effectively loaded into the aqueous core liposomes 
through an ion gradient across the membrane. Cationic anticancer drugs doxorubicin, and 
vinblastine were actively loaded into the liposomes when a membrane potential (∆ψ, 
negative inside) is generated across the vesicle membrane [97]. Membrane potentials 
were generated by forming liposomes in potassium glutamate buffer followed by 
exchange of unentrapped buffer with sodium chloride buffer using Sephadex G-50 
desalting columns.  Addition of K+ ionophore, valinomycin, induced K+ diffusion 
potential and improved the drug loading into the aqueous core of the vesicles when the 
drug was added. In this active loading technique, the retention time of doxorubicin was 
improved by an order of magnitude compared to liposomes loaded with passive trapping 
technique. Another strategy of active loading involves the use of transmembrane pH 
gradients (∆pH, acidic inside).  In this case, the liposomes were hydrated in presence of 
an acidic buffer (pH 4.6), unentrapped acidic buffer was exchanged with a buffer of 
higher pH (pH 7.5) to generate a transmembrane pH gradient. Addition of doxorubicin 
results in active loading due to the pH gradient. The loading and retention of doxorubicin 
was several folds higher than the liposomes with passive loading [102]. Although both 
techniques employing ∆ψ, and ∆pH improve drug loading efficiency, the use of ∆pH will 
be of practical significance because the techniques with ∆ψ require the presence of 
external ionophore but the techniques with ∆pH does not require any additives [95]. 
Since the drugs are loaded in to preformed liposomes in these remote loading techniques, 
harsh conditions of processing is avoided which is beneficial for labile drugs.  
 
Another remote loading approach uses ammonium sulfate gradient where the 
concentration of ammonium sulfate in the aqueous core is greater than the medium in 
which liposomes are suspended. The gradient of liposomal ammonium sulfate 
concentration to the concentration in the medium acts as a driving force and works by 
base exchange of ammonium ions for loading amphipathic weak bases [103].  
Doxorubicin was loaded by ammonium sulfate gradient method into liposomes such that 
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the concentration of doxorubicin in the aqueous core was more than 100-fold than the 
medium. In addition to pH gradient and ammonium ion diffusion potential, low 
permeability coefficient of sulfate ions through the bilayers is also crucial in stable 
accumulation. The low solubility of anthracycline sulfate salt formed in the aqueous core 
is further lowered by the presence of ammonium sulfate. Salting out effect of ammonium 
sulfate accelerates the flocculation and gelation of doxorubicin and improves the 
encapsulation and stability. 
 
 
1.2.4.3. Coencapsulation 
 
Almost all chemotherapeutic regimens for the treatment of cancer include 
combination of drugs. Administration of combination drugs loaded in liposomes will be 
less prone to development of drug resistance compared to therapies with single drug or 
drugs administered sequentially. Combining liposomal formulations of two drugs will 
have adverse effects associated with high lipids and hence coencapsulation of the 
combination drugs is sought. However, there are difficulties associated with efficient and 
stable encapsulation of two chemically different drugs. Methotrexate or cytosine 
arabinoside were loaded passively into the aqueous core of liposomes followed by active 
loading of doxorubicin through valinomycin induced K+ membrane potential [97]. Tardi 
et al showed that it is also necessary to maintain a constant ratio between two drugs to 
benefit from synergy of the treatment [104]. They developed liposomes containing 
irinotecan and floxuridine in the aqueous core of the liposomes. These drugs were loaded 
into the liposomes by simultaneous drug loading wherein floxuridine was passively 
loaded, and irinotecan was actively loaded in to the liposomes in presence of copper 
gluconate/triethylamine buffer. Biodistribution study in mice showed that the optimized 
formulation maintained irinotecan-floxuridine ratio of 1:1.   
 
Doxorubicin and combretastatin A4 were coencapsulated in Arg-Gly-Asp (RGD) 
peptide conjugated liposomes for targeted delivery to melanoma [105]. Combretastatin 
was loaded in the bilayer during the film formation step and doxorubicin was remote 
loaded in to the aqueous core of liposomes by ammonium sulfate gradient method. RGD 
conjugated formulation showed greater efficacy in regressing tumor volume in B16F10 
flank tumor melanoma xenograft model in C57BL/6 mice. The authors proposed that 
combretastatin disrupts the vascular matrix leaving the encapsulated gel like doxorubicin 
in the tumor site, and doxorubicin is released subsequently to exert cytotoxic effect 
 
The use of modulators to overcome drug resistance is a topic of interest in 
coencapsulation of liposomes. Calcium (Ca2+) channel blockers inhibit the tumor 
proliferation by inhibiting Ca2+ influx and evoke passive depletion of internal Ca2+ stores. 
Amlodipine was coencapsulated as a modulator for topotecan to overcome multi drug 
resistance in leukemia [106]. Both drugs were loaded in the aqueous core by ammonium 
sulfate gradient method. The results from in vitro apoptosis study in non resistant K562 
and resistant MDR HL-60 cell lines showed that amlodipine induces apoptosis by 
activation of caspase 3/7 and 8 activities. Depletion of internal Ca2+ stores by amlodipine 
lead to activation of caspase 8, then in the cascade, activation of other effector caspases 3 
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and 7. In vivo evaluation in female nude mice xenografts bearing MDR HL-60 tumor 
showed that the stealth liposomes containing topotecan and amlodipine showed a 
significantly lower change ratio for the tumor size compared to free topotecan, and stealth 
liposomal topotecan. The combination therapy worked by potentiating the apoptotic 
effect and reversing the resistance. 
 
 
1.2.5. Targeted Drug Delivery with Liposomes 
 
The drugs used in cancer chemotherapy often have severe adverse effects because 
they not only kill cancer cells but also kill normal cells. Encapsulation of these drugs in 
the liposomes can minimize systemic exposure of the drug, and therefore, minimize 
undesired systemic toxicity. Further, selective localization of the drug at the tumor sites 
would reduce the total amount of drug required for the therapy. Thus, an ideal liposomal 
drug delivery system for cancer chemotherapy should improve localization of the drug at 
the tumor sites and minimize exposure to normal tissues. Targeted drug delivery 
approaches with liposomes by means of active targeting and passive targeting will help 
accomplish these goals of an ideal delivery system. 
 
 
1.2.5.1. Passive Targeting 
 
Passive targeting refers to the accumulation of the therapeutic agent or carrier at the 
target site due to physicochemical and physiological factors [107]. An understanding of 
the pathophysiology of the tumor is necessary to design a successful targeted delivery 
system.  The ability to target drugs passively to the tumors using liposomes originated 
from the findings that the tumor blood vessels are more permeable to macromolecules 
than normal blood vessels [108, 109]. Tumor vessels have wide interendothelial 
junctions, large number of fenestrae and transendothelial channels formed by vesicles, 
and discontinuous or absent basement membrane [110]. Due to this leaky nature of the 
vasculature in the tumors, macromolecules can extravasate and accumulate in the tumors. 
In addition, the recovery of these macromolecules from tumors via blood or lymphatic 
drainage is impaired which results in high accumulation in the interstitial fluid 
compartment of the tumors [25, 111, 112]. This phenomenon of selective accumulation 
of macromolecules in the tumor is referred as enhanced permeability and retention (EPR) 
effect [113].  
 
Passive accumulation of liposomes in the tumors occurs by transvascular transport 
across the blood vessels. The transport is determined by size of the liposomes, and 
diameter of the pores in the vasculature. The cutoff size for the vasculature in several 
tumors has been studied [114, 115]. The cutoff size varies between tumors depending 
upon the stage of the tumor, size and location of the tumor. Tumors grown 
subcutaneously exhibited pore cutoff sizes between 200 to 1200 nm. The cutoff was 
reduced in intracranial tumors and tumors undergoing regression. Nevertheless, the 
majority of tumors exhibited a vascular pore cutoff size between 380 and 780 nm. So, the 
permeability of macromolecules will be independent of the pore size as long as the size 
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of the molecule is less than the pore diameter. Liposomes used in cancer chemotherapy 
are typically between 100 and 300 nm in size which means that they can extravasate and 
selectively accumulate in most of the tumors.  
 
The passive accumulation of liposomes in the tumors by EPR is a progressive 
phenomenon which requires several passages of the liposomes through the tumor blood 
vessels [51]. The liposomes should remain in circulation for a longer time to take 
advantage of selective accumulation in the tumors by EPR. However, the liposomes are 
considered foreign agents and are cleared by the reticuloendothelial system (RES) 
comprised of Kupffer cells of the liver and fixed macrophages of the spleen. Surface 
modifications of the liposomes with hydrophilic polymers such as PEG provides 
shielding effect and prevent the binding of opsonins to the liposomes which in turn 
minimize the recognition of these liposomes by RES [89]. If the liposomes remain in the 
circulation for a prolonged period of time, the chances of their accumulation by EPR in 
the tumor can be improved. Another important consideration for a longer circulation of 
liposomes is their size. The clearance of liposomes by RES increases with size [79]. The 
binding of opsonins and complement activation are dependent on size of the liposomes 
[81]. Even with the inclusion of PEG on the surface of the liposomes to minimize the 
clearance of the liposomes by RES, the cutoff size for the liposomes for long circulation 
remain between 150 and 200 nm [28]. 
 
 
1.2.5.2. Active Targeting 
 
Passive accumulation of liposomes at the tumors does not necessarily elicit an 
improved therapeutic response which is dependent on the cellular uptake of the 
liposomes. Cellular uptake of the liposomes can be improved by active targeting 
approach. Active targeting refers to the attachment of specific ligands to the therapeutic 
agent or carrier system to recognize and interact with the target receptors or proteins at 
the cellular or tissue components [20, 107, 116]. Although similar biodistribution and 
tumor accumulation is observed with liposomes by passive targeting and active targeting, 
an enhanced therapeutic response is accomplished with active targeting of liposomes 
directed against specific receptors due to improved cellular uptake [117, 118]. 
  
The primary role of targeting ligands is to enhance the cellular uptake into cancer 
cells and minimize the accumulation in normal tissue [22]. Thus, colloidal properties of 
liposomes will determine their biodistribution, and targeting ligands will ensure cellular 
uptake in the tumor. The number of ligands attached to the liposomes, distribution of 
target receptors in the tumors, and selectivity of the targeting ligands to those receptors 
will determine the intracellular uptake in the tumors. Under ideal conditions, the number 
of ligands bound to the tumors equals the number of available receptors [21]. The binding 
of targeting ligand is likely to have high nanomolar to low micromolar dissociation 
constants. So, more ligands are necessary than that may be accommodated to drive the 
equilibrium towards binding and receptor saturation. Once the receptors of the ligand are 
saturated, the specificity of the targeting ligand declines [119]. Excess of the targeted 
liposomes will be handled by the body as any non targeted liposomes. 
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Tumor cells or endothelial cells of tumor vasculature over express a number of 
receptors which makes cancer a disease that will be largely benefitted by targeted drug 
delivery. In addition, unique expression of certain receptors by these cells can improve 
the specificity of targeting.  To specifically target these receptors, ligands can be attached 
to the liposomes which on intravenous administration recognize these receptors. Binding 
of liposomes through these ligands to the target receptors results in an improved cellular 
uptake by receptor mediated endocytosis. The overall therapeutic effectiveness of the 
encapsulated drug can be improved while minimizing the exposure to normal cells.  
 
 
1.2.5.2.1.  Targeting Receptors Expressed by Tumor Cells  
 
Several proteins are over expressed or uniquely expressed by tumor cells. Targeting 
ligands attached to the surface of liposomes should improve the cellular uptake by 
receptor mediated endocytosis. However, the accumulation of liposomes in the tumor 
microenvironment depends on passive targeting due to leakiness of the vasculature, 
longer circulation time, and nature of the liposomes. While passive targeting results in 
accumulation of the liposomes in tumor, receptor mediated endocytosis improves the 
cellular internalization.  
 
 
1.2.5.2.1.1. Antibodies as targeting ligands to target tumor cells  
 
Several antibodies can be used as targeting ligands for liposomes to specifically target 
proteins or receptors expressed on cancer cell surfaces. The antibodies  can be covalently 
coupled with the reactive phospholipids in the membrane [120] or simply by hydrophobic 
bonding wherein the hydrophobic Fc portion of the antibody penetrates the lipid bilayer 
and immunologically active Fab portions extend into the aqueous phase and become 
available for interaction with receptors on the cell surface [121, 122].  The liposomes 
with antibodies attached to the surface of the liposomes are cleared rapidly by the RES. 
Coating of the liposome surface with hydrophilic polymers can help overcome the 
problems with clearance and improve circulation time. PEG coating of such liposomes 
with long PEG chains not only prevent the liposomes being recognized by the opsonins 
from plasma, but also hamper the interaction of the surface attached ligand with the target 
receptors. An interesting strategy was reported to overcome this issue by attaching the 
targeting ligand to the distal end of the PEG chains [123, 124]. The binding of these 
immunoliposomes containing entrapped doxorubicin resulted in an increased cytotoxicity 
to murine squamous lung carcinoma cells as compared to liposomes without antibody 
[124].  
 
The surface modification of liposomes with antibodies results in an enhanced uptake 
by the RES. Targeting ability with antibody depends on density of the antibody on the 
surface of the liposomes. Use of only Fabʹ fragment instead of whole antibody would 
minimize the RES uptake by avoiding Fc receptor mediated clearance mechanism. To 
improve targeting ability without compromising circulation time, Fabʹ  fragments of 
monoclonal antibody 21B2 specific for human carcinoembryonic antigen was coupled to 
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the distal end of the PEG lipid with maleimide functional group [125]. These liposomes 
showed longer circulation time and lower RES uptake compared to the immunoliposomes 
prepared with the whole antibody. These liposomes also showed a two-fold higher 
accumulation in the tumor tissue, as demonstrated in a xenograft model in BALB/c nu/nu 
mice bearing MKN-45 human gastric cancer cell lines. Similarly, Fabʹ fragment was used 
in the preparation of Anti- human epidermal growth factor receptor 2 (HER2) 
immunoliposomes for targeting breast cancer [24]. Phage antibody selection strategy has 
been used to identify antibody fragments to optimize cellular internalization. Small chain 
Fv (ScFv) fragments of anti-HER2 antibody, ScFv F5 was found to specifically recognize 
the extracellular domain of HER2 and showed more internalization in a panel of HER2 
over expressing cells [126]. Doxorubicin-loaded immunoliposomes containing Fabʹ or 
ScFv fragments have shown significant cure rates in HER2 over expressing mouse 
xenograft models [127]. 
 
Conjugation of antibodies to preformed liposomes containing coupling lipids, 
incorporated during liposomes formation, can leave reactive functional groups on the 
inner leaflet of bilayer and can potentially interfere with the encapsulated material [128, 
129]. In addition, some of the coupling agents may be incompatible with the processing 
conditions of liposomes. Uster et al demonstrated that 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-(methoxy(polyethylene glycol)-1900) (MPEG1900-DSPE) from 
micellar phase can be transferred in a time, and temperature dependant manner into 
preformed liposomes [130]. Post insertion of the micelles into preformed liposomes for 
the insertion of targeting ligands on to the external leaflet of liposomes was first 
demonstrated for oligopeptide and oligosaccharide ligands [129]. Ishida and coworkers 
designed doxorubicin-loaded immunoliposomes by post insertion method using sheep 
IgG or anti-CD19 monoclonal antibody coupled to micelles containing 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000) (MPEG2000-
DSPE) and the coupling lipid malemide-PEG2000-DSPE [131]. A very little (4%) 
doxorubicin was released in the transfer process, and anti-CD19 conjugated liposomes 
showed a three-fold increase in the association with human B lymphoma cell lines 
suggesting that the integrity and binding affinity of the these liposomes was not altered 
during the transfer process. The authors envisioned a combinatorial approach for making 
many different formulations of targeted liposomes with a simple procedure of selecting a 
vial of ligand-PEG-micelles for one-step incubation with the appropriate liposomal drug 
formulation. 
 
 
1.2.5.2.1.2. Folic acid  
 
Folic acid is a vitamin required for one-carbon transfer reaction in several metabolic 
pathways. Since folic acid is essential for the biosynthesis of nucleotide bases, its uptake 
is elevated in proliferating cells [132]. Of the two types of folate receptors, the folate 
receptor responsible for the internalization of oxidized folate by receptor mediated 
endocytosis is over expressed in cancer cells to compete for the vitamin available in 
limited quantity [133, 134]. In normal cells, folate receptors are selectively expressed on 
the apical membrane surface. On malignant transformation, the polarity is reversed and 
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the receptors are available for folate binding and internalization which makes them 
suitable for selective targeting.   
 
The length of the spacer used in coupling procedure has been shown to play a crucial 
role in the ability of folic acid to interact with KB cells expressing folate receptors [135]. 
The liposomes with longer PEG spacer chains showed better internalization in the cells 
compared to the ones with smaller or no spacer chains. Pretreatment of the cells with 
excess free folate or antiserum against folate receptors competitively inhibited the uptake 
of liposomes indicating that the targeting was mediated through receptor mediated 
endocytosis.  The use of folic acid conjugated PEG coated liposomes in targeted drug 
delivery was demonstrated in another study using doxorubicin-loaded liposomes [136]. 
The uptake of doxorubicin from these liposomes by KB cells was 45 and 1.6 times 
greater than non targeted liposomes or free drug respectively. The formulation also 
showed 86-fold higher cytotoxicity than non targeted liposomes and 2.7-fold higher 
cytotoxicity than free doxorubicin. The specificity of folate receptor mediated 
endocytosis was demonstrated in co-cultures containing human cervical carcinoma cell 
line Hela and human lung cancer cell line W138. Folate receptor over expressing Hela 
cells were killed completely following treatment with folate targeted liposomal 
doxorubicin leaving only folate non-expressing W138 cells in the culture dish. These 
results suggest that anticancer drugs can be targeted safely to cancer cells by folate 
mediated targeting while sparing normal cells.  
 
Goren et al showed that doxorubicin from folate targeted liposomes was rapidly 
internalized, released in the cytoplasm, and detected in the nucleus within 1-2 hours 
[137]. This mechanism was suggested as a strategy to overcome multi drug resistance of 
drugs which are substrates for efflux transporters. The uptake of doxorubicin by 
multidrug-resistant subline of M109-HiFR lung cancer cells (M109R-HiFR) was not 
affected by P-glycoprotein (P-gp) mediated efflux which was in sharp contrast to the 
uptake of free doxorubicin based on verapamil-blockade experiments with quantitation of 
cell-associated drug, and flow cytometry analysis. The cells pretreated with folate 
targeted liposomes also inhibited the tumor growth as demonstrated by in vivo adaptive 
tumor growth assay in mice. 
 
 
1.2.5.2.1.3. Transferrin  
 
Iron (Fe) is required in the active sites of the enzyme ribonucleotide reductase during 
DNA synthesis [138]. Due to redox activity and its potential to generate reactive oxygen 
species (ROS), the amount of free Fe is kept at minimum levels [139]. To control the 
amount of unbound Fe, the metal is transported bound specifically to the two high 
affinity binding sites of serum glycoprotein, transferrin (Tf). The uptake of Fe by the cells 
involves binding of the Fe-loaded Tf to transferrin receptor1 (TfR1) present on the cell 
surface. Binding induces receptor mediated endocytosis of Fe-Tf [140]. TfR1 is a 
glycoprotein expressed in all nucleated cells at low levels [141]. The expression of TfR1 
is elevated in proliferating cells which makes these receptors excellent choice for targeted 
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delivery to cancer [142]. Active targeting to tumor can be accomplished via Tf or 
antibodies to TfR1.  
 
The density of TfR1 on the surface of cells is correlated with the extent of cell growth 
and division, and consequently, the tumor cells express more TfR1 than normal cells. 
Eavarone et al demonstrated that transferrin coupled liposomes were taken up by C6 
glioma cells through receptor mediated endocytosis [143]. These liposomes with Tf 
coupled to the distal ends of PEG spacers have shown an increased uptake of doxorubicin 
as compared to other non targeted liposomal formulations. Anabousi and coworkers 
demonstrated cytotoxicity of Tf-coupled liposomal doxorubicin on lung cancer cells 
[144]. In addition to TfR1 mediated endocytosis, pH dependant cytoplasmic release was 
used as a strategy to improve the delivery of encapsulated  materials in T-leukemia cells 
[145]. Kakudo et al showed that intracellular trafficking of the liposomes after receptor 
mediated endocytosis can be controlled by attaching a pH dependant fusogenic peptide 
on to the surface of the liposomes [146]. When fusogenic peptide, GALA was introduced 
into liposomal membranes using a cholesteryl moiety for anchoring (Chol-GALA), the 
encapsulated rhodamines were efficiently released and diffused into the cytosol. 
 
Tf-PEG liposomes exhibited prolonged in vivo circulation time and low RES uptake 
in Colon 26 tumor bearing mice [147]. Longer circulation times resulted in enhanced 
extravasation of these liposomes in the tumor tissue. Electron microscopic analysis of the 
tumor tissues revealed that colloidal gold encapsulated Tf-PEG liposomes were 
internalized by receptor mediated endocytosis. The liposomes of size 60 and 120 nm 
showed higher accumulation in tumor tissue compared to 200 and 400 nm liposomes. Li 
et al showed that the tumor volume of mice bearing human hepatoma HepG2 tumor was 
reduced significantly by doxorubicin-loaded TfR1 targeted liposomes compared to non 
targeted liposomes and free drug [148]. Biodistribution studies indicated that doxorubicin 
can be efficiently targeted to tumors using liposomes while minimizing the uptake in 
heart and kidney. Cisplatin was delivered successfully by Tf targeted liposomes to mice 
bearing MKN45P gastric cancer with peritoneal dissemination [149]. Tf-PEG liposomes 
showed significantly higher survival rate compared to PEG liposomes, bare liposomes, 
and free drug. The mice in Tf-PEG liposome group maintained high liposome and 
cisplatin levels in ascites and showed a prolonged residence time in the peripheral 
circulation. Similarly, oxaliplatin-loaded Tf-PEG liposomes showed a reduced tumor 
growth ratio in mice bearing Colon 26 tumor [150]. Maruyama et al demonstrated 
improved survival rate in mice bearing Colon 26 tumor by boron neutron capture therapy 
(BNCT) with Tf-PEG liposomes encapsulated with mercaptoundecahydrododecaborate 
10B (BSH) [151]. The tumor to plasma ratio of 10B was 6 after 72 hours of administration. 
Neutron irradiation after 72 hours of dosing showed improved tumor suppression 
compared to PEG liposomes, bare liposomes, and free BSH. Decahydrodecaborate-10B 
(GB-10) have shown better therapeutic activity compared to BSH in BNCT using Tf-
PEG liposomes in the treatment of squamous cell carcinoma in mice [152]. 
 
Specific binding, internalization, and intracellular delivery of liposomes conjugated 
with anti-Tf receptor antibody was evaluated in three different cell lines for acute T cell 
leukemia [153]. Anti-TFR liposomes showed effective binding and internalization in all 
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three (MT-1, HUT-102, and Molt-4) cell lines. The growth inhibition of methotrexate-γ-
aspartate in MT-1, and HUT-102 cells which express interleukin-2 (IL-2) receptors was 
40 to 60 fold higher using anti-TFR liposomes compared to anti-Tac liposomes 
containing antibody directed against IL-2 receptors.  
 
Transferrin receptor mediated endocytosis has been shown to circumvent P-gp 
mediated multi drug resistance. The uptake of doxorubicin was 3.5 fold higher in multi 
drug resistant SBC-3/ADM human lung cancer cells from Tf targeted liposomes as 
compared to free doxorubicin [154]. The liposomes made of egg phosphatidylcholine 
(EPC) showed better accumulation than the liposomes made of hydrogenated egg 
phosphatidylcholine (HEPC) suggesting that the fluidity of the liposomal membrane 
contributes to rapid internalization and drug release which in turn minimizes P-gp 
mediated efflux. Krieger et al showed that TfR1 targeted and also non targeted 
PEGylated cisplatin-loaded liposomes caused increased drug levels in cisplatin resistant 
A2780 ovarian carcinoma cells and resulted in higher cytotoxicities than the free drug 
[155]. Verapamil, a calcium channel antagonist with P-gp inhibitory activity was 
coencapsulated with doxorubicin in Tf-PEG liposomes to improve drug delivery to 
doxorubicin resistant K562 leukemia cells [156]. Cytotoxicity of Tf-PEG coencapsulated 
liposomes was greater than non targeted liposomes, and Tf-PEG doxorubicin-loaded 
liposomes.  
 
A Tf liposomal formulation was evaluated for the delivery of 5-florouracil to brain 
[157]. The in vivo study showed selective uptake of Tf-liposomes from the brain capillary 
endothelial cells. The targeted liposomes showed 17, and 10 fold greater accumulation 
than free drug, and non targeted liposomes respectively [158]. Tf conjugated liposomes 
was proposed as strategy to improve the uptake of drug in brain. Paclitaxel was delivered 
to mice bearing C6 glioma tumors in the brain using Tf-PEG liposomes [159]. The 
uptake of Tf-PEG liposomes in the brain was supported by non invasive near infrared 
fluorescence (NIRF) imaging. Paclitaxel-loaded Tf-PEG liposomes showed a significant 
reduction in tumor burden compared to no treatment control. However, no significant 
reduction was observed with non targeted liposomes. 
 
A major drawback with targeting tumor cells is that the drugs do not generally 
penetrate farther than three to five cell diameters from the blood vessels [160]. This 
leaves many cells distant from blood vessels with no drug or low levels of drug which 
increases the propensity to development of resistance. 
 
 
1.2.5.2.2. Targeting Receptors Expressed by Tumor Vasculature  
 
Endothelial cells within angiogenic blood vessels of solid tumors express several 
proteins which are either absent or expressed at very low levels in well developed normal 
blood vessels [161-163]. These receptors include integrins, aminopeptidases, and 
vascular endothelial growth factor (VEGF). Specific ligands can be attached to the 
liposomes to target these receptors for drug delivery to solid tumors. An attractive 
advantage of targeting tumor vasculature is that the tumor blood vessels are readily 
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available for targeting than the tumor cells and thus specific targeting can be easily 
achieved. 
 
 
1.2.5.2.2.1. Integrins  
 
Peptides with Arg-Gly-Asp (RGD) or Asn-Gly-Arg (NGR) in a cyclic framework 
have been shown to bind specifically to tumor vasculature and cells over expressing αvβ3 
integrin receptors [163, 164]. Janssen et al demonstrated that RGD-PEG liposomes can 
be targeted specifically to proliferating endothelial cells using a Lewis lung carcinoma 
model in mice [165]. Intravital microscopy of skin fold chamber showed rhodamine 
labeled liposomes as fluorescent clusters in the tumor blood vessels within few minutes 
of administration. But PEG liposomes, and liposomes conjugated with control peptide 
were seen outside the tumor blood vessels indicating that these non specific liposomes 
extravasated deeper in to tumor interstitium.  In another study, doxorubicin-loaded RGD-
PEG liposomes showed improved tumor regression in doxorubicin resistant Colon 26 
tumors in mice [166]. The enhanced therapeutic efficacy in doxorubicin insensitive 
model suggested that the effect is mediated through binding of RGD-PEG liposomes to 
proliferating endothelial cells and not the tumor cells. Holig et al demonstrated that the 
concentration of RGD lipopeptide used in the liposomes played a crucial role in the blood 
circulation time [167]. The liposomes prepared with 0.1% of lipopeptide have shown 
prolonged circulation time compared to those with 1% lipopeptide.  
 
Xiong and coworkers used flow cytometry and confocal microscopy to demonstrate 
integrin receptor mediated intracellular delivery of doxorubicin from RGD-PEG 
liposomes in B16 or A375 melanoma cell lines [168]. The uptake of RGD-PEG 
liposomes was greater than PEGylated liposomes but was less than free drug.  Although 
the accumulation of RGD-PEG liposomes was greater in spleen compared to PEGylated 
liposomes, a better regression in tumor growth was observed in mouse melanoma model 
with the administration of single, and multiple doses. Replacing RGD peptide with RGD 
mimetic also provided better tumor regression compared to PEGylated liposomes and 
free drug [169, 170]. Zhao et al demonstrated improved uptake and cytotoxicity of 
paclitaxel-loaded RGD-PEG liposomes in SKOV-3 human ovarian carcinoma cell lines 
[171]. The targeted formulation also showed significant inhibition of tumor growth in 
mouse ovarian cancer xenograft model. In another study, combretastatin A4 and 
doxorubicin were coencapsulated in RGD-PEG liposomes to improve the therapeutic 
efficacy in mouse melanoma model [105].  
 
Patillo et al used αvβ3 up-regulation in irradiated tumors to selectively deliver 
combretastatin-loaded RGD-PEG liposomes to melanoma in mice [172]. Treatment with 
RGD-PEG liposomes and tumor irradiation resulted in a significant delay in tumor 
growth compared to treatment without radiation.  
 
Dubey et al showed that spontaneous lung metastasis and angiogenesis were 
prevented by RGD peptide anchored liposomes [173]. Cyclic RGD peptide anchored 
sterically stabilized liposomes containing 5-fluorouracil (5-FU) showed better activity 
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against B16F10 melanoma primary tumor and metastasis than the non-targeted sterically 
stabilized liposomes and free drug.  Murphy and coworkers evaluated the effect of 
doxorubicin-loaded RGD conjugated liposomes on primary tumor growth and 
spontaneous metastasis in orthotopic pancreatic and renal cell carcinoma models [174]. A 
reproducible modest effect on primary tumor growth and a substantial effect on 
metastasis were observed. Antitumor effect was observed with targeted liposomes at a 
dose one-fifteenth of the dose of free drug required to produce a similar effect. 
 
 
1.2.5.2.2.2. Aminopeptidase N (CD13)  
 
Endothelial cells of the angiogenic vessels over express membrane spanning 
molecules such as aminopeptidase N (CD13). NGR peptide has been shown to bind to 
aminopeptidase N isoform specific to the neovasculature, and can be used for targeting 
liposomes to angiogenic blood vessels. Pastorino et al used NGR conjugated 
doxorubicin-loaded liposomes for treating neuroblastoma in mouse orthotropic xenograft 
models [175]. The targeted liposomal formulation showed a complete regression of 
tumors in four out of six mice, and the two others showed more than 80% reduction in 
tumor mass.  The blood vessel density was also suppressed to more than 90%. These 
findings demonstrated that aminopeptidase N-targeted delivery of doxorubicin to blood 
vessels caused tumor regression because of its ability to promote apoptosis of the 
angiogenic endothelium. In addition, the mice treated with NGR liposomes did not show 
visible tumor metastasis. Garde et al demonstrated specific binding of NGR peptide 
conjugated liposomes in endothelial and tumor cells [176]. Doxorubicin was shown to 
internalize through the endosomal pathway, and then localize in cell nuclei. These 
liposomes exhibited selective cytotoxicity in CD13 expressing endothelial cells sparing 
CD13 negative colon cancer cells. Antitumor activity evaluation in PC3 prostate cancer 
xenograft showed significant inhibition of tumor growth and apparent reduction in 
vasculature. Antitumor effect was also improved in doxorubicin resistant HCT-116 colon 
carcinoma xenografts compared to free drug.  
 
In addition to targeting aminopeptidase N of the tumor vasculature, targeting 
aminopeptidase A, over expressed on the tumor perivascular cells (pericytes), has been 
explored to complement tumor targeting. Sequential administration of aminopeptidase A, 
and then aminopeptidase N targeted liposome formulations resulted in an enhanced 
antitumor activity of doxorubicin compared to either targeting used alone in a 
neuroblastoma model [177].  
 
 
1.2.5.2.2.3. Vascular endothelial growth factor (VEGF) 
 
VEGF receptor is involved in the proliferation of vascular endothelial cells. Blocking 
the interaction between VEGF and VEGF receptors is a promising strategy to inhibit 
angiogenesis. Janssen and coworkers demonstrated that the peptide with the sequence 
ATWLPPR shows affinity for VEGF receptor. A ten-fold higher binding was observed 
with ATWLPPR conjugated liposomes in human vascular endothelial cell lines 
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(HUVEC) compared to PEGylated liposomes. Kuesters and Campbell used bevacizumab, 
a humanized anti-VEGF-A monoclonal antibody to evaluate its targeting ability in human 
pancreatic cancer cell lines using cationic liposomes [178]. Bevacizumab conjugated 
liposomes showed an improved cellular uptake and tumor targeting of cationic liposomes 
compared to unmodified liposomes.  
 
 
1.2.5.2.3. Combination of Targeting of Tumor Vasculature, and Tumor Cells  
 
The combination of tumor vasculature targeting with tumor cell targeting can 
potentially overcome the drawbacks of both targeting approaches and improve the 
efficacy of targeted therapy. Pastorino et al demonstrated this concept by sequential 
administration of  doxorubicin-loaded liposomes conjugated with anti-GD2 monoclonal 
antibodies directed to disialoganglioside receptor (GD2), widely expressed on cancer 
cells of neuronal origin.  Then, NGR peptide conjugated liposomes directed to 
aminopeptidase N receptors, over expressed in tumor vasculature, was administered 
[179]. Evaluation of in vivo activity against two highly aggressive pseudo metastatic 
neuroblastoma animal models showed that there was a significant improvement in 
antitumor efficacy with the combination approach compared to either tumor cell or tumor 
vasculature targeting. It was suggested that tumor cell targeting results in direct killing of 
the cells, including cytotoxicity against cells at the periphery of the tumor and are 
independent of the tumor vasculature. On the other hand, vasculature targeted liposomes 
binds to and kills angiogenic blood vessels and consequently, kills the tumor cells 
supported by these cells, mainly in the tumor core. 
 
 
1.2.5.2.4. Dual Ligands to Improve Targeting  
 
Tumor cells over express some receptors which can be explored for targeting 
liposomes to tumors. It is rare that the target receptors are expressed exclusively by the 
tumor cells. These receptors are also expressed by normal cells but may not be at the 
same level as tumor cells which results in off-target accumulation of the targeted 
liposomes and toxicities associated with such binding.  Fortunately, tumor cells over 
express multiple types of receptors. This property was explored by Saul et al for targeted 
drug delivery of liposomes with a dual targeting approach [180]. Doxorubicin-loaded 
liposomes with two targeting ligands, for folic acid receptors and epidermal growth factor 
receptors (EGFR), was developed and evaluated for cytotoxicity in KB cell lines. The 
liposomes with dual targeting showed significantly higher cytotoxicity in cells expressing 
both receptors compared to controls in which expression of one or both of the receptors 
were blocked. The results indicated that dual targeting can improve selectivity to target 
tumor cells while sparing off-target cells. Similarly, dual-targeting daunorubicin 
liposomes were developed by conjugating with p-aminophenyl-α-D-mannopyranoside 
(MAN) and Tf for transporting drug across the blood brain barrier (BBB) and then 
targeting brain glioma [181]. The median survival time of tumor bearing rats was 
significantly longer with dual targeting compared to free daunorubicin, and other 
controls. Chen et al showed that multi-target RGD/octreotide-PEG-liposomes enhanced 
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antitumor action of dihydrotanshinone as compared to single-target RGD-PEG liposomes 
and octreotide-PEG-liposomes in AGS cell gastric cancer xenograft model [182]. 
 
 
1.2.6. Controlling Drug Release/Uptake from Liposomes 
 
Intracellular delivery of the drug is one of the key problems encountered in targeted 
drug delivery [183]. Targeted drug delivery of liposomes through receptor mediated 
endocytosis results in their entrapment in endosomes and eventually lysosomes. Active 
degradation process takes place in the lysosomes with the help of several lysosomal 
enzymes. By modification of the composition of liposomes, it is possible to control 
delivery of the drug. Some of the approaches used in improving intracellular delivery of 
liposomes in cancer chemotherapy will be discussed in the following sub sections.  
 
 
1.2.6.1. Cell-Penetrating Peptides 
 
Certain proteins and peptides can translocate across the plasma membrane and deliver 
their payload. This property can be used to overcome the barriers of intracellular delivery 
of liposomes to tumor cells. These proteins or peptides contain basic residues with 
domains of less than 20 amino acids, and are known as cell-penetrating peptides. 
Torchilin et al evaluated the effect of trans-activating transcriptional activator (TAT) 
protein on intracellular delivery of fluorescently labeled liposomes to Lewis lung 
carcinoma, BT20 human breast cancer, and H9C2 cardio myocyte cells [184]. Liposomes 
attached to TAT peptide using a PEG spacer showed high intracellular fluorescence. 
Liposomes with TAT attached directly to the liposome surface or to the PEG spacer 
shorter than the PEG chains used for steric stabilization did not show intracellular 
fluorescence indicating that free interaction between TAT and cellular surface is 
necessary for effective internalization. Low temperature or metabolic inhibitors, sodium 
azide or iodoacetamide did not show any effect on the translocation of TAT liposomes 
into cells confirming the energy-independent nature of this process. Tseng et al showed 
that the uptake of doxorubicin from TAT conjugated liposomes was increased by 12-fold 
in A431 human epidermoid carcinoma cells [185]. However, there was no difference in 
cytotoxicity or in vivo antitumor efficacy between liposomes with and without TAT. A 
pH responsive phospholipid was included in the formulation by Sawant and coworkers to 
improve TAT mediated intracellular uptake [186]. At low pH as in tumor 
microenvironment, the hydrazone link of the PEG-Hydrazone-PE hydrolyzed resulting in 
loss of protective PEG which in turn and improved the internalization of liposomes due to 
better interaction of TAT with the cell surface. Marty et al demonstrated that 
functionalized Antennapedia (Antp, aa 43-58) conjugated liposomes loaded with 
cytotoxic drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine-(5'- 5')-3'-C-
ethinylcytidine reduced IC50 by 70% on B16F1 melanoma cells compared to unmodified 
liposomes [187]. 
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1.2.6.2. pH-Sensitive Liposomes 
 
The pH-sensitive liposomes undergo selective destabilization on exposure to acidic 
environment. The rationale for the development of pH-sensitive liposomes for drug 
delivery to tumors is to take advantage of the acidic microenvironment of the tumor to 
trigger the release of encapsulated contents. The pH of the interstitium rarely reaches a 
value below 6.5 and is difficult to tailor liposomes to be stable at physiological pH and to 
destabilize at this small window. But, the pH in the endosomes and lysosomes reach as 
low as 5.0 which makes it possible to develop pH-sensitive liposomes that can destabilize 
following endocytosis. Several mechanisms of drug release from pH-sensitive liposomes 
have been described [188, 189]. These liposomes can undergo pH induced fusion with 
endosomal membrane and release encapsulated contents in cytosol. They can undergo 
destabilization in the endosome and cause destabilization of the endosomal membrane 
resulting in release of the drug into the cytosol. They can also destabilize completely in 
the endosome, and the drug diffuse out of the endosomal membrane to reach cytosol, and 
other organelles. 
 
The first class pH-sensitive liposomes are composed of polymorphic phospholipids 
with acidic stabilizers to maintain integrity at neutral pH. These liposomes are of less 
practical importance due to rapid clearance from the circulation. Kim et al used 
cholesterylhemisuccinate (CHEMS) as a pH-sensitive lipid in the development of 
gemcitabine-loaded epidermal growth factor receptor (EGFR) targeted liposomes [190].  
In vivo evaluation in A549 alveolar carcinoma bearing mice showed that the rate of tumor 
inhibition improved with the pH-sensitive targeted liposomes compared to other 
treatments. An increased apoptotic index revealed that the tumors treated with pH-
sensitive targeted liposomes resulted in an increased apoptosis of tumor cells, and 
consequently, increased tumor growth inhibition.  
 
The second class of liposomes contains bonds cleavable at low pH to expose the 
destabilizing components of the liposomes resulting in release of encapsulated drug. 
Ishida et al developed doxorubicin dioleylphosphatidylethanolamine (DOPE) liposomes 
containing cleavable lipid derivative of PEG in which PEG was linked to 
distearoylphosphatidylethanolamine (DSPE) via disulfide linkage [191]. Exposure of 
these liposomes to pH 5.5 resulted in release of encapsulated drug due to cleavage of the 
PEG chains and concomitant destabilization of the DOPE liposomes. These pH-sensitive 
liposomes, targeted to the CD19 epitope on B-lymphoma cells, showed enhanced 
delivery of doxorubicin into the nuclei of the target cells and increased cytotoxicity 
compared to non-pH-sensitive liposomes. Survival studies in mouse B-cell lymphoma 
model showed that the pH-sensitive liposomes improved the mean survival time of the 
animals compared to other controls.  
 
Another class of pH-sensitive liposomes uses pH-sensitive peptides for 
destabilization. The fusogenic peptides undergo changes in confirmation with changes in 
pH resulting in liposomes destabilization. They change from random coil at neutral pH to 
amphipathic helices at pH 5.0 [192]. Self association of these structures following 
conformational changes results in their insertion into lipid bilayer, destabilization of 
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liposomes, and release of encapsulated contents. Turk et al used a 29-amino acid peptide 
to enhance the cytotoxicity of cytosine arabinoside encapsulated in folate-targeted 
liposomes, and demonstrated a 30-fold increase drug potency in cultured KB cells [193].  
 
The recent class of pH-sensitive liposomes uses pH-titratable polymers to destabilize 
membranes following change of the polymer conformation at low pH. Upon acidification 
of the external medium, these polymers change from coil to globule phase, introduce 
curvature in the bilayer plane, induce membrane defects, and trigger release of entrapped 
cargo. The use N-isopropylacrylamide (NIPAM) as a pH-sensitive polymer was 
evaluated using cytosine arabinoside-loaded liposomes coupled with anti CD33 
monoclonal antibody to target leukemic cells [194]. Flow cytometry and confocal 
microscopy analyses showed that the pH-sensitive liposomes were efficiently internalized 
by various CD33+ leukemic cell lines. Highest cytotoxicity was observed with HL-60 
cells treated with pH-sensitive targeted liposomes compared to other treatments.  
 
 
1.2.6.3. Thermosensitive Liposomes 
 
Accumulation of liposomes in the tumor area does not guarantee that the drug is 
available inside the to the tumor cell to elicit therapeutic effect [195]. Use of mild 
hyperthermia, which involves heating of the tumor to temperatures up to 43°C, along 
with thermosensitive liposomes can improve the drug delivery and therapeutic outcome. 
Hyperthermia works in two ways. It increases vascular permeability, improves the 
accumulation of liposomes in the tumor, and also sensitizes the cells for chemotherapy. 
Secondly, heat triggers can be used to release drugs from thermosensitive liposomes in 
close proximity to the cancer cells, and thereby, improve the uptake of drug by the cells. 
Yatvin et al first demonstrated that liposomes can be designed to release entrapped drug 
preferentially at temperatures attainable by mild local hyperthermia [196]. They showed 
that liposomes containing phospholipids that undergoes gel-liquid crystalline phase 
transition temperatures around 42°C can release encapsulated neomycin in the presence 
of serum with a release ratio of 100:1 at 44°C and 37°C. Gaber and coworkers used in 
vivo fluorescence video microscopy to demonstrate the extravasation of liposomes, and 
the release of doxorubicin from thermosensitive liposomes in rat skin flap window 
chamber containing vascularized breast cancer [197]. The calculated intensity of free 
doxorubicin in the interstitial space was negligible at 34°C, and increased by with heat to 
38-fold at 42°C, and 76-fold at 45°C. Conventional thermosensitive liposomes required 
heating to temperatures of 43-45°C. These temperatures are higher than clinically 
relevant and attainable temperatures which are in the range of 39-42°C [198]. Needham 
et al included a lysolipid to further improve the permeability at phase transition 
temperatures of the phospholipids [199]. The lysolipid 1-palmitoyl-2-hydroxy-sn-
glycero-3-phosphocholine (MPPC) is kinetically trapped in the solid phase. At Tm, it 
melts and leaves the bilayer and enhances the permeability of the liposomes. These 
thermosensitive liposomes containing doxorubicin with mild hyperthermia showed 
highest tumor concentration of doxorubicin, and significant tumor regression in mouse 
xenografts of human squamous cell carcinoma compared to conventional thermosensitive 
liposomes, non thermosensitive liposomes and free drug [200]. These liposomes are 
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under clinical development under brand name TheromDox® (Celsion Corporation, New 
York, NY) for liver cancer and breast cancer. 
 
 
1.2.6.4. Target-Sensitive Liposomes 
 
Target-sensitive immunoliposomes have the ability to bind to the target specifically 
and destabilize upon target cell binding and release the entrapped drug. Ho et al 
developed target-sensitive immunoliposomes to specifically target herpes simplex virus 
(HSV) using phosphatidylethanolamine (PE) liposomes [201, 202]. PE cannot form 
stable liposomes by itself. Acylated monoclonal anti-HSV glycoprotein D stabilizes the 
bilayer phase of PE to form stable liposomes. The authors demonstrated that specific 
binding of these liposomes to HSV antigen containing glycoprotein D results in 
destabilization of the liposomes followed by release of encapsulated contents. 
Multivalent binding of these target specific liposomes were 10-fold more sensitive than 
the standard double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) for 
the determination of HSV. In another study, they demonstrated the potential use of target-
sensitive immunoliposomes for the delivery of cytotoxic nucleoside analogs into the 
virus-infected cells to inhibit virus replication using cytosine β-D-arabinoside, and 
acyclovir-loaded liposomes [203]. These liposomes have antibodies conjugated to  
N‐glutaryl‐phosphatidylethanolamine (NGPE) [204]. NGPE is equally distributed in the 
bilayer that stabilizes hexagonal phase forming lipids. Binding of these liposomes to the 
target cells result in capping of NGPE conjugated antibody, unequal distribution within 
the bilayer, and rapid destabilization. Hexagonal phase is formed releasing entrapped 
contents. Alternatively, liposomes with detachable polymer coating can be prepared  
[118]. These liposomes allow the flexibility of improving circulation time, and attaching 
targeting ligands to the distal end of PEG on the surface of the liposomes. 
 
 
1.2.6.5. Echogenic Liposomes  
 
Liposomes with air or other gases entrapped in the bilayer make them ultrasound 
active. These liposomes can be visualized at the target site, and can be disintegrated to 
release the encapsulated contents and by altering ultrasound energy. Alkan-Onyuksel et 
al developed  inherently echogenic liposomes by lipid film hydration-sonication-freeze 
drying method [205]. The liposomes when lyophilized in the presence of mannitol 
formed echogenic liposomes. Mannitol has been shown to play a crucial role in 
improving echogenicity of liposomes. It crystallizes on freezing and subsequently  causes 
defects in the liposomal bilayers [206]. These defects in bilayers remain in the cake and 
resealing takes place at the time of reconstitution entrapping air present in the 
atmosphere. Due to the presence of air, the liposomes have the potential for stress on 
activation by ultrasound and eventually release the contents at the target site. This 
phenomenon was explained by incorporating a fluorescent dye, calcein, into air-filled 
liposomes [35]. In vitro release studies showed an increase in the release of calcein with 
increasing applications of ultrasound.  The release of air measured by a custom designed 
method was in agreement with the release of calcein. Kopechek et al compared the 
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release of hydrophilic and lipophilic agents using color Doppler ultrasound in an 
exposure flow model [207]. Color Doppler effectively released hydrophilic calcein but 
not lipophilic papaverine. The authors explained this phenomenon by the fact that 
hydrophilic agents are entrapped in the aqueous core of the liposomes, the disruption of 
which by ultrasound results in the release of encapsulated contents into extraliposomal 
aqueous phase. On the other hand, lipophilic agents are strongly associated with the 
phospholipids in the bilayer. When the liposomes disintegrate, these agents may remain 
associated with phospholipids, may get incorporated in the micelles, but are not released 
into external aqueous phase.   
 
The disintegration of microbubbles under ultrasound can also improve vascular 
permeability as demonstrated by extravasation of fluorescein isothiocyante (FITC) 
labeled dextran in chick embryo model [36]. Electron microscopy revealed micron-sized 
focal endothelial gaps, disseminated belbs, vacuoles and filopodia extending across tens 
of microns.  Echogenic liposomes retain this property of microbubbles in addition to their 
ability to incorporate hydrophilic and lipophilic drugs, which makes them potential 
carriers for targeted drug delivery to solid tumors. These echogenic liposomes developed 
for imaging applications are ~800 nm in diameter, and may be cleared rapidly by the 
RES. So, careful consideration of size and surface modification is necessary in 
developing echogenic liposomes for targeted drug delivery to solid tumors. Although this 
approach will be applicable only to tissues accessible by ultrasound, the long-circulating 
and targeting capability of these liposomes should take care of the tumors which are not 
accessible to ultrasound or those metastasized to other organs or tissues. 
 
 
1.2.7. Lyophilization to Improve the Stability of Liposomes 
 
Phospholipids from the liposomes can undergo hydrolysis and/or oxidation and result 
in physical degradation when stored as aqueous dispersions. As a result, the encapsulated 
drug tends to leak from the vesicles. Apart from leakage, the liposomes can aggregate or 
fuse together resulting in an increase in particle size distribution. In a stability stand 
point, loss of encapsulated drug or increase in vesicle size is unacceptable. Freeze drying 
or lyophilization can prevent hydrolysis of phospholipids and physical degradation during 
storage of the liposomes [34]. However, lyophilization process itself can cause loss of 
encapsulated drug and fusion of the vesicles. Interaction of water with hydrophilic 
phosphate head groups of phospholipids plays a key role in the formation of liposomes 
and hence, removal of water presents more challenges. The ability of several 
carbohydrates to protect liposomes during lyophilization is described by two hypotheses. 
First is ‘water replacement’ hypothesis in which sugar molecules interact with 
phospholipids and replace water molecules in the microenvironment during dehydration 
[208-210]. In such case sugars can maintain the hydrated environment in a dried state. 
The vesicles can also be stabilized in the glassy state of good glass formers such as 
trehalose and sucrose. These sugars can encase the membranes in their amorphous matrix 
and thereby, impart stability as described by ‘vitrification’ hypothesis [211-213].  
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Organisms such as brine shrimp cysts and some species of nematodes survive 
dehydration which is related to their ability to produce nonreducing disaccharide 
trehalose [214, 215]. These anhydrobiotic organisms survive for several years in dry state 
and return to normal metabolic activities on rehydration. Using this analogy, the ability of 
trehalose and other sugars to maintain the structure, and integrity of liposomes was 
evaluated by Madden and coworkers [33]. The results showed that trehalose when used at 
concentrations of 125mM or higher protected the liposomes from structural changes of 
dehydration. The entrapped tracers 22Na+, and [3H]inulin were retained in the vesicles in 
presence of trehalose. The protection effect was greater when trehalose was present on 
both sides of the membrane as compared to when it was present only on the outer part of 
the membrane. To further evaluate the ability of trehalose to prevent leakage of drugs, 
adriamycin encapsulated liposomes were dehydrated in presence of 250 mM of trehalose. 
More than 90% of the drug was retained following drying and rehydration. The 
protection effect of trehalose was attributed to its ability to replace water molecules 
normally hydrogen-bonded to the polar head groups of lipids.  
 
Crowe et al evaluated the interaction of various carbohydrates on phospholipid 
monomolecular layers formed between air-water interface [216]. Trehalose and sucrose 
interacted with dipalmitoylphosphatidylcholine (DPPC) monolayer producing an 
increased area per molecule, and increased membrane fluidity than normally observed 
with water. This effect showed a strong correlation with the ability of trehalose and 
sucrose to stabilize membrane structures. They provided a more detailed explanation for 
the protection by trehalose using sodium isocitrate-loaded liposomes [217]. Freeze 
fracture study of fresh, dry, and rehydrated liposomes revealed that the liposomes freeze 
dried in the presence of trehalose were of the same size before and after drying and after 
rehydration. But the liposomes freeze dried without trehalose fused to form multilamellar 
liposomes or unilamellar liposomes of size about four-fold greater than fresh liposomes. 
The study on effect of trehalose on gel to liquid crystalline transition temperature using 
differential scanning calorimetry (DSC) showed that trehalose reduced the transition 
temperature such that the dried phospholipid remain in liquid crystalline phase at room 
temperature. The rehydrated form of liposomes also contains lipids at liquid crystalline 
phase, and hence there is no transition during rehydration. In contrast, the liposomes 
dried without trehalose remained at gel phase in room temperature. On rehydration, the 
lipids in these liposomes have undergone a transition to liquid crystalline phase. The 
transition of gel phase to liquid crystalline phase during rehydration was postulated as a 
mechanism for leakage of liposomal encapsulated contents. Results obtained with 
infrared spectroscopy showed that trehalose and DPPC interact by hydrogen bonding 
between the -OH groups of trehalose and polar head groups of DPPC [208]. It was shown 
that hydrogen bonding alters the spacing of the polar head groups and thereby decreases 
van der Waals interactions in the hydrocarbon chains of the DPPC.  
 
Residual water content was measured to compare the effect of different carbohydrates 
on their ability to interact with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) [218]. As the trehalose content was increased there was no significant change in 
residual water content but it increased sharply when critical trehalose concentration was 
reached, producing two regions. In region I, all of the trehalose interacts with 
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phospholipid and is unavailable for binding with water.  In region II, free trehalose is 
available for binding with water at a similar rate seen with trehalose lyophilized without 
lipid. The results suggested that the ability of different sugars to protect the liposomal 
bilayers depends on their strength of direct interaction with phospholipids and not on the 
residual water content. Maltose and trehalose showed high interaction with the lipid 
followed by sucrose and glucose. Inositol showed little or no interaction with the lipid. 
 
Fluorescence resonance energy transfer assay was used to demonstrate the protection 
effect of lyoprotectants against fusion of liposomes by incorporating donor and acceptor 
fluorophores into two separate liposome populations and then freeze drying with or 
without trehalose. The results indicated that the fusion was inhibited by almost 90% when 
trehalose is present on both inner and outer part of the membrane [219].  Maltose, 
sucrose, glucose, and fructose also prevented fusion of liposomes to a lesser extent than 
trehalose, but, this effect was evident only at high concentrations of these carbohydrates. 
Comparatively, trehalose prevented fusion at much lower concentrations than other 
carbohydrates. In contrast, raffinose, cellobiose, inositol, and glycerol showed minimal 
inhibitory effect on fusion.  The relative abilities of these carbohydrates to inhibit fusion 
correlated with their ability to interact with phospholipids, maintain fluidity, and preserve 
biological membranes.  
 
The ability of different saccharides to act as cryoprotectants for small unilamellar 
vesicles was evaluated with high resolution 1H-NMR (nuclear magnetic resonance) , 
Electron spin resonance (ESR) spin labeling and DSC [220, 221]. The study with sucrose, 
trehalose, and glucose showed that the stabilization effect is not sugar specific but is a 
general property of saccharides. The ability of these saccharides to replace water 
molecules of hydration by forming hydrogen bond with the polar phospholipid group, at 
same binding site as water, was suggested as the mechanism for cryoprotection. The 
fraction of liposomes unaffected during dehydration was dependant on the sugar to lipid 
molar ratio.  
 
Molecular dynamics simulations was used to characterize interaction of trehalose, 
maltose, and glucose with DPPC bilayer at atomic resolution [222]. These sugars 
interacted directly with phospholipid head group by hydrogen bonding. At higher 
temperature, these sugars prevented thermal disruption, and the protective effect 
correlated with the number of sugar-phospholipid head group hydrogen bonds. The 
ability of disaccharides to provide better protection compared to monosaccharides was 
attributed to their ability to bridge three or more lipid molecules. Trehalose preserves the 
integrity of biological membranes under thermal stress. But, trehalose alone does not 
preserve the integrity of phospholipid bilayers under mechanical stress in the form of 
lateral stretching [223].  
 
Fourier transform infra red (FTIR) spectrometric studies to determine hydrogen 
bonding of different phosphatidylcholines with cholesterol, and galactose revealed a 
downfield shift for P=O asymmetric stretch when galactose was present alone or in 
combination with cholesterol [224]. These results were consistent with molecular 
dynamics simulations with trehalose [225], suggesting that there is a hydrogen bonding 
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interaction between P=O of the phospholipid and -OH group of the carbohydrates during 
lyophilization [218].   
 
A study with increasing amounts of internal trehalose on retention of 
carboxyfluorescein-loaded liposomes showed that only a small amount of trehalose is 
required inside. Adding more sugar inside had no apparent effect on stability [226].  The 
authors also described that retention of the marker in the liposomes depends on the mass 
ratio of sugar and lipid and not the concentration of sugar in the bulk phase.  
 
In contrast to previous reports on internal/external ratio of carbohydrates in the 
liposomes for lyophilization, Ohtake et al reported that a combination of high inner/outer 
trehalose concentrations showed a decrease in Tm of DPPC or DPPC-cholesterol 
containing liposomes in the hydrated state [210]. The decrease in Tm was further 
amplified in the dehydrated state. The extent of Tm decrease is diminished with an 
increasing exterior concentration of trehalose. 
 
During freezing process, water crystallizes to form ice crystals. In this process, the 
vesicles and remaining solute are highly concentrated. Inclusion of lyoprotectant can 
form an amorphous matrix around the vesicles and protect the vesicles from fusion and 
prevent rupture caused by the crystallization of ice. Koster et al showed that vitrification 
of sugars occurs in the intermembrane region, and the resulting glassy state mechanically 
hinders conformational changes of lipid bilayers [212, 227]. These changes further result 
in alteration of phase behavior of the membranes. In the absence of sugars, Tm of the 
lipids increased during lyophilization. Inclusion of sugars diminished this increase of Tm. 
Thermal analysis by DSC showed that sugars vitrifying around liquid crystalline phase of 
lipids lowered Tm below the transition temperature of the fully hydrated lipid, To. On the 
other hand, sugars vitrifying around gel phase of lipids increased Tm during the first 
heating scan and, then lowered it below To in subsequent heating scans of the sample. 
However, vitrification alone is not sufficient to depress the Tm of lipids in dry state, but 
both vitrification, and direct interaction between phospholipid head group and 
carbohydrates is required [209]. 
 
The effect of freezing rate on the integrity of liposomes was evaluated using 
carboxyfluorescein-loaded liposomes in presence of sucrose, trehalose, and glucose as 
lyoprotectants [228]. The results showed that quick freezing in liquid nitrogen induced a 
stress vector on DPPC containing liposomes. The stress was realized only after drying 
and rehydration. This stress was dependant on composition of the liposomes i.e., 
inclusion of cholesterol in the formulation minimized the leakage. The leakage was 
further minimized by slower cooling rate of 0.5°C during freezing. In contrast, a change 
in freezing rate did not affect retention of carboxyfluorescein in EPC containing 
liposomes. The potential of modulated DSC (MDSC) to study the thermal properties of 
freeze dried and frozen phospholipid and carbohydrate mixtures has been described  
[229]. The MDSC measurements of slowly and quickly frozen liposomes showed that the 
glass transition for quick freezing occurred at lower temperatures than slow freezing. 
This effect with slow freezing was attributed to progression of freeze concentration to 
completion before the freeze concentrate solidifies. This leaves a smaller amount of water 
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that remains in sugar resulting in a higher glass transition. Viscoelastic properties can 
also be used to determine the effect of freezing rates on storage stability [230]. Longer 
shear relaxation times were observed for cationic liposomal formulations prepared by 
slow freezing compared to those prepared by quick freezing. The formulation prepared 
by slow freezing have a lower matrix mobility which is an indication of better storage 
stability. 
 
The lyoprotectants used in the formulation of liposomes should not only protect the 
liposomal bilayer against instability to prevent fusion and leakage of the encapsulated 
drug but also protect the linkers or molecules attached to the surface of the liposomes 
from degradation during lyophilization. Friede et al prepared liposomes with maleimide 
functional groups, and lyophilized in presence of sorbitol [231]. These liposomes served 
as shelf items for the preparation immunogenic liposomes or peptide conjugates. The 
results showed that the liposomes retained their maleimide functional groups on 
rehydration of lyophilized liposomes. The liposomes previously conjugated to a peptide 
also retained its immunogenic activity on lyophilization followed by rehydration. 
 
Multivesicular liposomes containing cytarabine was prepared by water-oil-water 
double emulsification method and the stability was evaluated for aqueous dispersions 
[232]. Almost no drug leaked from the liposomes when the concentration of trehalose on 
the outer part of the membrane was isotonic. Leakage was observed at higher 
concentrations of trehalose and when the liposomes were suspended in deionized water. 
The protection effect was explained on the basis of osmotic gradient. When the liposomes 
are suspended in hypertonic solution, the vesicles are subjected to shrinkage whereas 
hypotonic conditions as with deionized water results in expansion and rupture of the 
vesicles. Both these conditions can result in leakage of the drug. So the outer 
concentration of trehalose was kept constant at 9%, and the inner trehalose concentration 
was varied from 0 to 18% during lyophilization to study the effect of inner trehalose 
concentration of liposomes containing different phospholipids on leakage. Multivesicular 
liposomes made of EPC showed higher retention of cytarabine than DPPC liposomes 
which showed greater retention than DOPC liposomes after lyophilization. The retention 
increased with increasing inner trehalose concentrations up to 9% and then leveled off, 
which showed that only a small amount of trehalose is required in the inner part of the 
membrane and further addition of higher amounts of sugar does not have additional 
advantages. 
 
 
1.3. HYPOTHESIS AND SPECIFIC AIMS 
 
Breast cancer is the most common type of cancer and second leading cause of death 
from cancer in western women. About 20-30% of women diagnosed with breast cancer 
develop metastatic breast cancer. The most successful way of treating metastatic breast 
cancer is systemic therapy in the form of chemotherapy or immunotherapy. Paclitaxel is 
one of the most effective chemotherapeutic agents used in the treatment of metastatic 
breast cancers. It is an antimicrotubule agent that promotes the assembly of microtubules 
from tubulin dimers and stabilizes microtubules by preventing depolymerization. 
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Systemic administration of paclitaxel is associated with serious toxic effects including 
myelosuppression and peripheral neuropathy, in addition to hypersensitivity reactions due 
to the formulation components. So, development of formulation to specifically deliver 
paclitaxel to the tumor is necessary.  
 
Entrapment of paclitaxel in the bilayer of liposomes can alter pharmacokinetics and 
biodistribution of the drug, and thereby, minimize systemic toxicity and improve 
therapeutic efficacy. The liposomal composition needs to be optimized to maximize the 
loading of paclitaxel. Even though high loading can be obtained, retention of the loaded 
drug in the bilayer of liposomes is important to maintain storage stability. The optimal 
loading that can be retained in the liposomes during storage needs to be determined and 
factors affecting the same needs to be optimized.  
 
Conventional liposomes are cleared rapidly by the RES. The in vivo circulation time 
can be improved by circumventing RES uptake by reducing the size of the liposomes 
and/or by attaching hydrophilic polymers such as PEG onto the surface of the liposomes. 
Liposomes of size 100-300 nm should also improve localization of paclitaxel in the 
tumor by passive targeting via EPR effect due to leaky nature of the tumor vasculature, 
and impaired lymphatic drainage.  
 
Active targeting via receptor mediated endocytosis can be accomplished by 
modifying the surface of the liposomes with targeting ligands specific to the receptors 
expressed by the endothelial cells of tumor vasculature or tumor cells.  Actively 
proliferating endothelial cells of tumor vasculature over expresses αvβ3 integrin receptors. 
Peptides with RGD motif in a cyclic framework (cRGD) have been shown to effectively 
bind to αvβ3 integrin receptors. Surface modification of paclitaxel-loaded liposomes with 
cRGD peptide attached to the distal end of PEG chains should improve the localization of 
paclitaxel in the tumor. TFR1 receptors are over expressed by proliferating tumor cells. 
Transferrin attached to the surface of the liposomes by means of PEG spacer and a linker 
should improve the uptake of paclitaxel by the breast cancer cells through receptor 
mediated endocytosis.  
 
Long term storage stability of liposomes is a major concern due to leakage of the 
encapsulated drug and fusion/aggregation on storage. Lyophilization of the liposomes can 
overcome these drawbacks and improve long-term stability. The conditions used during 
lyophilization itself can be damaging to the bilayer of liposomes which requires careful 
selection or optimization of the formulation and process. 
 
In addition to the localization and uptake of these liposomes by natural cytosolic 
mechanisms, external triggers can be used to improve the permeability at the vasculature 
to improve localization. Design of paclitaxel-loaded targeted liposomes with air/gas 
incorporated in the bilayer will make these liposomes ultrasound active. Ultrasound can 
be used as an external trigger to disintegrate these liposomes to improve vascular 
permeability, and the uptake.  
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The objective of this dissertation work is to develop targeted liposomal formulations 
to improve localization of paclitaxel in tumor sites, and therefore, minimize toxicity, and 
improve the efficacy of the treatment of breast cancers. To accomplish this objective the 
following hypotheses are envisaged. 
 
I. Paclitaxel-loaded gas-filled liposomes can be developed so that they can be 
visualized with ultrasound, and disintegrated using high intensity ultrasound 
pulses  
II. Development of stable paclitaxel-loaded liposomes conjugated to either 
transferrin or cRGD peptide should improve the efficacy of the treatment of 
breast cancer 
 
To test these hypotheses, my specific aims were to: 
 
1) Develop prototype formulation of cRGD conjugated gas-filled liposomes. 
In this specific aim feasibility of developing ultrasound active, RGD 
conjugated targeted liposomes was evaluated. Formulation and process 
parameters critical to the target profile were identified and optimized to 
achieve an acceptable prototype formulation that can be utilized as a platform 
for drug-loaded liposomes for targeted drug delivery. 
2) Optimize paclitaxel loading in the liposomal formulation. Formulation and 
process parameters that influence paclitaxel loading in the liposomes were 
identified and optimized. Stability of the liposomal dispersion was evaluated 
for up to 10 days to determine the optimum composition of liposomes without 
the risk of leakage. Storage stability of the optimized liposomal dispersion 
was evaluated for three months. 
3) Develop cRGD conjugated paclitaxel-loaded gas-filled liposomes. The 
formulation and process parameters were optimized to obtain paclitaxel-
loaded cRGD conjugated gas-filled long-circulating liposomes (Pac-RGD-
GFTLCL). The echogenicity, and the ability to disintegrate these liposomes 
was evaluated using in vitro models with ultrasound. Stability of the 
formulation was evaluated for three months. 
4) Evaluate biodistribution and efficacy of the liposomes targeted to tumor 
vasculature, and to compare the efficacy of liposomes targeted to tumor 
vasculature and tumor cells in a mouse breast cancer model. Mouse 
xenografts bearing human MDA-MB-231 breast cancer were used for the 
evaluation of biodistribution and efficacy of the formulations. The localization 
cRGD conjugated liposomes were compared with long-circulating liposomes, 
and solution formulation using non invasive near infrared fluorescence 
(NIRF) imaging. The localization of paclitaxel-loaded liposomal formulations, 
and solution formulation was evaluated by measuring tumor tissue 
concentrations after 24 hours of administration. The efficacy of paclitaxel-
loaded long-circulating liposomes (Pac-LCL), and paclitaxel-loaded cRGD 
conjugated targeted long-circulating liposomes (Pac-RGD-TLCL) were 
compared to normal saline control, and paclitaxel solution formulation. To 
compare the effect of targeting tumor cells, paclitaxel-loaded transferrin 
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conjugated targeted liposomes (Pac-Tf-TLCL) were administered to another 
group of animals. The effect of these formulations on tumor volume was 
monitored as a measure of efficacy.  
5) Lyophilize the paclitaxel-loaded liposomes to improve long-term storage 
stability. The formulation was optimized to minimize the leakage of 
paclitaxel, and fusion/aggregation of the liposomes. Stability of the 
lyophilized formulation was evaluated for Pac-LCL, Pac-RGD-TLCL, and 
Pac-Tf-TLCL. 
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CHAPTER 2.  DEVELOPMENT OF PROTOTYPE FORMULATION OF GAS-
FILLED TARGETED LIPOSOMES 
 
 
Ultrasound is the transmission of pressure waves through a medium at frequencies 
above 20,000 Hz. Microbubbles are ultrasound contrast agents used in radiology for 
imaging organs and tissues accessible to ultrasound. Ultrasound travels more slowly in 
gas compared to aqueous medium. The difference in speed causes an acoustic impedance 
mismatch between tissue or blood surrounding the microbubbles [37]. As a result, 
microbubbles act as efficient reflectors of ultrasound energy, and used as contrast agents 
for imaging. The microbubbles can undergo cavitation, which can be explored for drug 
delivery applications. Cavitation is the formation and/or activity of microbubbles in a 
medium exposed to ultrasound [233]. When a medium containing microbubbles is 
exposed to ultrasound, the microbubbles expand at low pressures and contract at high 
pressures. If the resulting oscillation is stable over time with continuous expansion and 
contraction cycles, it is called ‘stable’ or ‘non inertial’ cavitation [38]. This oscillation 
causes micro streaming around the bubble with velocities and shear rates proportional to 
the amplitudes of oscillation. If the intensity of ultrasound is increased, the amplitude of 
oscillation increases such that the inward moving wall of the bubble obtain sufficient 
inertia that it cannot reverse the direction when the ultrasound pressure is reversed. The 
microbubble is compressed continuously creating high pressures within the bubble 
resulting in ‘collapse’ or ‘inertial’ cavitation. The collapse cavitation is detrimental to 
cells and vesicles because of high shear stress in the region of collapse, shock waves 
produced by the collapse, and free radicals generated due to high temperature. If the 
collapse occurs near a solid surface, an asymmetric collapse takes place producing liquid 
jets at sonic speeds which can pierce blood vessel walls. Stieger et al demonstrated that 
low frequency contrast enhanced ultrasound can increase vascular permeability resulting 
in convective extravasation of fluorescent labeled dextran in a chick embryo model [36].  
 
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and 
hydrophilic drugs [23]. Incorporation of gas in the bilayer of liposomes makes them 
acoustically active [205]. These echogenic liposomes have the potential for stress on 
activation by ultrasound, and eventually release the contents at the target site [35]. This 
phenomenon exhibited by echogenic liposomes can be explored for drug delivery 
applications.  But, the size of these echogenic liposomes used for imaging is ~ 800 nm, 
and would be cleared rapidly by the RES. The freeze drying method used for the 
preparation of echogenic liposomes causes an increase in the size of liposomes. 
Crystallization of mannitol present in the formulation causes rupture in the bilayer during 
the freeze drying process [35, 234]. In a dry cake, air passes through these gaps and fills 
up the bilayer. The ruptured bilayer reseals during reconstitution, entrapping air inside the 
bilayer. The extent of damage to the bilayer caused by crystallization of mannitol 
determines the amount of air/gas entrapped in the bilayer, which is reflected as final size 
of the liposomes. Since the use of liposomes of size greater than 150-200 nm is 
unsuitable for drug delivery due to rapid clearance by the RES [28], smaller sized 
liposomes are desired. By using suitable lyoprotectants and/or surfactants at adequate 
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proportions, we can control the crystallization of mannitol and minimize the increase in 
size of liposomes. 
 
An ideal carrier for therapeutic targeting to solid tumors must have a longer 
circulation time than those used for imaging and should possess targeting capability. In 
vivo circulation time can be increased by reducing the size of liposomes and/or modifying 
the surface with PEG derivatives [28].  Targeting capability can be achieved by attaching 
specific ligands onto the surface of the liposomes. The αvβ3 integrin receptors are highly 
expressed in actively proliferating endothelial cells of tumor vasculature and tumor cells 
[163, 235]. Peptides with Arg-Gly-Asp (RGD) motif in a cyclic framework have been 
shown to bind to these receptors and are effective in targeting solid tumors [172]. By 
attaching RGD peptide to the surface through PEG spacers, these liposomes can be 
targeted to solid tumors. The objective of this work is to identify and optimize the 
formulation and process parameters, and to develop a prototype parenteral formulation 
that serves as a platform for drug-loaded ultrasound active liposomes for targeted 
delivery to solid tumors. 
 
 
2.1. MATERIALS AND METHODS 
 
 
2.1.1. Materials 
 
The phospholipids used in this work were all of research grade. Hydrogenated soy 
phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-
(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from Northern Lipids 
(Burnbay, BC, Canada).  1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide 
poly(ethylene glycol)2000) (maleimide DSPE-PEG2000)  was obtained from Avanti Polar 
Lipids (Alabaster, AL). Cholesterol and sucrose were purchased from Sigma (St. Louis, 
MO). Mannitol was obtained from Mallinckrodt Chemicals (Phillipsburg, NJ). Cyclo 
(Arg-Gly-Asp-D-Phe-Cys) peptide (cRGD) was obtained from Peptides International 
(Louisville, KY). Poloxamer 188 was obtained from BASF (Mount Olive, NJ). High 
performance liquid chromatography (HPLC) grade water, acetonitrile, and methanol were 
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform was purchased 
from Acros Organics (Morris Plains, NJ). N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) buffer, 1M was obtained from Mediatech (Manassas, VA). 
All other chemicals and reagents were of analytical grade and used without further 
purification or characterization. 
 
 
2.1.2. Preparation of Long-Circulating Liposomes (LCL) 
 
Long-circulating liposomes were prepared by the lipid film hydration-extrusion 
method using HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by 
dissolving phospholipids and cholesterol in 9:1 chloroform-methanol. The solution thus 
obtained was evaporated in a round bottom flask using rotary evaporator under reduced 
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pressure at 45°C for 4-6 hours. The dry film was hydrated with 50 mM HEPES buffer pH 
6.5 at 65°C for 45-60 minutes. The multilamellar vesicles (MLVs) thus obtained were 
sized by sonication using Misonix Sonicator 3000 probe sonicator (Misonix, Inc., 
Farmingdale, NY) in the initial experiments for the evaluation of composition of 
liposomes. For the rest of the experiments, the liposomes were sized by extrusion through 
stacked polycarbonate membrane filters of varying pore diameters under high pressure to 
obtain small unilamellar vesicles (SUVs). The SUVs were characterized for particle size 
distribution, zeta potential, and morphology. The pore diameter of filters, pressure, and 
number cycles used in the extrusion process were optimized to obtain an average particle 
size of 110 ± 20 nm. 
 
 
2.1.3. Verification of Conjugation Reaction between cRGD and Maleimide 
DSPE-PEG2000 
 
The conjugation of RGD peptide was verified by mass spectrometry by the method 
reported by Desu [236] with slight modifications using Micromass Q-tof-2TM mass 
spectrometer (Micromass, Manchester, UK). The cRGD peptide and maleimide DSPE-
PEG2000 were dissolved separately in 50 mM HEPES buffer pH 6.5, and mixed in 
equimolar ratio. The reaction mixture was incubated at 25°C for 12 hours, and the 
unconjugated peptide was removed by dialysis through 2000 molecular weight cut-off 
(MWCO) Slide-A-Lyzer dialysis cassette against 50 mM HEPES buffer pH 6.5 at 5 ± 
3°C for 6 h. The conjugate was desalted through a Sephadex G-25 macro spin column 
(Harvard Apparatus, Holliston, MA) before analysis. For analysis, 20 µL of the conjugate 
was diluted with 0.3% formic acid and injected to the electrospray ionizer at a flow rate 
of 0.5 µL/min. The capillary and cone voltages were 2.80 KV and 45 V respectively. 
 
 
2.1.4. Preparation of cRGD Conjugated Targeted Long-Circulating Liposomes 
(RGD-TLCL) 
 
For the preparation of RGD-TLCL, a part of DSPE-PEG2000 was replaced with 
maleimide DSPE-PEG2000 and the liposomes were prepared as described in section 2.1.2 
to obtain SUVs with reactive maleimide functional group. The maleimide-LCL thus 
obtained was conjugated with cRGD peptide by incubation at 25°C for 12 h. The 
unconjugated peptide remaining after the reaction was removed from the liposomes by 
equilibrium dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo 
Fisher Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C 
overnight. The conjugation efficiency was determined by quantifying free RGD in the 
dialyzate by reversed phase high performance liquid chromatography (RPHPLC). 
 
 
2.1.5. Determination of Conjugation Efficiency  
 
The conjugation efficiency was determined by equilibrium dialysis through 10,000 
MWCO cellulose membrane using reusable dialyzers (Harvard Apparatus, Holliston, 
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MA). The amount of unreacted RGD in the dialyzate was quantified by RPHPLC as a 
measure of the conjugation efficiency.  The HPLC system comprised of Waters 600 
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector 
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was done using a 
Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA).  The 
gradient elution was performed using 0.05% v/v trifluoroacetic acid (TFA) in water (A) 
and 0.05% v/v TFA in acetonitrile (B) with a linear gradient of 10 to 60% B in 50 min at 
a flow rate of 1 mL/min The retention time for RGD was between 13 and 14 min at a 
detection wavelength of 220 nm. 
 
 
2.1.6. Determination of Particle Size and Zeta Potential 
 
The average diameter (Z-avg) of the liposomes was determined using dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped 
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered 
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC 
grade water for the determination of Z-avg. Three independent measurements were 
performed for each sample. Zeta potential was determined from electrophoretic mobility 
using samples suitably diluted with HPLC grade water.  
 
 
2.1.7. Preparation of Gas-Filled LCL (GFLCL) and Gas-Filled RGD-TLCL 
(RGD-GFTLCL) 
 
The LCL or RGD-TLCL was mixed with equal volume of mannitol solution (0-
17.5% w/v) containing sucrose (0-10% w/v) as a lyoprotectant, and poloxamer 188 (0-
0.5% w/v) as a surfactant. For the initial experiments to evaluate the composition of 
liposomes, the liposome-mannitol mixture was frozen at -80°C, and then freeze dried 
using Labconco FreeZone Plus 6 bench top freeze drier (Labconco Corporation, Kansas 
City, MO). For rest of the experiments, the lyophilization cycle was designed based on 
the glass transition temperature of maximally freeze-concentrated amorphous phase (Tg′), 
determined by differential scanning calorimetry (DSC). Lyophilization was carried out 
using a lab scale Virtis Genesis 25ES lyophilizer (The Virtis Company, Gardiner, NY). 
The primary drying temperature was selected based on Tg′ and the mixture was 
lyophilized in 5cc glass lyo vials.  The moisture content of the dry cake was monitored to 
ensure end point of secondary drying. On completion of the drying cycle, the vials were 
sealed under a partial vacuum.  Perfluoropropane was filled in the headspace above the 
vials at atmospheric pressure to obtain GFLCL and RGD-GFTLCL. The procedure used 
in the preparation of RGD-GFTLCL is summarized in Figure 2-1. The physical 
appearance of the dry cake was recorded as quality control parameter. The vesicle size, 
zeta potential, and echogenicity were monitored in reconstituted samples. The vials were 
stored at 5 ± 3°C until further use. 
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Figure 2-1.  Cartoon representing the method of preparation of RGD-GFTLCL 
 
Notes. The process of preparation of RGD-GFLCL is as follows: A. The liposomes 
are prepared by lipid film hydration extrusion method and then conjugated with cRGD 
peptide. B. The SUVs are mixed with mannitol (♦) solution. C. Lyophilization in 
presence of mannitol results in rupture of the bilayer due to crystallization of mannitol. D. 
The dried cake is equilibrated with perfluoropropane (●) filled in the head space of the 
vials. E. Reconstitution with water results in resealing of the bilayer with 
perfluoropropane entrapped in the bilayer. The diagram is not drawn to scale. 
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2.1.8. Thermal Analysis by DSC 
 
The effect of lyoprotectant and surfactant on crystallization of mannitol was 
monitored by DSC using a Q2000 differential scanning calorimeter equipped with 
refrigerated cooling system (TA Instruments, New Castle, DE). About 10-20 µL of the 
liposome mixture prior to lyophilization was placed in T-Zero aluminum pans and 
hermetically sealed.  An empty pan prepared in a similar manner was used as reference. 
The samples were equilibrated at 25°C and then cooled at 5°C/min to -70°C.  After 
equilibration, the samples were heated at the rate of 10°C/min to 25°C. The effect of 
sucrose and poloxamer 188 on crystallization peak of mannitol was evaluated. The Tg′ 
was also determined from these thermograms to design the lyophilization cycle. 
 
 
2.1.9. Determination of Moisture Content 
 
The moisture content of the lyophilized cake was determined using an Orion AF8 
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was 
calibrated on each day of analysis with a known quantity of water.  About 75 mg of the 
dried sample was weighed accurately and added to the titration vessel. The titration was 
started after allowing one minute for extraction.  
 
 
2.1.10. Determination of Echogenicity 
 
Acoustic activity of GFLCL and RGD-GFTLCL was characterized using an in vitro 
method utilizing Phillips ATL HDI-5000 ultrasound system and broadband L12-5 
transducer (Philips Healthcare, Andover, MA). A schematic representation of the set up 
used in the measurement of echogenicity is provided in Figure 2-2. It consists of a 
rectangular plexiglass chamber filled with 15 mL of normal saline (NS). A small 
magnetic stir bar was placed in the chamber to enable uniform mixing. The chamber was 
then placed on a magnetic stirrer. The transducer was positioned such that it has direct 
contact with NS filled in the tank. The images were acquired with a mechanical index 
setting of 0.1. The gas-filled liposomes were reconstituted with HPLC grade water. After 
acquiring the background image for 5 sec., 200 µL of the reconstituted liposomal product 
was injected into the tank with a 1 cc syringe, and the images were acquired for one 
minute. All image sequences were analyzed offline using a custom program using 
MATLAB 7.0.4 software (The MathWorks, Inc., Natick, MA). The pixel values in the 
region of interest (ROI) were compared to the pixel values in the background. The 
number of folds increase in mean gray scale value (MGSV) in the ROI over the 
background was calculated as the measure of acoustic activity.  
 
 
2.1.11. Characterization of Morphology of Liposomes 
 
Morphology of the liposomes was characterized by transmission electron microscopy 
(TEM) using a negative staining technique. Sequential two droplet method was used for  
43 
To ultrasound 
instrument
L12‐5 Transducer
Rectangular 
plexiglasschamber 
filled with normal 
saline 
Magnetic stirrer
Sample
Stir bar
 
 
 
Figure 2-2.  Schematic representation of the in vitro technique used for the 
measurement of echogenicity 
 
Notes. The apparatus used for the determination of echogenicity consists of a 
rectangular plexiglass chamber filled with normal saline. A magnetic stir bar was placed 
in the chamber to enable uniform mixing. The ultrasound transducer was immersed in 
normal saline up to not more than 0.5 cm from the top of the plexiglass chamber. The 
reconstituted echogenic liposomes were injected in to the tank using a syringe. The 
diagram is not drawn to scale. 
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staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film 
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM 
images were acquired using JEOL 2000EX transmission electron microscope (JEOL 
USA, Inc., Peabody, MA) equipped with high resolution digital camera.  
 
 
2.2. RESULTS AND DISCUSSION 
 
 
2.2.1. Effect of Liposomal Bilayer Composition 
 
The effect of composition of the bilayer of liposomes on the particle size distribution 
(PSD) was evaluated before and after freeze drying. These liposomes were sized by 
sonication using probe sonicator, and the liposome-mannitol mixture was freeze dried 
using bench top freeze dryer. Figure 2-3 shows the effect of increasing the concentration 
of cholesterol on the PSD after freeze drying. An increase in size was observed with all 
the bilayer compositions. The trend shows that cholesterol minimizes the increase in size 
of liposomes after freeze drying. Cholesterol is known to reduce the fluidity and improve 
the rigidity of the liposomes [59]. The higher rigidity in turn minimizes the rupture of the 
bilayer caused by the crystallization of mannitol. Since the final size of the liposomes 
after freeze drying depends on the amount of gas entrapped in the liposomes which 
depends on the extent of rupture to the bilayer caused by mannitol, the increase in rigidity 
provides better control on the final size of GFLCL. The composition with HSPC: DSPE-
PEG2000: Cholesterol in a ratio 45:5:50 was selected for further studies. The sonication 
process for sizing resulted in a high batch to batch variability (data not shown) even 
though the conditions were optimized and strictly controlled. Hence, an extrusion process 
was used for further studies. Similarly, the bench top freeze dryer did not have the 
options to control product temperature. So, further studies were carried out using a more 
robust lab scale lyophilizer. 
 
 
2.2.2. Effect of Lyoprotectant and Surfactant 
 
Mannitol undergoes crystallization from the frozen aqueous solutions during the 
warming phase of freeze drying [237-239]. The crystallization of mannitol has been 
shown to play a critical role in the preparation of echogenic liposomes [206]. The 
crystallization causes rupture in the bilayer of liposomes due to which air/gas is 
entrapped in the liposomes. But these liposomes developed for ultrasound contrast 
imaging were ~ 800 nm in diameter, and can be cleared rapidly by the RES. For drug 
delivery applications, liposomes of size 150-200 nm is desired to escape clearance by the  
RES [28]. Since the final size of these echogenic liposomes depends on the amount of gas 
entrapped in the liposomes which is determined by the extent of rupture to the bilayer 
caused by the crystallization of mannitol, we attempted to control the crystallization of 
mannitol to develop echogenic liposomes of size < 200 nm. The crystallization of 
mannitol can be controlled by altering the process parameters during freeze drying and by 
additives [238, 240, 241]. In our preliminary experiments, we evaluated sucrose and  
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Figure 2-3.  Effect of liposome composition on PSD of liposomes after freeze drying 
 
Notes. The liposomes were prepared by lipid film hydration sonication method. The 
PSD was determined before and after freeze drying in presence of mannitol. The freeze 
dried gas-filled liposome samples were reconstituted with HPLC grade water for the 
measurement of PSD. The results indicate mean ± standard deviation of three 
independent measurements (□ Before lyophilization; ■ After lyophilization).   
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trehalose as lyoprotectants, and poloxamer 188 and Solutol HS15 as surfactants. The 
combination of sucrose and poloxamer 188 provided better control on PSD (Data not 
shown), and hence they were selected for further evaluation. Figure 2-4 shows DSC 
heating profile of frozen liposomes in presence of mannitol and sucrose as a 
lyoprotectant. When only mannitol was present, an exothermic transition characteristic of 
crystallization of mannitol was observed with an onset temperature of -25.23°C and a 
peak temperature of -18.52°C. The crystallization peak was suppressed by sucrose 
showing that the crystallization of mannitol can be controlled by the inclusion non 
crystallizing solute sucrose in the formulation for lyophilization.  In contrast, the 
surfactant poloxamer 188 did not show any effect on the crystallization of mannitol. The 
lyophilization cycle for the preparation of GFLCL was designed based on Tg′, 
determined by DSC. The Tg′ of the formulations containing mannitol and sucrose was 
around -42°C and hence the primary drying temperature was set at -45°C. The influence 
of sucrose was also evident on the PSD of liposomes after lyophilization. Figure 2-5 
shows the effect of mannitol-sucrose ratio on the PSD before and after lyophilization. 
The liposomes prepared in presence of mannitol without lyoprotectant showed more than 
five-fold increase in size. This increase in size was minimized by the addition of 
lyoprotectant sucrose. Increasing concentrations of sucrose in the formulation reduced the 
final size of GFLCL. This effect could be attributed the control of crystallization of 
mannitol by the inclusion of non crystallizing solute sucrose in the formulation. Control 
in crystallization resulted in minimal rupture to the bilayer and thereby minimal 
entrapment of gas in the liposomes. The effect of surfactant on the PSD of liposomes 
after lyophilization is depicted in Figure 2-6. Although there was no evidence on control 
of crystallization of mannitol from DSC, the addition of surfactant, poloxamer 188 
showed a decrease in the final size of GFLCL. This effect could be attributed to the 
formation of monolayer on the surface of liposomes which in turn minimize the 
aggregation due to steric effects. 
 
 
2.2.3. Effect of Sucrose Concentration on Echogenicity 
 
The effect of increasing concentrations of sucrose in the formulation on echogenicity 
of the GFLCL was evaluated in a custom in vitro model. The data is presented in Figure 
2-7.  A maximum increase in gray scale intensity was observed in the ROI with GFLCL 
formulation that was lyophilized without sucrose. Inclusion of sucrose reduced the 
echogenicity of GFLCL. The trend was similar to that observed with the PSD. A decrease 
in echogenicity was expected with the addition of sucrose because the smaller liposomes 
contain less amount of gas per vesicle compared to larger liposomes. The high 
echogenicity in the mannitol containing formulation serves as further proof of the role of 
crystallization of mannitol on size and echogenicity. In contrast, the formulation without  
mannitol also showed echogenicity similar to the formulation containing both mannitol 
and sucrose suggesting that other factors are also involved in determining echogenicity of 
liposomes. The mean grayscale intensity in the ROI for all the formulations decreased 
with time on continuous exposure to ultrasound. The decrease in intensity could be due to 
loss perfluoropropane from vesicles due to diffusion or due to disintegration induced by 
ultrasound. The formulation with intermediate mannitol-sucrose ratio of 4:3, and a  
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Figure 2-4.  DSC thermograms showing the effect of sucrose and poloxamer on 
crystallization of mannitol 
 
Notes. The liposomes were mixed with equal volume of mannitol solution with or 
without sucrose or poloxamer 188. The samples were hermetically sealed in aluminum 
pans, and cooled at the rate of 5°C/min to -70°C. After equilibration at -70°C, the 
samples were heated at the rate of 10°C/min to 25°C. The heating profile is shown in the 
figure. Heat flow is shown on an arbitrary scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
1:0 5:2 4:3 3:4 0:1
0
100
200
300
400
500
600
Mannitol-Sucrose Ratio
Z-
Av
er
ag
e 
(n
m
)
 
 
 
Figure 2-5.  Effect of mannitol-sucrose ratio on PSD of liposomes after lyophilization 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method. The 
PSD was determined before and after freeze drying in presence of varying ratios of 
mannitol and sucrose in presence of 0.15% w/v poloxamer 188. The freeze dried gas-
filled liposome samples were reconstituted with HPLC grade water for the measurement 
of PSD. The results indicate mean ± standard deviation of three independent 
measurements (■ Before lyophilization; ▲After lyophilization). 
 
 
 
 
 
 
 
 
 
 
49 
0 0.05 0.15 0.25
100
125
150
175
Poloxamer Concentration (% w/v)
Z-
Av
er
ag
e 
(n
m
)
 
 
 
Figure 2-6.   Effect of poloxamer on PSD of liposomes after lyophilization 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method. The 
PSD was determined before and after freeze drying in presence of mannitol and sucrose 
at varying concentrations of poloxamer 188. The freeze dried gas-filled liposome samples 
were reconstituted with HPLC grade water for the measurement of PSD. The results 
indicate mean ± standard deviation of three independent measurements (■ Before 
lyophilization; ▲After lyophilization). 
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Figure 2-7.  Effect of mannitol-sucrose ratio on echogenicity of GFLCL 
 
Notes. The echogenicity was determined in an in vitro model with Philips ATL-HDI 
5000 ultrasound system and L12-5 broadband transducer. The freeze dried gas-filled 
liposome samples were reconstituted with HPLC grade water for the measurement of 
echogenicity. After acquiring background images for 5 sec., 200 µL of the sample was 
added using a syringe, and the acquisition was continued for up to one minute. The data 
was processed off-line with a custom MATLAB program. Three ROIs were randomly 
selected, and the average increase in mean grayscale intensity in the ROI from the 
background was calculated. The results represent mean ± standard deviation for three 
samples (Mannitol-sucrose ratios were ■ 1:0; ▲ 5:2; ● 4:3; ♦ 3:4; ▼0:1). 
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poloxamer concentration of 0.15% w/v was selected as optimum based on size and 
echogenicity for further development of RGD conjugated echogenic liposomes. 
 
 
2.2.4. Determination of Conjugation Efficiency 
 
One of the most stable and efficient conjugation reactions, the formation of covalent 
thioether bond by the reaction between sulfhydryl group and maleimide group [172, 242-
244] was used for conjugation of cRGD to maleimide DSPE-PEG2000. The formation of 
conjugate was verified by reacting cRGD and maleimide DSPE-PEG2000 in 1:1 ratio. The 
conjugate was purified, and analyzed by quadrupole time-of-flight (Q-TOF) mass 
spectrometry using electrospray ionizer in MS only positive ion mode. The analysis of 
mass/charge ratio of the product ions confirmed the formation of conjugate in the 
reaction (Figure 2-8). For the preparation of RGD-TLCL, maleimide DSPE-PEG2000 was 
incorporated in the liposome bilayer during film formation step to form Maleimide-LCL 
with reactive maleimide functional groups. The cRGD peptide was added to preformed 
liposomes with maleimide functional group on the distal end of the PEG spacer chains, 
and incubated at 25°C for the conjugation reaction. The amount of unreacted peptide 
present in the dialyzate after equilibrium dialysis was quantified as a measure of 
conjugation efficiency. Figure 2-9 shows HPLC chromatogram of dialyzate obtained 
from equilibrium dialysis of the liposomes immediately after conjugation reaction. The 
cRGD in free form elutes between 12-14 min as shown in the chromatogram for standard. 
The peak for cRGD was not detectable in the dialyzate, indicating that the reaction was 
nearly complete.    
 
 
2.2.5. Characteristics of GFLCL and RGD-GFTLCL 
 
RGD-GFTLCL was prepared using RGD-TLCL similar to the procedure for the 
preparation of GFLCL. The particle size of the RGD-GFTLCL was similar to GFLCL 
with an average diameter ~ 150 nm which is favorable for longer circulation time (Figure 
2-10). These liposomes can escape RES, and also benefit from passive targeting due to 
EPR effect. The zeta potential of both GFLCL and RGD-GFTLCL was -36.27 ± 2.14 and 
-32.60 ± 0.46 mV respectively indicating that these liposomes will have good colloidal 
stability. The zeta potential measurements before and after lyophilization showed a drop 
from -22.8 mV to -36.27 mV for GFLCL, and -26.4 mV to -32.60 mV for RGD-GFTLCL 
after lyophilization. This phenomenon could be attributed to ionic drift across the bilayer 
during lyophilization. The moisture content of the dried cake was less than 1% w/v. The 
dried cake exhibited acceptable physical properties with respect to appearance, cake 
integrity, cake height vs volume, and ease of reconstitution. The TEM images showed 
that both GFLCL and RGD-GFTLCL were spherical in structure (Figure 2-11). Electron 
transparent regions were observed in electron dense vesicles corresponding to areas of 
gas localization as suggested in literature [245, 246].The liposomes appeared similar to 
lipid shelled microbubbles with planar microdomains [247] separated by defects which 
affect mechanical properties and gas permeability [248]. The echogenicity of RGD-
GFTLCL was also comparable to GFLCL (Data not shown). 
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Figure 2-8.  Conjugation reaction between maleimide-DSPE-PEG2000 and cRGD 
 
Notes. An equimolar ratio of cRGD and DSPE-PEG2000 solution in 50 mM HEPES 
buffer were mixed and incubated for 12 h. The conjugate was purified and analyzed by 
mass spectrometry. A segment of product ion mass spectrum is shown. 
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Figure 2-9.  HPLC chromatogram of the dialyzate obtained from equilibrium dialysis 
in comparison to standard solution of cRGD 
 
Notes. The liposomes were dialyzed by equilibrium dialysis through 10,000 MWCO 
cellulose membrane. The dialyzate obtained was analyzed by HPLC (top panel). The 
lower panel shows the chromatogram obtained for a standard solution of cRGD. The 
HPLC conditions were as follows: Mobile phase - Solvent A (0.05% v/v TFA in water) 
and Solvent B (0.05% v/v TFA in acetonitrile) with a linear gradient of 10 to 60% B in 
50 min; Column- Nov-Pak C18; Detection wavelength - 220 nm. 
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Figure 2-10.  PSD of GFLCL and RGD-GFTLCL before and after lyophilization 
 
Notes. The PSD was determined before and after lyophilization. The freeze dried gas-
filled liposome samples were reconstituted with HPLC grade water for the measurement 
of PSD. The results indicate mean ± standard deviation of three independent 
measurements (□ Before lyophilization; ■ After lyophilization). 
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Figure 2-11.  TEM images of GFLCL (A) and RGD-GFTLCL (B) 
 
Notes. The samples were prepared by negative staining with uranyl acetate using 
sequential two drop technique on formvar coated copper grids. The results are shown at a 
magnification of 250,000x. 
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2.3. SUMMARY AND CONCLUSIONS 
 
The formulation and process parameters were identified and optimized in the 
preparation of GFLCL. The crystallization of mannitol was controlled by the inclusion of 
lyoprotectant sucrose so that echogenic liposomes of size less than 200 nm, suitable for 
drug delivery can be prepared. The formulations containing mannitol showed over two-
fold higher echogenicity compared to formulations containing mannitol and sucrose. An 
interesting observation was that the liposomes prepared without mannitol also showed 
echogenicity despite negligible increase in the average diameter. The optimum 
formulation contained both mannitol and sucrose in a ratio 4:3 to meet the target 
requirements for size and echogenicity. Although poloxamer 188 did not show any effect 
on crystallization of mannitol, its steric effects improved the formulation with respect to 
control in size of the liposomes during lyophilization. The cRGD peptide was 
successfully conjugated to the PEG termini on the surface of the liposomes. The RGD-
GFTLCL was similar to GFLCL in size, charge, and echogenicity demonstrating that the 
conjugation procedure did not affect the properties of these echogenic liposomes. These 
echogenic liposomes can serve as a potential platform for the delivery of hydrophilic 
and/or lipophilic drugs for targeted drug delivery to solid tumors. The ultrasound activity 
can be used for visualizing these agents at the target site, and by changing the ultrasound 
intensity they can be disintegrated to release the encapsulated drugs. The uptake at the 
tumor sites can also be improved by enhanced vascular permeability mediated by 
ultrasound disintegration. 
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CHAPTER 3. OPTIMIZATION OF PACLITAXEL LOADING AND PHYSICAL 
STABILITY IN THE DEVELOPMENT OF LONG-CIRCULATING LIPOSOMES 
 
 
Paclitaxel is one of the most effective drugs used in chemotherapy of cancer and is a 
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It 
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin 
dimers and stabilizes microtubules by preventing depolymerization. The stability results 
in inhibition of the normal dynamic reorganization of the microtubule network that is 
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel is marketed as 
Taxol® (Bristol-Myers Squibb Company, Princeton, NJ) for the treatment of ovarian, 
breast, non-small cell lung cancers, and AIDS related Kaposi’s sarcoma [249]. Since 
paclitaxel is highly insoluble in water, Taxol® was formulated with ethanol and 
Cremophor®EL. Although the formulation is diluted before use, the concentration of 
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral 
administration, which require pretreatment with antihistamines and corticosteroids [15]. 
In addition, the use of free paclitaxel can affect normal tissues and result in systemic 
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, it is imperative 
to deliver paclitaxel locally to the tumor sites to minimize systemic toxicity.  In addition, 
failure to maintain adequate concentration at the tumor microenvironment can result in 
regrowth of the tumor cells and development of resistance [5]. 
 
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and 
hydrophilic drugs [23]. Encapsulating drugs within vesicles has the potential advantage 
of higher drug carrying capacity compared to attaching them to single polymer chain 
[250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and 
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced 
efficacy of the treatment [251]. The maximum tolerated dose of paclitaxel has been 
shown to increase with the liposomal formulation compared to the administration of 
Taxol® [252]. The liposomal formulation of paclitaxel was also effective in delaying 
tumor progression in paclitaxel resistant Colon 26 tumor in mice [251, 253], suggesting 
that the development of liposomes opens up newer avenues to overcome drug resistance 
in cancer.  
 
Conventional liposomes are cleared rapidly by the reticuloendothelial system (RES) 
comprised of Kupffer cells of the liver, and fixed macrophages of the spleen [80]. 
Clearance of liposomes by the RES is directly proportional to the vesicle size [79]. 
Liposomes of size ~100 nm can escape clearance by the RES and remain in circulation 
for a prolonged period of time. In addition, coating the surface of the liposomes with 
hydrophilic polymers such as PEG can provide a shielding effect to the liposomes and 
prevent recognition and binding of opsonins [88]. Therefore, these liposomes can escape 
clearance by the RES and remain in circulation for a longer period of time. If the 
liposomes remain in circulation for a longer time, the possibility of their passive 
accumulation in the tumors by enhanced permeability and retention (EPR) effect will be 
improved. Even with PEG coating to minimize the clearance by the RES, the cutoff size 
for the liposomes for long circulation remain between 150 and 200 nm [28]. 
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Loading paclitaxel in the bilayer of the liposomes, and retaining the encapsulated 
drug during storage requires special consideration in product development because the 
encapsulated drug tends to precipitate at higher loading. Paclitaxel is incorporated into 
the acyl chain portion of the liposome bilayer [254]. At lower concentrations, it partitions 
into the upper bilayer domain towards the aqueous interface. When the concentration is 
increased, it partitions into to deeper parts of the bilayer. Higher concentrations can 
induce self aggregation which can act as nucleation for precipitation of paclitaxel as 
needle shaped crystals.  Partitioning of paclitaxel in the bilayer of liposomes induces 
conformational changes which are different for saturated and unsaturated lipids [255]. 
Thermotropic phase behavior of phospholipids is altered inducing fluidity in the gel 
phase of saturated lipids, and slight rigidity in unsaturated lipids. It also affects bilayer 
spacing of planar phospholipids in lipid specific, and concentration dependant manner 
[256]. Thus, drug-lipid interaction plays a major role in determining the physical stability 
of the liposomes [257]. It has been suggested that a tradeoff exists between the drug 
content and duration of stability in aqueous dispersion [252]. Even though high drug 
loading has been reported with certain lipid compositions [249, 258, 259], the physical 
stability of the liposomes varied with each composition. Apart from that, inclusion of 
PEGylated lipids has been shown to reduce drug loading and physical stability of 
liposomes [258]. The extent of paclitaxel loading in the liposomes, and the stability of 
such liposomes is dependent on the nature and concentration of phospholipids, and drug-
lipid interaction determined by the drug-lipid ratio. So, there is a need to optimize these 
parameters to achieve adequate stability of the liposomes. The objective of this work is to 
determine, and optimize the factors influencing drug loading, and physical stability of 
paclitaxel-loaded long-circulating liposomes (Pac-LCL). 
 
 
3.1. MATERIALS AND METHODS 
 
 
3.1.1. Materials 
 
Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The 
phospholipids used in this work were all of research grade. Egg phosphatidylcholine 
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from 
Northern Lipids (Burnbay, BC, Canada).  Cholesterol and α-tocopherol were purchased 
from Sigma (St. Louis, MO). HPLC grade water, acetonitrile, and methanol were 
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform was purchased 
from Acros Organics (Morris Plains, NJ). N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) buffer, 1 M was obtained from Mediatech (Manassas, VA). 
All other chemicals and reagents were of analytical grade and used without further 
purification or characterization. 
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3.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL) 
 
The Pac-LCL was be prepared by the lipid film hydration-extrusion method using 
HSPC, DSPE-PEG2000, cholesterol, and/or EPC. The lipid film was prepared by 
dissolving paclitaxel, phospholipids, cholesterol, and /or α-tocopherol in 9:1 chloroform-
methanol. The solution thus obtained was evaporated in a round bottom flask using rotary 
evaporator under reduced pressure at 45°C for 4-6 h. The dry film was hydrated with 
50mM HEPES buffer pH 6.5 at 65°C for 45-60 min. The multilamellar vesicles (MLVs) 
thus obtained were sized by extrusion through stacked polycarbonate membrane filters of 
varying pore diameters under high pressure to obtain small unilamellar vesicles (SUVs). 
The SUVs were characterized for particle size distribution, zeta potential, paclitaxel 
loading and morphology. The pore diameter of filters, pressure, and number cycles used 
in the extrusion process were optimized to obtain an average particle size of 100 ± 20 nm. 
 
 
3.1.3. Determination of Paclitaxel Loading Efficiency 
 
The loading efficiency of paclitaxel in the liposomes was determined by minicolumn 
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus, 
Holliston, MA) similar to the method described by Zhang et al [249] with modifications. 
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and 
was allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C for 
4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to 
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the 
column. The column saturation with placebo liposomes was repeated for a total of three 
times. The gel columns were placed in fresh collection tubes for use with drug-loaded 
liposomes. The Pac-LCL samples were diluted with 50 mM HEPES buffer pH 6.5. About 
100 µL of the diluted sample was added to the gel column, and centrifuged for 4 minutes. 
The eluate in the collection tube, containing only entrapped paclitaxel was analyzed by 
RPHPLC. The encapsulation efficiency was calculated from total paclitaxel determined 
before passing through Sephadex G-25, using the formula, Entrapment efficiency = 
(Entrapped paclitaxel x 100)/Total paclitaxel). 
 
 
3.1.4. Quantification of Paclitaxel from Liposomes 
 
The total and entrapped paclitaxel in the liposomes was quantified by RPHPLC 
method. The HPLC system comprised of Waters 600 Controller, Waters 717 Plus 
Autosampler, and Waters 2996 Photodiode Array Detector (Waters Corporation, Milford, 
MA) was used. The RPHPLC analysis was performed using a Nova-Pak C18 column (3.9 
x 150 mm, 4 µm) (Waters Corporation, Milford, MA).  An isocratic elution was 
performed using acetonitrile-water in a ratio 55: 45 v/v at a flow rate of 1 mL/min, and 
detection wavelength of 230 nm. The liposomes were digested with absolute ethanol, and 
suitably diluted before injection.  
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3.1.5. Determination of Particle Size and Zeta Potential 
 
The average diameter (Z-avg) of the Pac-LCL was determined using dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped 
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered 
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC 
grade water for the determination of Z-avg. Three independent measurements were 
performed for each sample. Zeta potential was determined from electrophoretic mobility 
using samples suitably diluted with HPLC grade water.  
 
 
3.1.6. Stability Evaluation of Pac-LCL 
 
Stability of Pac-LCL was evaluated at two stages. Initially, the stability was evaluated 
for 7-10 days for the optimization of the liposome composition. The Pac-LCL samples 
were stored in 7 mL glass scintillation vials at 5 ± 3ºC. Aliquots were withdrawn at 
specific intervals. The entrapped paclitaxel was determined by minicolumn centrifugation 
method followed by analysis of the eluate by RPHPLC method. In the stability evaluation 
stage, the optimized formulation was stored in 2 cc amber glass vials at 5 ± 3ºC for three 
months. Samples were withdrawn at specific intervals and analyzed for total and 
entrapped paclitaxel, entrapment efficiency, PSD, and zeta potential.   
 
 
3.1.7. Characterization of Morphology of Pac-LCL 
 
Morphology of the Pac-LCL was characterized by transmission electron microscopy 
(TEM) using a negative staining technique. Sequential two droplet method was used for 
staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film 
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM 
images were acquired using JEOL 2000EX transmission electron microscope (JEOL 
USA, Inc., Peabody, MA) equipped with high resolution digital camera.  
 
 
3.2. RESULTS AND DISCUSSION 
 
 
3.2.1. Optimization of Paclitaxel Loading 
 
The target concentration in the paclitaxel liposome dispersion was set at 1.0 – 1.5 
mg/mL with a size of 100 ± 20 nm. The initial composition for the liposomes was HSPC: 
DSPE-PEG2000: cholesterol in a ratio of 45: 5: 50, and a total lipid concentration of 10 
mM. The entrapment efficiency of paclitaxel was calculated by minicolumn 
centrifugation method using Sepadex G-25 columns. The columns were pretreated with 
placebo liposomes three times to completely saturate the column so that non-specific 
adsorption and subsequent loss of paclitaxel-loaded liposomes can be minimized. The 
total and entrapped paclitaxel in the liposome formulation was calculated from standard 
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curve which was liner between 0.256 to 20 µg/mL with a coefficient of determination (r2) 
value of 0.9999.  
 
The effect of total phospholipids on paclitaxel loading is shown in Figure 3-1. As 
expected, an increase in total phospholipids resulted in an increase in the amount of 
paclitaxel per mL of liposomes. But, the entrapment efficiency was low with a total 
entrapped paclitaxel concentration of ~ 4.0 µg/mL at the highest concentration tested for 
phospholipids. Inclusion of cholesterol in the bilayer of liposomes has been shown to 
improve the rigidity of the bilayer, and thereby, improve in vitro and in vivo stability of 
the liposomes [59, 61, 64]. It also reduces leakage of encapsulated contents from the 
liposomes. Cholesterol was included in the formulation to improve the rigidity, and to 
minimize drug leakage. Figure 3-2 shows the effect of cholesterol on paclitaxel loading 
in the LCL formulation. Reducing cholesterol content from 50 to 30 moles % did not 
show any change in the paclitaxel loading. But, a sharp increase in loading was observed 
at 10 moles % of cholesterol with an entrapped drug content of ~ 100 µg/mL. The 
negative effect of cholesterol on paclitaxel loading was consistent with similar reports in 
literature [249, 258]. It has been suggested that paclitaxel competes with cholesterol for 
hydrophobic space in the bilayer of liposomes [249]. If more molecules of cholesterol are 
present, there would be less space for paclitaxel to occupy. Cholesterol can restrict the 
flexibility of hydrocarbon chains and prevent penetration of paclitaxel into the bilayer 
[249]. In contrast, inclusion of cholesterol even at lower concentrations in PEGylated 
liposomes, have shown a positive effect in improving serum stability by preventing 
exchange of phospholipids with high density lipoproteins. So the lowest concentration of 
cholesterol was selected for further studies. 
 
High rigidity of HSPC, a saturated phospholipid, can restrict the loading of paclitaxel 
into the bilayer of liposomes. So we evaluated the effect of EPC, an unsaturated 
phospholipid, using different ratios on paclitaxel loading (Figure 3-3). With a 1: 1 ratio 
of HSPC-EPC, the paclitaxel loading increased to ~ 800 µg/mL. The results were 
consistent with literature reports on paclitaxel loading using unsaturated phospholipids 
[171, 249, 260, 261]. Unsaturated lipids have a low gel to liquid crystalline transition 
temperature (Tm), and form liposomes which are more flexible in nature to accommodate 
lipophilic drugs [249]. Though inclusion of unsaturated lipids have a positive influence, 
they cannot be used solely to prepare liposomes because of problems related to 
aggregation of paclitaxel-loaded liposomes made of PC alone [252]. Further increases in 
EPC showed only a minimal increase in drug loading. Nevertheless, paclitaxel 
precipitated from all the liposome compositions within few days of storage at 5 ± 3ºC 
suggesting that further refinement of the formulation is necessary. When the total lipids 
content of HSPC-EPC ratio 1:3 was increased to 100 mM, the entrapped paclitaxel 
content increased to ~ 1.9 mg/mL but precipitation was observed within few days of 
storage. A further increase in the lipid concentration was not feasible because the 
multilamellar vesicles (MLVs) formed a gel during hydration stage. High loading being 
achieved, the optimum amount paclitaxel loading that result in physically stable 
formulation needs to be determined. 
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Figure 3-1.  Effect of total phospholipids on paclitaxel loading 
 
Notes. The liposome composition was HSPC: DSPE-PEG2000: cholesterol in a ratio of 
45: 5: 50. The liposomes were subjected to minicolumn centrifugation in Sephadex G-25 
macro spin columns to separate free paclitaxel from total paclitaxel. The eluate 
containing entrapped paclitaxel was digested with ethanol, and quantified by RPHPLC 
method. Two injections were made for each sample, and the average was calculated. 
Three Sephadex columns were prepared for each composition and the results indicate the 
mean ± standard deviation for three gel filtration columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
50 30 10
0
25
50
75
100
Cholesterol Content (Moles %)
Pa
cl
ita
xe
l C
on
ce
nt
ra
tio
n 
(µ
g/
m
L)
 
 
 
Figure 3-2.  Effect of cholesterol concentration on paclitaxel loading 
 
Notes. The liposome composition was HSPC: DSPE-PEG2000: cholesterol in a ratio of 
x: 5: x moles % with a total lipid concentration of 50 mM. The liposomes were subjected 
to minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. Two injections were made for each 
sample, and the average was calculated. Three Sephadex columns were prepared for each 
composition and the results indicate the mean ± standard deviation for three gel filtration 
columns. 
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Figure 3-3.  Effect of saturated-unsaturated lipid ratio on paclitaxel loading 
 
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol with 
a total lipid concentration of 50 mM. The moles % of DSPE-PEG2000 and cholesterol 
were maintained constant at 5% and 10% respectively. The liposomes were subjected to 
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. Two injections were made for each 
sample, and the average was calculated. Three Sephadex columns were prepared for each 
composition and the results indicate the mean ± standard deviation for three gel filtration 
columns. 
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3.2.2. Optimization of Physical Stability 
 
Drug-lipid interaction is a major determining factor of physical stability of the 
liposomes and is dependent on the concentration of drug and phospholipids [257]. Higher 
to drug-lipid ratio can minimize the total amount of phospholipids administered and thus 
reduce toxicities associated with high lipid doses. On the other hand, the ratio needs to be 
optimum to attain adequate physical stability. Thus, the optimum formulation is the one 
which has the highest drug-lipid ratio achievable for physically stable liposomes. A 
paclitaxel-lipid ratio of 1:30 or less has been used to develop formulations with different 
phospholipid compositions with good loading efficiency [249, 252, 258]. We evaluated 
the effect of drug-lipid ratio on paclitaxel loading in LCL at different ratios. With 
increasing drug-lipid ratio, an increase in drug loading was observed (Figure 3-4) with a 
maximum loading obtained at the ratio of 1:30. Further increase in drug-lipid ratio to 
1:20 resulted in a decrease in loading due to precipitation (Data not shown). This was 
consistent with literature reports suggesting that the ratios above 1:30 can result in 
aggregate formation that can act as nucleation for precipitation [254]. The LCL 
containing three different drug-lipid ratios were stored in scintillation vials at 5 ± 3ºC to 
evaluate the physical stability of these liposomes. At specific intervals, aliquots were 
withdrawn from these vials after vortexing to ensure uniform mixing. The liposomes 
were passed through Sephadex G-25 gel column by minicolumn centrifugation method to 
separate the free drug from the dispersion. The entrapped paclitaxel in these LCL 
formulations were plotted against time (Figure 3-5) to evaluate the physical stability. The 
entrapped paclitaxel decreased to nearly 20% of the initial concentration in five days for 
the drug-lipid ratio of 1:30. The formulation with 1:45 also showed a steady decline in 
entrapped paclitaxel through the 10 days of observation. The ratio of 1:60 was stable for 
up to 10 days. Even though high loading was achieved with the drug-lipid ratios 1:30, 
and 1:45, they were not physically stable in this bilayer composition. This could be 
attributed to over saturation of the bilayer with paclitaxel in the liposomes at higher 
temperatures above the storage temperature. On returning to the storage temperature, 
paclitaxel in the oversaturated liposomes started to precipitate. The precipitate acted as 
nucleation and induced further precipitation of remaining paclitaxel reducing the 
encapsulated paclitaxel content to a lower level even below that was seen with the ratio 
1:60. The liposome bilayer composition was further modified to minimize the negative 
factors that affect paclitaxel loading. HSPC-EPC ratio was changed to 1:5, and 
cholesterol concentration was reduced to 5 moles %. The amount of entrapped drug for a 
given drug-lipid ratio increased for these formulations. The effect of various drug-lipid 
ratios on the physical stability of the improved composition was evaluated at 5 ± 3ºC for 
one week, and the data is presented in Figure 3-6. Similar to the previous observations 
the drug to lipid ratio of 1:30 showed a decrease in entrapped paclitaxel but at a slower 
rate. Other ratios were stable for one week. The intermediate stable drug-lipid ratio of 
1:60 was selected as the optimum formulation for three-month stability evaluation.  
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Figure 3-4.  Effect of drug-lipid ratio on paclitaxel loading 
 
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol 
(21.25: 63.75: 5: 10) with a total lipid concentration of 100 mM. The liposomes were 
subjected to minicolumn centrifugation in Sephadex G-25 macro spin columns to 
separate free paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel 
was digested with ethanol, and quantified by RPHPLC method. Two injections were 
made for each sample, and the average was calculated. Three Sephadex columns were 
prepared for each composition and the results indicate the mean ± standard deviation for 
three gel filtration columns. 
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Figure 3-5.  Effect of drug-lipid ratio on physical stability of Pac-LCL 
 
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol 
(21.25: 63.75: 5: 10) with a total lipid concentration of 100 mM. The liposomes were 
stored at 5 ± 3ºC in scintillation vials. Aliquots were withdrawn at specific intervals and 
subjected to minicolumn centrifugation in Sephadex G-25 macro spin columns to 
separate free paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel 
was digested with ethanol, and quantified by RPHPLC method. Two injections were 
made for each sample, and the average was calculated. Three Sephadex columns were 
prepared for each composition and the results indicate the mean ± standard deviation for 
three gel filtration columns (Drug-lipid ratios are ■ 1:30; ▲ 1:45; ● 1:60). 
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Figure 3-6.  Effect of drug-lipid ratio on physical stability of improved Pac-LCL 
 
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol (15: 
75: 5: 5) with a total lipid concentration of 100 mM. The liposomes were stored at 5 ± 
3ºC in scintillation vials. Aliquots were withdrawn at specific intervals and subjected to 
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. Two injections were made for each 
sample, and the average was calculated. Three Sephadex columns were prepared for each 
composition and the results indicate the mean ± standard deviation for three gel filtration 
columns (Drug-lipid ratios are ■ 1:30; ▲ 1:45; ● 1:60; ♦ 1:75). 
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3.2.3. Optimization of the Extrusion Process 
 
The extrusion process used in the preparation of LCL to reduce the vesicle size can 
affect drug loading depending upon the number of extrusion cycles and the extrusion 
pressure. The effect of number of extrusion cycles on PSD, and entrapment efficiency is 
presented in Figure 3-7. The results are shown for the drug-lipid ratio of 1:30, and 
polycarbonate membrane filter combination of 200 nm stacked over 100 nm. As 
expected, the size of the liposomes decreased with increasing number of extrusion cycles. 
There was no significant decrease in the entrapped paclitaxel up to five extrusion cycles. 
A slight decrease in entrapment was observed with 10 extrusion cycles but it was within 
the target loading desired. The effect of extrusion pressure is presented in Figure 3-8. 
The particle size decreased proportionately with increase in extrusion pressure. The 
entrapment efficiency did not show any significant change with increasing extrusion 
pressure although there was a slight decrease in loading observed at extrusion pressure of 
300 PSI. The understanding about the process helped in reaching the target size of 100 ± 
20 nm with a paclitaxel loading of 1-1.3 mg/mL with changes in polycarbonate filter 
combinations, extrusion pressure, and number of extrusion cycles. The TEM images of 
the Pac-LCL formulation showed that these vesicles were spherical in structure with a 
diameter of 100 ± 20 nm (Figure 3-9). 
 
 
3.2.4. Stability Evaluation of Pac-LCL Dispersion 
 
The stability of the Pac-LCL dispersion was evaluated at 5 ± 3ºC in light protected 
container for three months. The stability data presented in Figure 3-10 shows that the 
liposomes maintained their size, charge, and integrity through the evaluation period. A 
slight decrease was observed in paclitaxel retention in the first few days. This could be 
attributed to partitioning of the drug form the bilayer of liposomes to the dispersion 
medium to maintain equilibrium. Once the equilibrium is reached, the paclitaxel retention 
remained constant.  
 
 
3.3. SUMMARY AND CONCLUSIONS 
 
The loading of paclitaxel in the liposomes can vary depending upon number of 
factors including the nature and concentration of lipids in the bilayer, the amount of drug, 
and the process used in the preparation of liposomes. Even though high loading can be 
achieved, the physical instability of the liposomes in the dispersion is a challenging issue 
and needs to be addressed to ensure long-term stability during storage. The factors 
affecting drug loading have been identified and optimized to improve the loading 
efficiency. A proportionate increase in loading was observed with increase in the total 
phospholipid content. Cholesterol and saturated lipid content in the bilayer showed a 
negative influence on paclitaxel loading. Reducing the concentration of cholesterol 
showed a significant increase in paclitaxel loading. The increase in loading was further 
augmented by the inclusion of EPC, an unsaturated lipid to replace a part of HSPC, a 
saturated lipid. The increased flexibility of the acyl chains of the unsaturated lipids  
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Figure 3-7.  Effect of number of extrusion cycles on PSD and paclitaxel loading 
 
Notes. Liposomes were sized by extrusion process and the samples were taken at 
different number of cycles and evaluated for entrapped paclitaxel and PSD. For entrapped 
paclitaxel determination, the eluate from gel filtration through Sephadex G-25 was 
digested with ethanol, and quantified by RPHPLC method. Two injections were made for 
each sample, and the average was calculated. Three Sephadex columns were prepared for 
each stage of evaluation in the extrusion process. The results indicate the mean ± 
standard deviation for three gel filtration columns. For PSD, the results indicate mean ± 
standard deviation of three independent measurements at each stage of evaluation (■ 
PSD; ▲ Paclitaxel loading). 
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Figure 3-8.  Effect of extrusion pressure on PSD and paclitaxel loading 
 
Notes. Liposomes were sized by extrusion process using different extrusion pressures, 
and evaluated for entrapped paclitaxel and PSD. For entrapped paclitaxel determination, 
the eluate from gel filtration through Sephadex G-25 was digested with ethanol, and 
quantified by RPHPLC method. Two injections were made for each sample, and the 
average was calculated. Three Sephadex columns were prepared for each extrusion 
pressure. The results indicate the mean ± standard deviation for three gel filtration 
columns. For PSD, the results indicate mean ± standard deviation of three independent 
measurements at extrusion pressure (■ PSD; ▲ Paclitaxel loading). 
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Figure 3-9.  TEM image depicting morphology of Pac-LCL 
 
Notes. The samples were prepared by negative staining with uranyl acetate using 
sequential two drop technique on formvar coated copper grids. The results are shown at a 
magnification of 300,000x. 
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Figure 3-10.  Stability of Pac-LCL dispersion at 5 ± 3ºC 
 
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol (15: 
75: 5: 5) with a total lipid concentration of 100 mM. The liposomes were stored at 5 ± 
3ºC in 2 cc amber vials. Samples were withdrawn at specific intervals. A. For the 
determination of paclitaxel retention, the samples were subjected to minicolumn 
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from 
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and 
quantified by RPHPLC method. The results indicate the mean ± standard deviation for 
three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel retained in the 
liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard deviation 
of three independent measurements (● PSD; ♦ Zeta potential). 
 
 
 
 
 
 
A 
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allowed higher amounts of paclitaxel to be accommodated in the bilayer. Although high 
loading is achieved with these compositions, the entrapped paclitaxel precipitated out of 
the bilayer within few days of storage at 5 ± 3ºC. The influence of drug-lipid ratio on 
drug loading showed that the loading increased with an increase in the drug-lipid ratio. 
But, LCL with a drug-lipid ratio of 1:30 was physically unstable. The short-term stability 
evaluation of liposomes prepared with different drug-lipid ratios demonstrated that 1:60 
as the optimum drug-lipid ratio to achieve a loading of 1-1.3 mg/mL without the risk of 
physical instability. The optimized formulation was stable at 5 ± 3ºC for three months. 
The formulation and process parameters were optimized to achieve a physically stable 
formulation of Pac-LCL that maintains the size, charge, and integrity during storage.  
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CHAPTER 4. DEVELOPMENT OF PACLITAXEL-LOADED RGD 
CONJUGATED GAS-FILLED LIPOSOMES  
 
 
Cancer is a dangerous disease and is the second leading cause of death in United 
States [2, 3]. About 1.5 million new cases of cancer and more than half-a-million deaths 
have been estimated in the United States for the year 2009 [4]. Solid tumors account for 
more than 85 percent of all the cases reported with cancer [5, 6]. Breast cancer is the 
most commonly diagnosed form of solid tumors and is the second leading cause of death 
in western women. About 20-30% women with breast cancers develop metastatic breast 
cancers. Chemotherapy is a form of systemic therapy of solid tumors and is also more 
useful in the treatment of metastatic cancers. The cytotoxic effect of these 
chemotherapeutic agents on cancer cells is highly beneficial for the therapy, but, adverse 
effects were also observed with these agents due to their effect on normal cells.  Thus, 
there is a need for an effective drug delivery system that produces cytotoxic 
concentrations of the drug at the tumor sites without affecting normal tissues.  
 
Paclitaxel is one of the most effective drugs used in chemotherapy of cancer and is a 
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It 
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin 
dimers and stabilizes microtubules by preventing depolymerization. The stability results 
in inhibition of the normal dynamic reorganization of the microtubule network that is 
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel is marketed as 
Taxol® (Bristol-Myers Squibb Company, Princeton, NJ) for the treatment of ovarian, 
breast, non-small cell lung cancers, and AIDS related Kaposi’s sarcoma [249]. Since 
paclitaxel is highly insoluble in water, Taxol® was formulated with ethanol and 
Cremophor®EL. Although the formulation is diluted before use, the concentration of 
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral 
administration, which require pretreatment with antihistamines and corticosteroids [15]. 
In addition, the use of free paclitaxel can affect normal tissues and result in systemic 
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, it is imperative 
to deliver paclitaxel locally to the tumor sites to minimize systemic toxicity.  In addition, 
failure to maintain adequate concentration at the tumor microenvironment could result in 
regrowth of the tumor cells and development of resistance [5]. 
 
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and 
hydrophilic drugs [23]. Encapsulating drugs within the vesicles has the potential 
advantage of higher drug carrying capacity compared to attaching them to single polymer 
chains [250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and 
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced 
efficacy of the treatment [251]. In addition, flexibility in the design of liposomes allows 
tailoring to achieve passive as well as active targeting. The release of drug from these 
liposomes, at the target site, is determined by natural cytosolic mechanisms [23]. It will 
be an added advantage to have a control over drug release and/or uptake at the target site 
so that high cytotoxic concentrations can be achieved. Secondly, the unique nature of 
solid tumors with heterogeneity in vasculature, and high interstitial pressure pose a 
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formidable barrier to drug delivery [19].  Apart from targeting and controlled release, it is 
also necessary to improve permeability at the tumor vasculature. Incorporation of gases 
in the bilayer of liposomes makes them acoustically active [205]. These echogenic 
liposomes have the potential for stress on activation by ultrasound, and eventually release 
the contents at the target site [35]. The disintegration of gas-filled species by contrast 
enhanced ultrasound produces liquid jets that can produce small gaps in the vasculature 
and improve the permeability [36]. Thus, cavitation effect of ultrasound on the echogenic 
liposomes provides a control over drug release, and also enhances drug permeability by 
producing small gaps in the endothelial walls of vasculature [36-39]. This phenomenon 
can be explored for targeted delivery wherein the targeted liposomes maintain basal 
levels of the drug by virtue of cytosolic transport, and by altering intensity of ultrasound, 
high cytotoxic concentrations of the drug can be achieved at the target site.  
 
The size of these echogenic liposomes used for imaging is ~ 800 nm, and would be 
cleared rapidly by the reticuloendothelial system (RES). So, there is a need to control the 
size of these echogenic liposomes to approximately 150-200 nm to minimize clearance 
by the RES. An ideal carrier for therapeutic targeting to solid tumors must have a longer 
circulation time than those used for imaging and should possess targeting capability. In 
vivo circulation time can be increased by reducing the size of liposomes and/or modifying 
the surface with PEG derivatives [28].  Targeting capability can be achieved by attaching 
specific ligands onto the surface of the liposomes. The αvβ3 integrin receptors are highly 
expressed in actively proliferating endothelial cells of tumor vasculature and tumor cells 
[163, 235]. Peptides with Arg-Gly-Asp (RGD) motif in a cyclic framework have been 
shown to bind to these receptors and are effective in targeting solid tumors [172]. By 
attaching RGD peptide to the surface through PEG spacers, these liposomes can be 
targeted to solid tumors. The objective of this work is to develop parenteral echogenic 
RGD conjugated liposomes containing paclitaxel for ultrasound mediated targeted drug 
delivery.  Owing to unique nature of the proposed parenteral dosage form, there is a 
potential to overcome the barriers in cancer chemotherapy. 
 
 
4.1. MATERIALS AND METHODS 
 
 
4.1.1. Materials 
 
Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The 
phospholipids used in this work were all of research grade. Egg phosphatidylcholine 
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from 
Northern Lipids (Burnbay, BC, Canada).  1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) (maleimide DSPE-
PEG2000)  was obtained from Avanti Polar Lipids (Alabaster, AL). Cholesterol, α-
tocopherol, and sucrose were purchased from Sigma (St. Louis, MO). Mannitol was 
obtained from Mallinckrodt Chemicals (Phillipsburg, NJ). Cyclo (Arg-Gly-Asp-D-Phe-
Cys) peptide (cRGD) was obtained from Peptides International (Louisville, KY). 
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Poloxamer 188 was obtained from BASF (Mount Olive, NJ). HPLC grade water, 
acetonitrile, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC 
grade chloroform was purchased from Acros Organics (Morris Plains, NJ). N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) buffer, 1M was obtained 
from Mediatech (Manassas, VA). All other chemicals and reagents were of analytical 
grade and used without further purification or characterization. 
 
 
4.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL) 
 
The Pac-LCL was be prepared by the lipid film hydration-extrusion method using 
EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by dissolving 
paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1 chloroform-methanol. The 
solution obtained was evaporated in a round bottom flask using rotary evaporator under 
reduced pressure at 45°C for 4-6 h. The dry film was hydrated with 50 mM HEPES 
buffer pH 6.5 at 65°C for 45-60 min. The multilamellar vesicles (MLVs) thus obtained 
were sized by extrusion through stacked polycarbonate membrane filters of varying pore 
diameters under high pressure to obtain small unilamellar vesicles (SUVs). The SUVs 
were characterized for particle size distribution, zeta potential, and total and entrapped 
paclitaxel content.  
 
 
4.1.3. Preparation of Paclitaxel-Loaded cRGD Conjugated Targeted Long-
Circulating Liposomes (Pac-RGD-TLCL) 
 
For the preparation of Pac-RGD-TLCL, a part of DSPE-PEG2000 was replaced with 
maleimide DSPE-PEG2000 and the liposomes were prepared as described in section 4.1.2 
to obtain SUVs with reactive maleimide functional groups. The maleimide-Pac-LCL thus 
obtained was conjugated with cRGD peptide by incubation at 25°C for 12 h. Aliquots 
were withdrawn for the determination of conjugation efficiency. The unconjugated 
peptide remaining after the reaction was removed from the liposomes by equilibrium 
dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher 
Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C overnight. The 
conjugation efficiency was determined by quantifying free RGD in the liposomal 
dispersion by reversed phase high performance liquid chromatography (RPHPLC). 
 
 
4.1.4. Determination of Conjugation Efficiency 
 
Conjugation efficiency was determined by an indirect method to quantify the 
unconjugated cRGD peptide. The method was validated by adding different amounts of 
cRGD to the liposomes, and by quantifying unreacted peptide. An increasing amount of 
cRGD was added to a constant volume of maleimide-Pac-LCL. The same amounts were 
also added to Pac-LCL as a control for non-specific binding, and to HEPES buffer pH 
6.5, 50 mM as a negative control. The reaction was performed in triplicates at three 
different amounts of cRGD. After the incubation period for the conjugation reaction, the 
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samples were digested with absolute ethanol, and the free cRGD remaining was 
quantified by RPHPLC method. The gradient elution was performed using 0.05% v/v 
trifluoroacetic acid (TFA) in water (A) and 0.05% v/v TFA in acetonitrile (B) with a 
linear gradient of 10 to 60% B in 25 min at a flow rate of 1 mL/min. The amount of 
cRGD in HEPES buffer was taken as total unbound. The amount of cRGD consumed in 
Pac-LCL was taken as non-specific binding.   The conjugation efficiency was calculated 
from free cRGD remaining in maleimide-Pac-LCL after subtracting the loss due to non-
specific binding. For day to day analysis, a slightly excess of cRGD peptide than required 
for the reaction was added to maleimide-Pac-LCL, Pac-LCL, and HEPES buffer. The 
conjugation efficiency was determined as described above.  
 
 
4.1.5. Preparation of Gas-Filled Pac-LCL (Pac-GFLCL) and Gas-Filled Pac-
RGD-TLCL (Pac-RGD-GFTLCL) 
 
The Pac-LCL or Pac-RGD-TLCL was mixed with equal volume of sucrose solution 
containing poloxamer 188 with or without mannitol. The lyophilization cycle was 
designed based on the glass transition temperature of maximally freeze-concentrated 
amorphous phase (Tg′), determined by differential scanning calorimetry (DSC). 
Lyophilization was carried out using a lab scale Virtis Genesis 25ES lyophilizer (The 
Virtis Company, Gardiner, NY). The primary drying temperature was selected based on 
Tg′ and the mixture was lyophilized in 2 cc glass amber vials.  The moisture content of 
the dry cake was monitored to ensure end point of secondary drying. On completion of 
the drying cycle, the vials were sealed under a partial vacuum.  Perfluoropropane was 
filled in the headspace above the vials at atmospheric pressure to obtain Pac-GFLCL and 
Pac-RGD-GFTLCL. The vesicle size, zeta potential, total and entrapped paclitaxel 
content, and echogenicity were monitored in samples reconstituted with HPLC grade 
water.  The vials were stored at 5 ± 3°C until further use.  
 
 
4.1.6. Thermal Analysis by DSC 
 
The glass transition of maximally freeze concentrated amorphous phase (Tg′) of 
mixture of liposomes and sucrose with or without mannitol was determined by 
differential scanning calorimetry (DSC) using a Q2000 differential scanning calorimeter 
equipped with refrigerated cooling system (TA Instruments, New Castle, DE). About 10-
20 µL of the liposome mixture prior to lyophilization was placed in T-Zero aluminum 
pans and hermetically sealed.  An empty pan prepared in a similar manner was used as 
reference. The samples were equilibrated at 25°C and then cooled at 5°C/min to -70°C.  
After equilibration, the samples were heated at the rate of 10°C/min to 25°C.  
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4.1.7. Characterization of Pac-LCL, Pac-RGD-TLCL, Pac-GFLCL, Pac-RGD-
GFTLCL 
 
The average diameter (Z-avg) of the liposomes was determined using dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped 
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered 
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC 
grade water for the determination of Z-avg. Three independent measurements were 
performed for each sample. Zeta potential was determined from electrophoretic mobility 
using samples suitably diluted with HPLC grade water.  
 
The loading efficiency of paclitaxel in the liposomes was determined by minicolumn 
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus, 
Holliston, MA) similar to the method described by Zhang et al [249] with modifications. 
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and 
was allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C for 
4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to 
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the 
column. The column saturation with placebo liposomes was repeated for a total of three 
times. The gel columns were placed in fresh collection tubes for use with drug-loaded 
liposomes. The Pac-LCL samples were diluted with 50 mM HEPES buffer pH 6.5. About 
100 µL of the diluted sample was added to the gel column, and centrifuged for 4 minutes. 
The gas-filled liposomes were reconstituted with HPLC grade water prior to dilution. The 
eluate in the collection tube, containing only entrapped paclitaxel was analyzed by 
RPHPLC. Paclitaxel in the liposomes before passing through Sephadex G-25 was 
quantified for the total drug content. The HPLC system comprised of Waters 600 
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector 
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was performed 
using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA).  
An isocratic elution was performed using acetonitrile-water in a ratio 55: 45 v/v at a flow 
rate of 1 mL/min, and detection wavelength of 230 nm. The liposomes were digested 
with absolute ethanol, and suitably diluted before injection. The encapsulation efficiency 
was calculated using the formula, Entrapment efficiency = (Entrapped paclitaxel x 
100)/Total paclitaxel). 
 
The moisture content of the lyophilized cake was determined using an Orion AF8 
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was 
calibrated on each day of analysis with a known quantity of water.  About 75 mg of the 
dried sample was weighed accurately and added to the titration vessel. The titration was 
started after allowing one minute for extraction.  
 
Morphology of the liposomes was characterized by transmission electron microscopy 
(TEM) using a negative staining technique. Sequential two droplet method was used for 
staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film 
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM 
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images were acquired using JEOL 2000EX transmission electron microscope (JEOL 
USA, Inc., Peabody, MA) equipped with high resolution digital camera.  
 
 
4.1.8. Determination of Echogenicity 
 
Acoustic activity of Pac-GFLCL and Pac-RGD-GFTLCL was characterized using an 
in vitro method utilizing Phillips ATL HDI-5000 ultrasound system and broadband L12-5 
transducer (Philips Healthcare, Andover, MA). A rectangular plexiglass chamber was 
filled with 15 mL of normal saline (NS). A small magnetic stir bar was placed in the 
chamber to enable uniform mixing. The chamber was then placed on a magnetic stirrer. 
The transducer was positioned such that it has direct contact with NS filled in the tank. 
The images were acquired with a mechanical index setting of 0.1. The Pac-GFLCL was 
reconstituted with HPLC grade water. After acquiring the background image for 5 sec., 
50 µL of the reconstituted liposomal product was injected into the tank with a 1 cc 
syringe, and the images were acquired for one minute. All image sequences were 
analyzed offline using a custom program using MATLAB 7.0.4 software (The 
MathWorks, Inc., Natick, MA). The pixel values in the region of interest (ROI) were 
compared to the pixel values in the background. The number of folds increase in mean 
gray scale value (MGSV) in the ROI over the background was calculated as the measure 
of acoustic activity. For demonstrating the ability to disintegrate the Pac-RGD-GFTLCL, 
VisualSonicsTM Vevo® 2100 ultrasound instrument with MS 200 transducer 
(Visualsonics, Inc., Toronto, Ontario, Canada) was used in contrast mode. A MTV-1 
restrained tail vein infusion catheter (Braintree Scientific, Braintree, MA) was mounted 
in the plexiglass tank such that a portion of the catheter is completely immersed in water 
filled in the tank (Figure 4-1).  The MS 200 transducer was positioned above the catheter 
with water in the tank as interface. The gas-filled liposomes were reconstituted with 
HPLC water, the sample was drawn into a 1 cc syringe, and the syringe was connected to 
the catheter. The sample was slowly injected through the catheter and the liposomes were 
visualized by ultrasound at 12.5 MHz center frequency at 10% power. The flow was 
stopped during the measurement sequence to determine the ability to disintegrate gas-
filled liposomes with ultrasound. A high intensity pulse was applied for a duration of one 
second at 50% of the cine loop sequence. The contrast mean power at the region of 
interest was calculated. 
 
 
4.1.9. In vitro Drug Leakage Study 
 
Paclitaxel leakage from Pac-RGD-GFTLCL was determined by equilibrium dialysis 
of the liposomal dispersion using 10,000 MWCO Slide-A-Lyzer dialysis cassettes 
(Thermo Fisher Scientific, Rockford, IL) against pH 7.4 phosphate buffered saline (PBS) 
containing 0.1 % w/v Tween 80 in a jacketed beaker maintained at 37°C. Samples of 1 
mL were withdrawn at specific intervals for a period of 72 hours, and then 1 mL of fresh 
medium was added to the release vessel for replacement. The samples were analyzed by 
RPHPLC method. The drug released/leaked was evaluated as a function of time. 
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Figure 4-1.  The in vitro model used for demonstrating disintegration of gas-filled 
liposomes 
 
Notes. The apparatus used for demonstrating disintegration of gas-filled liposomes 
consists of a rectangular plexiglass chamber filled with water. A tail vein infusion 
catheter was mounted so that it is immersed in water. The MS 200 transducer was placed 
above the catheter using water as the interface. The reconstituted echogenic liposomes 
were injected through the catheter, viewed and disintegrated by ultrasound. The diagram 
is not drawn to scale. 
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4.1.10. Stability Evaluation of Pac-RGD-GFTLCL 
 
Stability of Pac-RGD-GFTLCL was evaluated for three months. The optimized 
formulation in 2 cc amber glass vials was stored at 5 ± 3ºC for three months. Samples 
were withdrawn at specific intervals and analyzed for total and entrapped paclitaxel, 
entrapment efficiency, PSD, zeta potential, and moisture content.  
 
 
4.2. RESULTS AND DISCUSSION 
 
The optimized composition of paclitaxel-loaded liposomes from chapter 3 was mixed 
with mannitol solutions containing 0.3 % w/v poloxamer 188 and different amounts of 
sucrose, and then lyophilized. The particle size of the liposomes increased to above 400 
nm irrespective of the concentration of sucrose in the formulation. This could be due to 
fusion or aggregation of liposomes during lyophilization. The results were in contrast to 
the optimized formulation obtained for the prototype formulation in chapter 2. The 
possible reasons for the increase in PSD could be the changes in the lipid composition, 
lipid concentration, and inclusion of paclitaxel in the formulation. So, attempts were 
made to lyophilize the formulation with sucrose and poloxamer 188 to determine the 
optimum lipid-sugar ratio for a better control in PSD. Then, mannitol was included in the 
composition to determine its effects on PSD and echogenicity. The optimization of the 
formulation for lyophilization was performed with Pac-LCL, and then Pac-RGD-TLCL 
was used with the optimum composition to prepare Pac-RGD-GFTLCL. Comparisons 
were made between Pac-GFLCL, and Pac-GFTLCL. 
 
 
4.2.1. Effect of Lyoprotectant and the Manufacturing Process on PSD of Pac-
GFLCL 
 
Phospholipids can undergo hydrolysis or oxidation during storage of liposomes in the 
form of dispersion. As a result, the liposomes can aggregate or fuse together resulting in 
an increase in particle size distribution. Freeze drying or lyophilization can prevent 
hydrolysis of phospholipids and physical degradation during storage of the liposomes 
[34]. However, lyophilization process itself can cause loss of encapsulated drug and 
fusion of the vesicles. Interaction of water with hydrophilic phosphate head groups of 
phospholipids plays a key role in the formation of liposomes and hence, removal of water 
presents more challenges. Inclusion of lyoprotectants can help maintain the structure, and 
integrity of liposomes during lyophilization [33]. The effect of different lipid-sugar ratios 
on PSD of Pac-LCL after lyophilization was evaluated with sucrose. The heating profile 
of DSC showed that the Tg′ of these liposome-sucrose mixtures was between -35 to -
39ºC (Figure 4-2). The trend showed that there was a slight increase in the Tg′ with an 
increase in the concentration of sucrose. Figure 4-3 shows the effect of lipid-sugar ratio 
on PSD of the liposomes after lyophilization. The increase in size of liposomes after 
lyophilization was minimized at lipid-sugar ratios below 1:5. Further changes in the ratio 
showed a trend of decrease in size of the liposomes with increasing amounts of sucrose in 
the formulation up to a ratio of 1:7. Additional increases in sucrose concentration did not  
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Figure 4-2.  DSC thermograms showing the effect of lipid-sucrose ratio on Tg′ 
 
Notes. The liposomes were mixed with equal volume of sucrose solution containing 
0.3% w/v poloxamer 188 at different lipid-sucrose ratios. The samples were hermetically 
sealed in aluminum pans, and cooled at the rate of 5°C/min to -70°C. After equilibration 
at -70°C, the samples were heated at the rate of 10°C/min to 25°C. The heating profile is 
shown in the figure. Heat flow is shown on an arbitrary scale. 
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Figure 4-3.  Effect of lipid-sugar ratio on PSD after lyophilization of Pac-LCL 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method. The 
PSD was determined before and after freeze drying in presence of varying lipid-sugar 
ratios with sucrose. The freeze dried paclitaxel-loaded gas-filled liposome samples were 
reconstituted with HPLC grade water for the measurement of PSD. The results indicate 
mean ± standard deviation of three independent measurements (■ Before lyophilization; 
▲ After lyophilization). 
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show any appreciable effect.  The results were consistent with findings in literature on the 
ability of different saccharides to act as cryoprotectants for small unilamellar vesicles 
[220, 221]. The ability of these saccharides to replace water molecules of hydration by 
forming hydrogen bond with the polar phospholipid group, at same binding site as water, 
was suggested as the mechanism for cryoprotection. These reports also suggested that the 
fraction of liposomes unaffected during dehydration was dependant on the sugar to lipid 
molar ratio. The lipid-sugar ratio of 1:7 was selected as optimum for further studies. In 
addition, the lyoprotectants are known to provide better protection to liposomes during 
lyophilization when they are present on both sides of the membrane [33]. The total 
amount of sugar was divided into internal-external ratio and the internal sucrose portion 
was added to the hydration medium during the preparation of liposomes. The external 
sucrose along with poloxamer 188 was mixed with preformed Pac-LCL containing 
different internal amounts of sucrose. The effect of internal-external ratio of sucrose on 
PSD of Pac-LCL before and after lyophilization is presented in Figure 4-4. The 
liposomes prepared with internal sucrose showed minimal increase in size compared to 
those prepared without internal sucrose. This could be attributed to the lyoprotectant 
effect on inner portions of the bilayer. Further increase in concentration of internal 
sucrose did not show any effect as reported in literature [226] suggesting only a small 
fraction of lyoprotectant is required inside the aqueous core of the liposomes. Although 
these gas-filled liposomes were of size 150-200 nm in size, within the target size required 
for drug delivery, a closer observation of the intensity distribution of the average 
diameter showed a secondary peak appearing at approximately 1 µm diameter suggesting 
the process needs to be fine tuned further for a narrow size distribution.  
 
The effect of number of extrusion cycles used in the preparation of Pac-LCL on the 
PSD after lyophilization was evaluated (Figure 4-5). The vesicle size decreased with 
increase in number of extrusion cycles. It was interesting to note that the size after 
lyophilization was almost similar for all the liposomes prepared with different numbers of 
extrusion cycles even though they were of different size before lyophilization. The 
difference between the size before and after lyophilization increased with increasing 
numbers of extrusion cycles. The polydispersity index (PDI), which describes variation in 
the size distribution, showed a trend of increase suggesting that the distribution was 
broader when the number of extrusion cycles was increased. Folds increase in PDI 
increased with increase in the number of extrusion cycles though not significant. One 
extrusion cycle with minimal increase in size and PDI after lyophilization was selected 
for further evaluation. Further attempts were made to minimize the increase in PDI after 
lyophilization. The effect of HEPES buffer, concentration of the buffer, rate of cooling 
during the freezing phase of lyophilization process, and primary drying temperature on 
PSD after lyophilization of Pac-LCL was evaluated. When the primary drying 
temperature was set closer to the Tg′ of the frozen liposome-sucrose mixture, the increase 
in PDI after lyophilization was minimized (Figure 4-6). 
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Figure 4-4.  Effect of inravesicular-extravesicular ratio of sucrose on PSD of Pac-LCL 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method with 
different amounts of intravesicular sucrose. The PSD was determined before and after 
freeze drying in presence of varying extravesicular amounts of sucrose. The freeze dried 
paclitaxel-loaded gas-filled liposome samples were reconstituted with HPLC grade water 
for the measurement of PSD. The results indicate mean ± standard deviation of three 
independent measurements (■ Before lyophilization; ▲After lyophilization). 
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Figure 4-5.  Effect of number of extrusion cycles on the PSD and PDI after 
lyophilization 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method with 
different numbers of extrusion cycles. The PSD was determined before and after freeze 
drying. The freeze dried paclitaxel-loaded gas-filled liposome samples were reconstituted 
with HPLC grade water for the measurement of PSD and PDI. The results indicate mean 
± standard deviation of three independent measurements (■ Particle size before 
lyophilization; ▲Particle size after lyophilization; ● Folds increase in PDI after 
lyophilization). 
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Figure 4-6.  Effect of primary drying temperature on PDI after lyophilization of Pac-
LCL 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method. The 
primary drying of the frozen liposome-sucrose mixture was started at -45ºC or -40ºC. The 
PSD was determined before and after freeze drying. The freeze dried paclitaxel-loaded 
gas-filled liposome samples were reconstituted with HPLC grade water for the 
measurement of PSD and PDI. The results indicate mean ± standard deviation of three 
independent measurements (□ Before lyophilization; ■ After lyophilization). 
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4.2.2. Effect of Mannitol Concentration 
 
Mannitol undergoes crystallization from frozen aqueous solutions during the warming 
phase of freeze drying [237-239]. Crystallization of mannitol has been shown to play a 
critical role in the preparation of echogenic liposomes [206]. The crystallization causes 
rupture in the bilayer of liposomes due to which air/gas is entrapped in the liposomes. 
Mannitol was included in the formulation to evaluate its effect on the PSD and 
echogenicity of paclitaxel-loaded gas-filled liposomes. DSC thermograms showed that 
there was a decrease in Tg′ with an increase in mannitol concentration in liposome-
sucrose mixtures containing poloxamer 188 (Figure 4-7). However, no exothermic peak,  
characteristic of crystallization of mannitol was observed at the concentrations studied. 
This could be due to the presence of high concentrations of non-crystallizing solute 
sucrose in the formulation which minimized the crystallization of mannitol during the 
heating phase. The effect of mannitol on the PSD of Pac-LCL before and after 
lyophilization is presented in Figure 4-8. An increase in mannitol concentration resulted 
in an increase in average diameter of Pac-GFTLCL. Although there was no evidence of 
crystallization of mannitol from the DSC thermograms, inclusion of mannitol played a 
role in determining the particle size after lyophilization. The particle size distribution was 
broader in presence of mannitol as exemplified by an increase in PDI. The examination 
of intensity distribution for PSD revealed that formulations containing mannitol have a 
bimodal distribution with secondary peak appearing at size greater than 1 µm. In contrast, 
a single unimodal distribution was observed in the absence of mannitol. The possible 
reasons for the effect of mannitol on the PSD could be due to the crystallization of 
mannitol which might have occurred at a level that is not perceivable by DSC 
thermograms at the concentrations studied. The effect of crystallization of mannitol 
during warming phase of lyophilization of liposomes is well known. It ruptures the 
bilayer and thereby increases the entrapment of gas in the bilayer resulting in an increase 
in size. Another possibility is that a decrease in the concentration of lyoprotectant sucrose 
in the formulation which was adjusted to accommodate mannitol to maintain a constant 
lipid-sugar ratio. Adequate concentrations of sucrose was not available to provide 
lyoprotectant effect which could have resulted in rupture to the bilayer, increased 
entrapment of gas in the bilayer, and an increase in size.  
 
Ultrasound measurements showed that the formulations containing mannitol were 
more echogenic than the formulations without mannitol (Figure 4-9). The formulations 
prepared with different concentrations of mannitol were comparable with ~50-fold 
increase in reflectivity over background. In the absence of mannitol, ~20 fold increase in 
reflectivity was observed. The echogenicity of the formulation that contained only 
sucrose was similar to that observed with prototype formulation described in Chapter 2 
(Figure 2-7) though only a fourth of the concentration was used. This could be attributed 
to changes in the lipid concentration, lipid composition, and inclusion of a hydrophobic 
drug paclitaxel in the bilayer of the liposomes. Even though the presence of mannitol 
contributes to improve acoustic activity of Pac-GFLCL similar to the formulations 
described in Chapter 2, its presence has a negative impact on PSD and PDI. Mannitol 
containing formulations were slightly larger in size with a broader PDI compared to the 
formulation without mannitol.  Though the echogenicity was lower with the formulation 
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Figure 4-7.  Effect of mannitol concentration on Tg′ 
 
Notes. The liposomes were mixed with equal volume of sucrose solution containing 
0.3% w/v poloxamer 188 and different concentrations of mannitol. The samples were 
hermetically sealed in aluminum pans, and cooled at the rate of 5°C/min to -70°C. After 
equilibration at -70°C, the samples were heated at the rate of 10°C/min to 25°C. A 
segment of heating profile is shown in the figure. The heat flow is shown on an arbitrary 
scale. 
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Figure 4-8.  Effect of mannitol concentration on the PSD and PDI after lyophilization 
 
Notes. The liposomes were prepared by lipid film hydration extrusion method. The 
Pac-LCL was mixed with equal volume of sucrose solution containing 0.3% w/v 
poloxamer 188 at different concentrations of mannitol. The PSD was determined before 
and after freeze drying. The freeze dried paclitaxel-loaded gas-filled liposome samples 
were reconstituted with HPLC grade water for the measurement of PSD and PDI. The 
results indicate mean ± standard deviation of three independent measurements (■ Particle 
size before lyophilization; ▲Particle size after lyophilization; ● Folds increase in PDI 
after lyophilization). 
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Figure 4-9.  Effect of mannitol concentration on echogenicity of Pac-GFLCL 
 
Notes. The echogenicity was determined in an in vitro model with Philips ATL-HDI 
5000 ultrasound system and L12-5 broadband transducer. The Pac-GFLCL samples were 
reconstituted with HPLC grade water for the measurement of echogenicity. After 
acquiring background images for 5 sec., 50 µL of the sample was added using a syringe, 
and the acquisition was continued for up to one minute. The data was processed off-line 
with a custom MATLAB program. Three ROIs were randomly selected, and the average 
increase in mean grayscale intensity in the ROI from the background was calculated. The 
results represent mean ± standard deviation for three samples (Mannitol concentrations 
were ■ 0 mM; ▲ 50 mM; ● 100 mM; ♦ 150 mM). 
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prepared without mannitol, if the acoustic activity is adequate for visualization and 
disintegration, this formulation is expected to have a longer in vivo circulation times due 
to smaller size. On the other hand, if the acoustic activity is not adequate for visualization 
and disintegration, the mannitol containing formulations can be taken forward with a 
slight compromise in their circulation times due to slightly larger size than sucrose 
containing formulations. Although mannitol containing formulations have the potential 
for further development, we took the formulation without mannitol for further studies to 
have better control over the PSD. 
 
 
4.2.3. In vitro Leakage Study with Pac-GFTLCL 
 
The release or leakage profile of the reconstituted Pac-GFTLCL is presented in 
Figure 4-10. An approximately 7% of the encapsulated paclitaxel was released or leaked 
from the Pac-GFTLCL formulation over 72 h period in physiological conditions. These 
results indicate that the amount of free paclitaxel available in the systemic circulation can 
be minimized by loading paclitaxel in the Pac-GFTLCL and therefore, undesirable 
toxicities due to systemic exposure of paclitaxel to normal tissues can be minimized. 
 
 
4.2.4. Conjugation Efficiency of cRGD to Maleimide-Pac-LCL 
 
One of the most stable and most efficient conjugation reactions in chemistry, the 
formation of covalent thioether bond by the reaction between sulfhydryl group and 
maleimide group [172, 242-244] was used for conjugation of cRGD to maleimide DSPE-
PEG2000 present on the surface of preformed liposomes. The method used to determine 
the conjugation efficiency was validated by adding different amounts of cRGD to the 
reaction buffer, Pac-LCL, and maleimide-Pac-LCL. The amount of unreacted cRGD was 
quantified by the RPHPLC method from the samples digested with absolute ethanol. The 
cRGD recovered from the reaction buffer was taken as total unbound. The cRGD 
consumed by the Pac-LCL which does not contain the reactive maleimide functional 
group was taken as non-specific binding. The amount of cRGD consumed by maleimide-
Pac-LCL after subtracting for non-specific binding was taken as the amount conjugated 
to the liposomes. Figure 4-11 shows the amount of cRGD recovered from buffer, Pac-
LCL, and maleimide-Pac-LCL. Almost all of the cRGD added to the reaction buffer was 
recovered after the incubation period. There was a decrease in the amount of cRGD 
recovered from Pac-LCL. This could be attributed to non-specific charge interactions of 
cRGD containing residual positive charge with negatively charged liposomes. The 
nonspecific binding was constant and did not change with an increase in the amount of 
cRGD added to the liposomes suggesting that it can be saturated. Almost all the cRGD 
was consumed in the reaction with maleimide-Pac-LCL when the amount of peptide 
added was equivalent to that is needed for the reaction. The amount consumed in the 
reaction slightly increased with increasing amounts of cRGD added suggesting the 
conjugation efficiency can be increased by adding excess of cRGD peptide. The 
unreacted peptide can be removed after the end of the reaction by equilibrium dialysis or 
ultrafiltration. Further reactions for conjugation were performed at slightly excess of 
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Figure 4-10.  In vitro drug leakage study of Pac-GFLCL 
 
Notes. Pac-GFTLCL was reconstituted with HPLC grade water and 3 mL of the 
reconstituted sample was dialyzed through 10,000 MWCO Slide-A-Lyzer dialysis 
cassettes against pH 7.4 phosphate buffered saline (PBS) containing 0.1 % w/v Tween 80 
in a jacketed beaker maintained at 37°C. Samples of 1 mL were withdrawn at specific 
intervals for a period 72 hours and analyzed by RPHPLC method. The results indicate 
mean ± standard deviation of results from three dialysis cassettes. 
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Figure 4-11.  Verification of conjugation efficiency of cRGD 
 
Notes. An increasing amount of cRGD was added to a constant volume of Pac-
Maleimide LCL, Pac-LCL, and HEPES buffer pH 6.5, 50 mM. The reaction was 
performed in triplicates at three different amounts of cRGD. After the incubation period 
of 12 h. at 25ºC for the conjugation reaction, the samples were digested with absolute 
ethanol, and the free cRGD remaining was quantified by RPHPLC method. The results 
indicate mean ± standard deviation of three reactions (■ Maleimide-Pac-LCL; ▲ Pac-
LCL; ● HEPES buffer pH 6.5, 50 mM). 
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cRGD than required for maleimide-Pac-LCL. The Pac-LCL, and the reaction buffers 
were used as controls for non-specific binding, and total unbound respectively. 
 
 
4.2.5. Characteristics of Pac-RGD-GFTLCL 
 
The Pac-RGD-GFTLCL was prepared using Pac-RGD-TLCL similar to the 
procedure for the preparation of Pac-GFLCL. The amount of entrapped paclitaxel in both 
the formulations after reconstitution was similar, and was approximately 500 µg/mL with  
more than 90% of paclitaxel retained in the liposomes. The particle size of the Pac-RGD-
GFTLCL was also similar to Pac-GFLCL with an average diameter between 150-200 nm 
which is favorable for longer circulation time. These liposomes can escape RES, and also 
benefit from passive targeting due to EPR effect. The zeta potential of Pac-GFLCL and 
Pac-RGD-GFTLCL was -30.80 ± 6.95 and -35.07 ± 1.55 mV respectively. The zeta 
potential values of approximately ~ -30 mV suggest that these vesicles have adequate 
repulsive forces for better colloidal stability. The moisture content of the dried cake was 
less than 1% w/v. The lyophilized cake exhibited acceptable physical properties with 
respect to appearance, cake integrity, cake height vs volume, and ease of reconstitution. 
The TEM images showed that both Pac-GFLCL and Pac-RGD-GFTLCL were spherical 
in structure (Figure 4-12).  
 
 
4.2.6. Visualization and Disintegration of Pac-RGD-GFTLCL with Ultrasound 
 
The ability to visualize and disintegrate the Pac-RGD-GFTLCL with ultrasound was 
evaluated using MTV-1 tail vein infusion catheter mounted in a rectangular plexiglass 
tank filled with water. The effect of high intensity ultrasound pulses on contrast mean 
power in the ROI is shown in Figure 4-13. The Pac-RGD-GFTLCL were visualized with 
ultrasound in the catheter which is about 0.2 mm internal diameter suggesting that these 
gas-filled liposomes can withstand shearing forces in the blood vessels. With a 
continuous flow of the liposomes through the catheter, the disintegration of the gas-filled 
liposomes was not perceivable due to rapid reperfusion in the ROI. So, the flow was 
stopped for the measurement sequence to determine the effect of high intensity 
ultrasound pulses on the Pac-RGD-GFTLCL. The contrast mean power decreased after 
application of ultrasound pulses indicating that these liposomes were disintegrated in the 
ROI. The contrast mean power increased to baseline within few seconds after application 
of high intensity ultrasound pulses due to reperfusion of fresh Pac-RGD-GFTLCL to the 
ROI. Even when the flow was stopped, reperfusion occurred which could be attributed to 
the Brownian motion of these particles of colloidal nature. We also made attempts to 
demonstrate visualization and disintegration of these gas-filled liposomes using 
subcutaneous breast cancer model in mice. We experienced difficulties in visualizing 
these liposomes in vivo. The loss of signal in the animal model could be the result of 
several factors. One reason is the presence of fewer barriers when these gas-filled 
liposomes were tested by an in vitro model in which the signals were received by the 
transducer with no or minimal attenuation. In contrast, the animal model presents several 
barriers that can affect signal to attenuation ratio. The second reason could be the ability  
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Figure 4-12.  TEM images of Pac-GFLCL (A) and Pac-RGD-GFTLCL (B) 
 
Notes. The samples were prepared by negative staining with uranyl acetate using 
sequential two drop technique on formvar coated copper grids. The results are shown at a 
magnification of 300,000x. 
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Figure 4-13.  Disintegration of Pac-RGD-GFTLCL with ultrasound pulses 
 
Notes. The Pac-RGD-GFTLCL was reconstituted with HPLC grade water and drawn 
into 1cc syringe. The syringe was connected to infusion catheter and the sample was 
slowly injected to fill the catheter. A cine loop sequence was started with high intensity 
pulse occurring at 50% of the loop for a duration of 1 sec. The cine loop was processed to 
calculated contrast mean power in the ROI. 
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of the transducer to resolve these nano-sized liposomes. Interference from the tissue can 
make it even more difficult to resolve these liposomes. The third reason could be the 
dilution of these liposomes in the blood stream reducing the concentration available at the 
target site for visualization. The amount of gas present in each liposome, and the number 
of liposomes containing certain amount of gas in a given sample of gas-filled liposomes 
can also affect the average intensity received by the transducer. From the formulation 
development point of view, the liposomal bilayer should have adequate rigidity to retain 
gas in the bilayer in presence of shearing forces and blood pressure experienced in vivo.  
 
The resonant frequency of nano-sized bubbles is in the range of 25-50 MHz [262]. 
But, the theoretical predictions of resonant frequency are based on assumption that the 
bubbles exhibit linear behavior. The predictions of harmonic generation from submicron 
ultrasound contrast agents by Zheng et al shows that the nanobubbles of size ~ 200 nm 
exhibit non-linear behavior at frequencies relevant to clinical ultrasound instruments 
[263]. The same reason also explains the high backscatter obtained in the in vitro 
experiments at clinically relevant frequencies. The question of whether or not these gas-
filled liposomes can be used to produce cavitation induced effect in vivo with clinical 
ultrasound instruments is still debatable. The use of correlation imaging can substantiate 
the data and help in demonstrating cavitation induced effects [264]. Nevertheless, these 
gas filled liposomes can be used for ultrasound mediated drug delivery, because the 
radiation forces can bring these liposomes closer to the cell surface and improve the 
chances of uptake by the cells [265, 266].   
 
 
4.2.7. Stability of Pac-RGD-GFTLCL 
 
The stability of the Pac-RGD-GFTLCL in 2 cc amber vials was evaluated at 5 ± 3ºC 
for three months. The moisture content of the formulation was maintained below 1% w/v 
through the evaluation period. The cake retained acceptable physical properties of 
appearance, and ease of reconstitution. The entrapped paclitaxel content, percent 
paclitaxel retained, PSD, and zeta potential were evaluated in reconstituted samples. The 
stability data is presented in Figure 4-14.  The Pac-RGD-GFTLCL maintained their size, 
charge, and integrity through the evaluation period. Paclitaxel content and percent 
paclitaxel retained in the liposomes was within ± 10% of the initial values suggesting that 
the formulation has adequate stability. 
 
 
4.3. SUMMARY AND CONCLUSIONS 
 
The formulation and process parameters in the development of paclitaxel-loaded gas-
filled liposomes were identified and optimized. The particle size of the paclitaxel-loaded 
liposomes increased more than four-fold after lyophilization. The lipid-sugar ratio played 
a key role in controlling the particle size increase during lyophilization in the preparation 
of Pac-GFLCL, and the optimum lipid-sugar ratio was found to be 1:7. Inclusion of 
mannitol in the formulation caused an increase in PSD, and PDI of the liposomes after 
lyophilization. The mannitol containing Pac-GFLCL formulations showed higher  
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Figure 4-14.  Stability of Pac-RGD-GFTLCL 
 
Notes. The Pac-RGD-GFTLCL was stored at 5 ± 3ºC in 2 cc amber vials. Samples 
were withdrawn at specific intervals, and reconstituted with HPLC water and analyzed. 
A. For the determination of paclitaxel retention, the samples were subjected to 
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. The results indicate the mean ± 
standard deviation for three gel columns (▲ Paclitaxel concentration; ■ Percent 
paclitaxel retained in the liposomes). B. For PSD, and zeta potential, the results indicate 
mean ± standard deviation of three independent measurements. The zeta potential results 
at 15, and 30 days indicate a single measurement (● PSD; ♦ Zeta potential). 
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echogenicity than the formulation without mannitol. In spite of its positive effect on the 
echogenicity, mannitol was excluded from the formulation to have a better control of the  
PSD, and to avoid possible decrease in the in vivo circulation time due to slightly larger 
size. Nevertheless, mannitol containing formulations also have the potential for future 
development for their higher acoustic activity.   
 
We have evaluated an indirect method for determining conjugation efficiency of 
cRGD to preformed liposomes containing reactive maleimide functional groups on the 
surface. The thioether bond is formed readily by covalent conjugation of sulfhydryl group 
and maleimide group. The conjugation can be verified by mass, and nuclear magnetic 
resonance spectroscopic methods in the pure form of the conjugate. But, it is difficult to 
quantify the conjugation efficiency by these direct methods when the peptide is 
conjugated to maleimide functional groups present on the surface of preformed 
liposomes. The RPHPCL method can quantify free cRGD, and so we quantified 
unreacted cRGD as a measure of conjugation efficiency. We have shown that there is 
non-specific binding of cRGD to the liposome surface and it can be saturated. The 
conjugation efficiency of cRGD to maleimide-Pac-LCL increased with an increase in the 
amount of cRGD added in the reaction. Thus, a slightly excess of cRGD than needed for 
the reaction is required to saturate non-specific binding, and to improve conjugation 
efficiency.  
 
The Pac-RGD-GFTLCL was similar to Pac-GFLCL in terms of size, charge, 
echogenicity, and entrapped paclitaxel content. The Pac-RGD-GFTLCL was stable for 
three months at 5 ± 3ºC and maintained size, charge and integrity through the evaluation 
period. The in vitro experiments using mouse tail vein infusion catheter showed that Pac-
RGD-GFTLCL can be visualized by ultrasound, and can be disintegrated with high 
intensity ultrasound pulses. The paclitaxel-loaded gas-filled targeted liposomes has the 
potential for improving the efficacy of the treatment of breast cancer by improving the  
uptake of the liposomes due to improved vascular permeability caused by disintegration 
using high intensity ultrasound pulses. While localized ultrasound pulses can be used for 
improving the therapy of tumors accessible by ultrasound using Pac-RGD-GFTLCL, the 
targeted nature of the liposomes can improve the therapy of tumors metastasized to other 
tissues and organs not accessible by ultrasound. The unique nature of this parenteral 
formulation has the potential to overcome the barriers in chemotherapy of drugs to solid 
tumors. 
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CHAPTER 5. IN VIVO EVALUATION OF BIODISTRIBUTION AND EFFICACY 
OF TUMOR VASCULATURE TARGETED LIPOSOMES AND COMPARISON 
OF EFFICACY WITH TUMOR CELL TARGETED LIPOSMES  
 
 
Cancer is the second leading cause of death in United States [2, 3] with about 1.5 
million new cases and more than half-a-million deaths estimated for the year 2009 [4]. 
Solid tumors account for more than 85 percent of all the cases reported with cancer [5, 6]. 
Breast cancer is the most commonly diagnosed form of solid tumors and is the second 
leading cause of death in western women. About 20-30% women with breast cancers 
develop metastatic breast cancers. Paclitaxel, one of the most effective drugs used in 
chemotherapy of breast cancer, is a natural product isolated from bark of the Pacific Yew 
tree, Taxus brevifolia [8, 9]. It exhibits cytotoxic activity by promoting the assembly of 
microtubules from tubulin dimers and stabilizes microtubules by preventing 
depolymerization. Paclitaxel is marketed as Taxol® and AbraxaneTM as an adjuvant in the 
treatment of node-positive breast cancer or second line treatment of breast cancer after 
failure of combination chemotherapy for metastatic disease or relapse within 6 months of 
adjuvant chemotherapy.  Due to poor aqueous solubility of paclitaxel, Taxol® was 
formulated with ethanol and Cremophor®EL. Although the product is diluted before use, 
the concentration of Cremophor®EL is high enough to cause serious hypersensitivity 
reactions on administration requiring pre-medication with corticosteroids and 
antihistamines [15]. AbraxaneTM, albumin-bound nanoparticle formulation of paclitaxel, 
addressed solvent related adverse effects of Taxol® and eliminated the need for 
premedication with corticosteroids. But, phase III clinical trials in metastatic breast 
cancer patients showed higher rates of sensory neuropathy compared to Taxol® treatment 
[16]. Apart from the toxicity associated with the formulations, administration of free 
paclitaxel itself is associated with systemic toxicities such as myelosuppression, and 
peripheral neuropathy [17]. It is imperative to deliver paclitaxel locally to the tumor sites 
to minimize the exposure of normal tissues with free paclitaxel, and to reduce systemic 
toxicities.  Hence, there is a need for an effective drug delivery system for chemotherapy 
with paclitaxel to produce cytotoxic concentrations of the drug at the tumor sites without 
affecting normal tissues.  
 
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and 
hydrophilic drugs [23]. Encapsulating drugs within vesicles has the potential advantage 
of higher drug carrying capacity compared to attaching them to single polymer chain 
[250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and 
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced 
efficacy of the treatment [251]. The maximum tolerated dose of paclitaxel has been 
shown to increase with the liposomal formulation compared to the administration of 
Taxol® [252]. The liposomal formulation of paclitaxel was also effective in minimizing 
the percent increase in the tumor size of paclitaxel resistant Colon 26 cancer in mice 
[251, 253], suggesting that the development of liposomes can be used a strategy to 
overcome drug resistance in cancer. Conventional liposomes are cleared rapidly by the 
reticuloendothelial system (RES) comprised of Kupffer cells of the liver, and fixed 
macrophages of the spleen [80]. Clearance of liposomes by the RES is directly 
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proportional to the vesicle size [79]. Liposomes of size ~100 nm can escape clearance by 
the RES and remain in circulation for a prolonged period of time. In addition, coating the 
surface of the liposomes with hydrophilic polymers such as PEG can provide a shielding 
effect to the liposomes and prevent recognition and binding of opsonins [88]. Therefore, 
these long-circulating liposomes can escape clearance by the RES and remain in 
circulation for a longer period of time. If the liposomes remain in circulation for a longer 
time, the possibility of their passive accumulation in the tumors by enhanced 
permeability and retention (EPR) effect will be improved.  Such passive targeting of 
liposomes at the tumors does not necessarily elicit an improved therapeutic response 
which is dependent on the cellular uptake of the liposomes. Cellular uptake can be 
improved by an active targeting approach. Active targeting refers to the attachment of 
specific targeting ligands to the therapeutic agent or carrier system to recognize and 
interact with the target receptors or proteins at the cellular or tissue components [20, 107, 
116]. Although similar biodistribution and tumor accumulation is observed with 
liposomes by passive targeting as well as active targeting, an enhanced therapeutic 
response is accomplished with active targeting of liposomes directed against specific 
receptors due to improved cellular uptake [117, 118]. 
 
Endothelial cells within angiogenic blood vessels of solid tumors express several 
proteins which are either absent or expressed at very low levels in well developed normal 
blood vessels [161-163]. The αvβ3 integrin receptors are highly expressed in actively 
proliferating endothelial cells of tumor vasculature and tumor cells [163, 235]. Peptides 
with Arg-Gly-Asp (RGD) motif in a cyclic framework have been shown to bind to these 
receptors and are effective in targeting solid tumors[172]. By attaching RGD peptide to 
the surface of the paclitaxel-loaded liposomes through PEG spacers, paclitaxel can be 
delivered specifically at the tumor site minimizing its exposure to normal tissues. An 
attractive advantage of targeting tumor vasculature is that the tumor blood vessels are 
readily available for targeting than the tumor cells and thus specific targeting can be 
achieved. 
 
Iron (Fe) is required in the active sites of the enzyme ribonucleotide reductase during 
DNA synthesis [138]. Due to redox activity and its potential to generate reactive oxygen 
species (ROS), the amount of free Fe is kept at minimum levels [139]. To control the 
amount of unbound Fe, the metal is transported bound specifically to the two high 
affinity binding sites of serum glycoprotein, transferrin (Tf). The uptake of Fe by the cells 
involves binding of the Fe-loaded Tf to transferrin receptor1 (TfR1) present on the cell 
surface. Binding induces receptor mediated endocytosis of Fe-Tf [140]. TfR1 is a 
glycoprotein expressed in all nucleated cells at low levels [141]. The density of TfR1 on 
the surface of cells is correlated with the extent of cell growth and division, and 
consequently, the tumor cells express more TfR1 than normal cells. Thus, the expression 
of TfR1 is elevated in proliferating cells which makes these receptors excellent choice for 
targeted delivery to cancer [142]. By attaching Tf to the surface of the paclitaxel-loaded 
liposomes through PEG spacers and linkers, paclitaxel can be delivered specifically to the 
tumor cells over expressing TfR1.  
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The objective of this work is to develop paclitaxel-loaded RGD conjugated targeted 
long-circulating liposomes (Pac-RGD-TLCL). The biodistribution of these tumor 
vasculature targeted liposomes was evaluated by non-invasive near infrared fluorescence 
(NIRF) imaging using DiR-loaded RGD conjugated targeted long-circulating liposomes 
(DiR-RGD-TLCL) in mouse xenografts bearing MDA-MB-231 breast cancer. The 
biodistribution was also verified by quantifying paclitaxel in plasma and tumor tissues 24 
hours after the administration of paclitaxel-loaded liposomes. The antitumor efficacy of 
these tumor vasculature targeted liposomes were evaluated in comparison to tumor cell 
targeted paclitaxel-loaded transferrin conjugated targeted long-circulating liposomes 
(Pac-Tf-TLCL). 
 
 
5.1. MATERIALS AND METHODS 
 
 
5.1.1. Materials 
 
Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR) was obtained from 
Molecular Probes (Eugene, OR). The phospholipids used in this work were all of 
research grade. Egg phosphatidylcholine (EPC), hydrogenated soy phosphatidylcholine 
(HSPC) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(poly(ethylene 
glycol)2000) (DSPE-PEG2000) were obtained from Northern Lipids (Burnbay, BC, 
Canada).  1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene 
glycol)2000) (maleimide DSPE-PEG2000) and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(biotinyl poly(ethylene glycol)2000) (biotinyl DSPE-PEG2000)  
were obtained from Avanti Polar Lipids (Alabaster, AL). Cyclo (Arg-Gly-Asp-D-Phe-
Cys) peptide (cRGD) was obtained from Peptides International (Louisville, KY). Biotin 
labeled human transferrin (Tf), cholesterol and α-tocopherol were purchased from Sigma 
(St. Louis, MO). Streptavidin was obtained from PROzyme (Hayward, CA). Dulbecco’s 
Modified Eagle Medium (D-MEM) with high glucose, heat inactivated fetal bovine 
serum (FBS), penicillin-streptomycin (10,000 U/mL Penicillin G, 10,000 µg/mL 
streptomycin), and 0.25% Trypsin EDTA were obtained from Invitrogen (Carlsbad, CA). 
BD MatrigelTM basement membrane matrix was obtained from BD Biosciences (Bedford, 
MA). HPLC grade water, acetonitrile, and methanol were obtained from Fisher Scientific 
(Fair Lawn, NJ). HPLC grade chloroform was purchased from Acros Organics (Morris 
Plains, NJ). All other chemicals and reagents were of analytical grade and used without 
further purification or characterization. 
 
 
5.1.2. Cell Culture 
 
MDA-MB-231 human breast cancer cell lines were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). The cells were cultured in D-MEM 
supplemented with 10% v/v FBS, and 1% v/v antibiotics (100 U/mL of penicillin G and 
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100 µg/mL of streptomycin). The cells were maintained in an incubator at 37ºC in a 
humidified atmosphere, and 5% carbon dioxide. 
 
 
5.1.3. Preparation of Long-Circulating Liposomes Loaded with DiR (DiR LCL) 
or Paclitaxel (Pac-LCL) 
 
The DiR LCL or Pac-LCL was be prepared by the lipid film hydration-extrusion 
method using EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared 
by dissolving DiR or paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1 
chloroform-methanol. The solution obtained was evaporated in a round bottom flask 
using rotary evaporator under reduced pressure at 45°C for 4-6 h. The dry film was 
hydrated with 50 mM HEPES buffer pH 6.5 at 65°C for 45-60 minutes. The 
multilamellar vesicles (MLVs) thus obtained were sized by extrusion through stacked 
polycarbonate membrane filters of varying pore diameters under high pressure to obtain 
small unilamellar vesicles (SUVs). The SUVs were characterized for particle size 
distribution, zeta potential, and total and entrapped DiR or paclitaxel content. DiR was 
quantified by spectrofluorimetry, and paclitaxel was quantified by reversed phase high 
performance chromatography (RPHPLC). The liposomes were sterilized by filtration 
through 0.22 µm membrane filter in an aseptic environment and stored in light protected 
vials at 5 ± 3ºC until further use. 
 
 
5.1.4. Preparation of cRGD Conjugated Targeted Long-Circulating Liposomes 
Loaded with DiR (DiR-RGD-TLCL) or Paclitaxel (Pac-RGD-TLCL) 
 
For the preparation of DiR-RGD-TLCL or Pac-RGD-TLCL, a part (0.5 moles %) of 
DSPE-PEG2000 was replaced with maleimide DSPE-PEG2000 and the liposomes were 
prepared as described in section 5.1.3 to obtain SUVs with reactive maleimide functional 
groups. The maleimide-DiR-LCL or maleimide-Pac-LCL thus obtained was conjugated 
with cRGD peptide by incubation at 25°C for 12 h. The reaction was quenched by the 
addition of 2-mercaptoethanol to block free maleimide. The unconjugated peptide and 2-
mercaptoethanol remaining in reaction mixture were removed from the liposomes by 
equilibrium dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo 
Fisher Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C 
overnight. The liposomes were sterilized by filtration through 0.22 µm membrane filter in 
an aseptic environment and stored in light protected vials at 5 ± 3ºC until further use. 
 
 
5.1.5. Preparation of Paclitaxel-Loaded Transferrin Conjugated Targeted Long-
Circulating Liposomes (Pac-Tf-TLCL) 
 
For the preparation of Pac-Tf-TLCL, a part (0.01 moles %) of DSPE-PEG2000 was 
replaced with biotinylated DSPE-PEG2000 and the liposomes were prepared similar to 
5.1.3 using phosphate buffered saline pH 7.2 (PBS) instead of HEPES buffer. Transferrin 
was non-covalently conjugated to biotin on the distal end of the PEG spacers of the 
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biotinylated SUVs using the procedure established in our laboratory [159]. Briefly, 
streptavidin was dissolved in PBS to prepare a 2 nM solution. To the streptavidin solution 
in a scintillation vial, biotinylated liposomes was added, and mixed. The reaction mixture 
was incubated at 25ºC for 30 min, and the free streptavidin was removed by ultrafiltration 
using Centricon 100 centrifugal filter device (100 KD MWCO, Millipore, Bedford, MA) 
at 5000 g for 30 min to obtain purified streptavidin conjugated long-circulating liposomes 
(SALCL). Biotin labeled human transferrin was dissolved in PBS (2 nM) and added to 
the SALCL, incubated at 25ºC for 30 min, and the free transferrin was removed by 
ultrafiltration. The liposomes were sterilized by filtration through 0.22 µm membrane 
filter in an aseptic environment and stored in light protected vials at 5 ± 3ºC until further 
use. 
 
 
5.1.6. Characterization of Liposomes 
 
The average diameter (Z-avg) of the liposomes was determined using dynamic light 
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped 
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered 
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC 
grade water for the determination of Z-avg. Three independent measurements were 
performed for each sample. Zeta potential was determined from electrophoretic mobility 
using samples suitably diluted with HPLC grade water.  
 
The loading efficiency of DiR or paclitaxel in the liposomes was determined by 
minicolumn centrifugation method using Sephadex G-25 macro spin columns (Harvard 
apparatus, Holliston, MA) similar to the method described by Zhang et al [249] with 
modifications. Briefly, the Sephadex G-25 particles in the column were suspended in 
0.1% w/v TFA and were allowed to swell for 15 minutes. The columns were centrifuged 
at 1500 g at 25°C for 4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, 
Asheville, NC) to remove TFA. About 100 µL of placebo LCL was added and 
centrifuged to saturate the column. The column saturation with placebo liposomes was 
repeated for a total of three times. The gel columns were placed in fresh collection tubes 
for use with drug-loaded liposomes. The liposome samples for analysis were diluted with 
the dispersion medium of the liposomes. About 100 µL of the diluted sample was added 
to the gel column, and centrifuged for 4 minutes. The eluate in the collection tube, 
containing only entrapped DiR or paclitaxel was analyzed by spectrofluorimetry or 
RPHPLC respectively. The total DiR or paclitaxel in the liposomes was determined form 
samples before passing through Sephadex G-25 columns. For quantification of DiR, the 
liposomes were digested with 70% isopropanol and the concentration of DiR was 
determined in 96 well black non transparent microplates by spectrofluorimetry using 
SpectraMax M2e Microplate/Cuvette Reader (Molecular Devices, Sunnyvale, CA) at the 
excitation wavelength of 750 nm and the emission wavelength of 780 nm. For 
quantification of paclitaxel, the liposomes were digested with absolute ethanol, and 
suitably diluted before injection to the HPLC system. The HPLC system comprised of 
Waters 600 Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode 
Array Detector (Waters Corporation, Milford, MA) was used. The RPHPLC analysis was 
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performed using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, 
Milford, MA).  An isocratic elution was performed using acetonitrile-water in a ratio 55: 
45 v/v at a flow rate of 1 mL/min, and detection wavelength of 230 nm. The 
encapsulation efficiency for DiR or paclitaxel was calculated using the formula, 
Entrapment efficiency = (Entrapped DiR or paclitaxel x 100)/Total DiR or paclitaxel). 
 
 
5.1.7. Stability Evaluation of Pac-RGD-TLCL and Pac-Tf-TLCL 
 
Stability of Pac-RGD-LCL and Pac-Tf-TLCL was evaluated in 2 cc amber glass vials 
at 5 ± 3ºC for three months.  Samples were withdrawn at specific intervals and analyzed 
for total and entrapped paclitaxel, entrapment efficiency, PSD, and zeta potential.   
 
 
5.1.8. Breast Cancer Mouse Xenograft Model 
 
The animal studies were conducted in accordance with the protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) of The University of Tennessee 
Health Science Center, Memphis, TN. Female athymic nude mice (Harlan Laboratories, 
Indianapolis, IN) of 5-6 weeks age were used for the development of human breast 
cancer xenograft model. The MDA-MB-231 cells were detached from approximately 
90% confluent cultures by brief exposure to 0.25% trypsin EDTA. The harvested cells 
were washed, and suspended in serum free D-MEM. The cell viability was verified by 
trypan blue dye exclusion method, and the viable cell count was recorded. The cell 
suspension was centrifuged and the cell pellet was resuspended in serum free D-MEM to 
get ~5 x 106 cells in 0.1 mL. The resulting cell suspension was mixed with equal volume 
of cold MatrigelTM and mixed well. The mice were anesthetized with isoflurane prior to 
tumor inoculation, and 0.2 mL of the cell suspension-MatrigelTM mixture was injected 
subcutaneously into the breast tissue of each mouse in the right axillary region. The 
tumor size was measured with calipers twice a week, and the tumor volume was 
calculated using the formula V = 0.5ab2 (V - tumor volume; a - largest diameter; b - 
smallest diameter). 
 
 
5.1.9. Evaluation of Biodistribution of Tumor Vasculature Targeted Liposomes 
by Near Infrared Fluorescence (NIRF) Imaging 
 
To evaluate the localization of the tumor vasculature targeted cRGD conjugated 
liposomes, athymic nude mice bearing MDA-MB-231 breast cancer in the axillary region 
were used. The tumors were allowed to grow up to 200 mm3 to initiate the study. The 
animals were randomly divided into four groups of five mice each. The animals were 
anesthetized with isoflurane, and DiR Solution formulation (Prepared by dissolving DiR 
in 50: 50 Cremophor® ELP and Ethanol, and the resulting formulation was diluted to four 
times with normal saline prior to administration), DiR LCL, and DiR-RGD-TLCL 
containing 5 µg of DiR in ~ 50 µL of the formulation, and normal saline as control was 
injected by retro-orbital injection. The animals were anesthetized with isoflurane and the 
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whole body optical imaging was performed at 1, 4, 8, 24, 48, and 72 h using Xenogen 
IVIS® Lumina imaging system (Caliper LifeSciences, Hopkinton, MA). The excitation 
wavelength was 745 nm and the emission wavelength was 780 nm. The animals were 
maintained under isoflurane anesthesia by Xenogen X91-8 Gas Anesthesia System 
(Caliper LifeSciences, Hopkinton, MA) during the measurement. The fluorescence 
intensity in the region of interest (ROI) was calculated in tumor, peritoneal cavity, and 
flank tissue using Living Image® 3.2 Software (Caliper LifeSciences, Hopkinton, MA). 
The pixel intensity of the dye in tumor was compared to the intensity in the surrounding 
normal tissues as a measure of the concentration in the circulation. Tumor to normal 
tissue (T/N) accumulation ratio was calculated to estimate the tumor targeting index as a 
measure of localization of liposomes in the tumors. The mice were euthanized after 72 
hours. The tumor, liver, and spleen were isolated and the images of the isolated organs 
were acquired. 
 
 
5.1.10. Evaluation of Biodistribution of Paclitaxel from Tumor Vasculature 
Targeted Liposomes 
 
To evaluate the effect of size, and tumor vasculature targeting on biodistribution of 
paclitaxel from liposomes, athymic nude mice bearing MDA-MB-231 breast cancer in 
the axillary region were used. The tumors were allowed to grow up to 200 mm3 to initiate 
the study. The animals were randomly divided into four groups of three mice each. The 
animals were anesthetized with isoflurane, and paclitaxel solution formulation (Prepared 
by dissolving paclitaxel in 50: 50 Cremophor® ELP and Ethanol, and the resulting 
formulation was diluted to four times with normal saline prior to administration), Pac-
LCL (160 nm), and Pac-RGD-TLCL (160 nm), and Pac-RGD-TLCL (80 nm) containing 
at a total paclitaxel dose of 7.5 mg/kg was injected by retro-orbital injection. After 24 h, 
the blood samples were collected by retro-orbital bleeding under anesthesia. The animals 
were euthanized and tumor tissues were collected, washed with normal saline and stored 
at -20ºC until analyzed. Plasma was separated from blood by centrifugation and stored at 
-20ºC until analyzed. The paclitaxel content from the plasma and tumor tissues were 
quantified by the RPHPLC method similar to the method described by Yang et al [260] 
with slight modifications. The paclitaxel from plasma was extracted by vortexing 50 µL 
of plasma with 2 mL of ethyl acetate. The mixture was centrifuged for 5 minutes at 3000 
rpm. The supernatant was collected, and the extraction was repeated with another 2 mL 
of ethyl acetate. The supernatants containing paclitaxel were pooled and evaporated in a 
fume hood to dryness. The residue was dissolved in absolute ethanol, centrifuged for 5 
minutes at 3000 rpm and the supernatant containing paclitaxel was analyzed by the 
RPHPLC method described in 5.1.6. For quantification of tissue paclitaxel, the tumor 
tissues were homogenized in 2 mL of Dulbecco’s phosphate buffered saline (DPBS) 
using Omni International 2000 tissue homogenizer (Omni International, Kennesaw, GA). 
The homogenate was extracted twice with 2-3 mL of ethyl acetate as described for 
plasma samples. The ethyl acetate fractions were combined and evaporated to dryness. 
The residue was dissolved in absolute ethanol, centrifuged for 5 minutes at 3000 rpm and 
the supernatant containing paclitaxel was analyzed by the RPHPLC method described in 
5.1.6. 
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5.1.11. Evaluation of Antitumor Efficacy of Paclitaxel-Loaded Tumor 
Vasculature Targeted Liposomes and Tumor Cell Targeted Liposomes 
 
The antitumor efficacy of tumor vasculature targeted Pac-RGD-TLCL and tumor cell 
targeted Pac-Tf-TLCL was evaluated in athymic nude mice bearing MDA-MB-231 breast 
cancer in the axillary region. The tumors were allowed to grow up to 100-200 mm3 to 
initiate the study. The tumor bearing animals were randomly divided into five groups of 
five mice each. The treatment groups were normal saline (100 µL) as a control to 
evaluate the effect of no treatment, paclitaxel solution formulation (Prepared by 
dissolving paclitaxel in 50: 50 Cremophor® ELP and Ethanol, and the resulting 
formulation was diluted to four times with normal saline prior to administration) to 
evaluate the effect of Taxol® formulation as treatment, Pac-LCL formulation to evaluate 
the effect of passive targeting, Pac-RGD-TLCL to evaluate the effect of tumor 
vasculature targeting, and Pac-Tf-TLCL to evaluate the effect of tumor cell targeting. The 
animals were anesthetized with isoflurane and the formulations were injected by retro-
orbital injection at a paclitaxel dose of 7.5 mg/kg on 8. 11, and 14 days post tumor 
inoculation. The effect on tumor size was monitored for six weeks. The animals were 
euthanized when tumors reached 20 mm in diameter. 
 
 
5.1.12. Statistical Analysis 
 
The statistical analysis was performed by one-way analysis of variance (ANOVA) for 
paclitaxel tissue distribution study, and two-way ANOVA for NIRF imaging study and 
antitumor efficacy study using GraphPad Prism 3.0 Software (GraphPad Software, La 
Jolla, CA). Bonferroni post test analysis was performed to compare between the 
treatment groups. The results with p < 0.05 were accepted as statistically significant. 
 
 
5.2. RESULTS AND DISCUSSION 
 
 
5.2.1. Characterization of the Liposomal Formulations 
 
The characteristics of paclitaxel-loaded liposomal formulations are presented in 
Table 5-1. The paclitaxel loading in these formulations were between 1.0 to 1.2 mg/mL 
with entrapment efficiency greater than 90%. The liposomal paclitaxel concentration thus 
achieved allowed dosing volumes similar to paclitaxel solution formulation (Taxol®) 
which is equivalent to 1.5 mg/mL when diluted with normal saline. The higher 
entrapment efficiency minimizes the amount of free drug in the formulation which will 
help minimize the systemic toxicities associated with the administration of free drug and 
its exposure to normal tissues. The vesicle size of these liposomes was within 100 ± 20 
nm indicating that they can escape clearance by the RES. The PEG coating on the surface 
of these liposomes forms a hydrophilic coating on the surface which can prevent the 
binding of opsonins to the surface and thereby prevent recognition by the RES. Due to 
combined effect of size and PEG coating, these liposomes can remain in circulation 
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Table 5-1.  Characteristics of paclitaxel-loaded liposomes 
 
 
Property of liposomes 
Formulation 
Pac-LCL Pac-RGD-TLCL Pac-Tf-TLCL 
Total paclitaxela (µg/mL) 1249.12 ± 1.16 1165.75 ± 1.89 1153.32 ± 1.91 
Entrapped paclitaxelb (µg/mL) 1153.21 ± 2.41 1073.36 ± 0.65 1085.29 ± 4.42 
Entrapment efficiencyc 92.32 92.07 94.10 
Z-Averaged (nm) 86.40 ± 0.77 91.29 ± 0.19 108.27 ± 0.28 
Zeta Potentiale (mV) -24.17 ± 1.00 -27.87 ± 2.52 -11.53 ± 0.51 
 
aThe liposomes were digested with absolute ethanol and the concentration was 
determined by RPHPLC method. The results indicate mean ± standard deviation of three 
injections. 
 
bThe liposomes were subjected to minicolumn centrifugation in Sephadex G-25 macro 
spin columns to separate free paclitaxel from total paclitaxel. The eluate containing 
entrapped paclitaxel was digested with ethanol, and quantified by RPHPLC method. The 
results indicate mean ± standard deviation of three injections. 
 
cThe entrapment efficiency was calculated from the formula, Entrapment efficiency = 
(Entrapped paclitaxel x 100)/Total paclitaxel. 
 
dThe samples were suitably diluted with HPLC grade water and measurements were 
made using dynamic light scattering method. The results indicate mean ± standard 
deviation of three measurements. 
 
eThe samples were suitably diluted with HPLC grade water and measurements were 
made from electrophoretic mobility. The results indicate mean ± standard deviation of 
three measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
for a longer time.  The leaky nature of the tumor vessels and compromised lymphatic 
drainage together with long circulation property of these liposomes can improve the 
passive uptake of these liposomes in the tumor by the EPR effect. The liposomes have a 
slight negative charge which can improve the colloidal stability.   
 
 
5.2.2. Stability of Paclitaxel-Loaded Targeted Liposomes 
 
The stability of the Pac-RGD-TLCL and Pac-Tf-TLCL dispersions was evaluated at 5 
± 3ºC in light protected container for three months. The stability data presented in 
Figures 5-1 and 5-2 shows that the liposomes maintained their size, charge, and integrity 
through the evaluation period. A similar trend of slight decrease in entrapped paclitaxel 
was observed with both targeted liposomes the first few days. This could be attributed to 
partitioning of the drug form the bilayer of liposomes to the dispersion medium to 
maintain equilibrium. Once the equilibrium is reached, the paclitaxel retention remained 
constant. The conjugation with either cRGD or transferrin did not affect the stability of 
the liposomes. The stability data is consistent with non targeted Pac-LCL formulation 
presented in Chapter 3. 
 
 
5.2.3. Near Infrared Fluorescence Imaging 
 
Near infrared fluorescence (NIRF) imaging is a non-invasive whole body imaging 
technique that can offer valuable information on biodistribution and tumor targeting 
ability [267, 268]. NIRF imaging techniques are cost effective, have high detection 
sensitivity, and use non-ionizing radiation [269, 270]. Imaging performed at the NIR 
region can also minimize auto fluorescent signal of tissue which increases at wavelengths 
less than 600 nm. Inclusion of a fluorescent dye that can be imaged by NIRF imaging in 
the bilayer of liposomes will allow direct visualization of kinetics and localization of the 
liposomes in a non-invasive manner. So, DiR, a lipophilic carbocyanine dye was loaded 
in the bilayer of LCL and RGD-TLCL to evaluate the biodistribution of these liposomes 
in mouse xenografts bearing breast cancer. The DiR-LCL, and DiR-RGD-TLCL were of 
the size 88.30 ± 1.21 nm, and 86.45 ± 0.33 nm respectively. The zeta potential of DiR-
LCL, and DiR-RGD-TLCL were -25.63 ± 0.57 mV, and -26.73 ± 0.76 mV respectively. 
These liposomes were similar to paclitaxel-loaded liposomes in size, charge, and 
composition. The in vivo circulation of these DiR-loaded liposomes are expected to 
represent the fate of paclitaxel-loaded liposomes. Since NIRF imaging is non-invasive in 
nature, localization of the liposomes in the tumor tissues can be determined at several 
time points in the same animal without the need sacrifice the animal. The kinetic data 
thus obtained can be extrapolated to determine the fate of paclitaxel-loaded liposomes 
with the assumption that DiR and paclitaxel-loaded liposomes behave in a similar 
manner. In this study, DiR-loaded liposomal formulations were compared with DiR 
micellar solution formulation as a positive control, and normal saline as a negative 
control. Representative images from each group at different time points are presented in 
Figure 5-3. The DiR solution formulation showed maximum accumulation in the tumor 
within 8 h of administration and the intensity decreased with time till 72 h time point.  
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Figure 5-1.  Stability data for Pac-RGD-TLCL dispersion 
 
Notes. The liposomes were stored at 5 ± 3ºC in 2 cc amber vials. Samples were 
withdrawn at specific intervals and analyzed for paclitaxel retention, PSD, and zeta 
potential. A. For the determination of paclitaxel retention, the samples were subjected to 
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. The results indicate the mean ± 
standard deviation for three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel 
retained in the liposome). B. PSD and zeta potential was determined in samples suitably 
diluted with HPLC grade water. The results indicate mean ± standard deviation of three 
independent measurements (● PSD; ♦ Zeta potential). 
A 
B 
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Figure 5-2.  Stability data for Pac-Tf-TLCL dispersion 
 
Notes. The liposomes were stored at 5 ± 3ºC in 2 cc amber vials. Samples were 
withdrawn at specific intervals and analyzed for paclitaxel retention, PSD, and zeta 
potential. A. For the determination of paclitaxel retention, the samples were subjected to 
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free 
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested 
with ethanol, and quantified by RPHPLC method. The results indicate the mean ± 
standard deviation for three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel 
retained in the liposome). B. PSD and zeta potential was determined in samples suitably 
diluted with HPLC grade water. The results indicate mean ± standard deviation of three 
independent measurements (● PSD; ♦ Zeta potential). 
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Figure 5-3.  Representative NIRF images of localization of DiR formulations in mice 
bearing MDA-MB-231 breast cancer 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 50 µL of normal 
saline (A), 5 µg of DiR in ~ 50 µL of micellar solution formulation (B), or LCL 
formulation (C) or RGD-TLCL formulation (D). NIRF images were acquired at 1, 4, 8, 
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The images from 
representative animal in each treatment group are presented. 
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The liposome formulations showed gradual increase in accumulation in the tumors and 
reached the maximum intensity in 24-48 hours. DiR fluorescent intensity from the 
liposomal formulations in the tumor tissue was observed up to 72 h and was higher 
compared to DiR solution formulation. DiR fluorescence intensity was also higher in the 
abdominal region of the mice which received liposomal formulations. This could be due 
to clearance of the liposomal particles by the Kupffer cells of liver and fixed 
macrophages of spleen. The uptake in the liver and spleen for DiR-RGD-TLCL was 
higher compared to DiR-LCL or DiR solution formulation and was more clearly evident 
in the images acquired with isolated tissues (Figure 5-4).  
 
The fluorescence intensity of DiR was calculated in tumor tissue and normal tissue 
selected as the region of interest. These ROI measurement results can be expressed in 
terms of photon emission from the subject or radiance. The radiance unit of 
photons/sec/cm2/sr is the number of photons per second that leave a square centimeter of 
tissue and radiate into a solid angle of one steradian (sr). The measurement of units of 
radiance takes into account measurement settings like F/stop, binning, and field of view. 
The images acquired in the same session with the same animal with different camera 
settings will produce same signal amplitude because the photon emission of the animal 
remains the same. On the other hand, the fluorescent signal detected from the animal 
depends on the amount of fluorophore present in the animal and the intensity of the 
incident excitation light. But, the excitation light incident on the animal stage is not 
uniform over the field of view. The amount of fluorophore being constant, the 
fluorescence emission image needs to be normalized to incident excitation intensity. The 
user manual for Living Image® 3.2 software (Caliper Life Sciences, Hopkinton, MA) 
suggests that calculating fluorescent image data in terms of efficiency (Efficiency = 
Radiance of the subject/Illumination intensity) can eliminate the variable excitation light 
from the measurement and enable a more quantitative comparison of fluorescent signals. 
Normalizing all the variables in the measurement is important for the kinetic 
measurements because the amount of DiR remaining in the animal can vary with time 
which can be quantitatively monitored even if the measurements were made at different 
camera settings, and differing intensity of light.  
 
The total efficiency data with tumor selected as the region of interest is presented in 
Figure 5-5. The total efficiency for the solution formulation increased steadily up to 8 h 
and then decreased until 72 h. The DiR-LCL formulation showed a biphasic distribution 
with an increase in the initial 4 h of administration, a decrease from 4-8 h, and then a 
steady increase to a maximum in 48 h. The total efficiency in the tumor was maintained 
for 72 h. The DiR-RGD-TLCL formulation also showed similar kinetics but the total 
efficiency was lower compared to DiR-LCL. Bonferroni post test analysis of two-way 
ANOVA showed that all the DiR containing formulations were statistically significant (p 
< 0.01) from normal saline control. At 48 h time point, the total efficiency of DiR-LCL 
was significantly higher (p < 0.001) than DiR-RGD-TLCL, and DiR micellar solution 
formulation. But, the total efficiency of DiR-RGD-TLCL was not significantly different 
from DiR micellar solution formulation. The total efficiency in the flank region to 
represent the concentration of DiR in the circulation is presented in Figure 5-6. The total 
efficiency in the normal tissue decreased with time. The normal tissue accumulation  
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Figure 5-4.  NIRF images of tissues isolated 72 h post injection showing the 
accumulation of DiR in tumor, liver, and spleen 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 5 µg of DiR in ~ 
50 µL of micellar solution formulation or LCL formulation or RGD-TLCL formulation. 
The animals were sacrificed after 72 hours and the tissues were isolated. NIRF images 
were acquired using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The representative images of 
tissues from the animals shown in Figure 5-3 for each of the DiR treatment group are 
shown. 
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Figure 5-5.  Localization of DiR-loaded liposomal formulations in tumor tissue 
calculated from NIRF imaging 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 50 µL of normal 
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL 
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8, 
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was 
calculated in tumor selected as region of interest. The results indicate mean ± SEM of 
ROI measurements from five animals. 
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Figure 5-6.  Localization of DiR formulations in the flank region to represent the 
concentration in the circulation 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 50 µL of normal 
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL 
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8, 
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was 
calculated in flank region to represent normal tissue and the concentration in circulation. 
The results indicate mean ± SEM of ROI measurements from five animals. 
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followed a similar trend as tumor accumulation with lower levels of DiR micellar 
solution formulations from 24-48 hours. DiR-LCL showed higher normal tissue levels 
than DiR-RGD-TLCL at 48 h.  
 
The targeting with cRGD peptide is expected to improve the accumulation of the 
liposomes due to receptor mediated endocytosis. But, the tumor accumulation of DiR-
RGD-TLCL was lower than DiR-LCL in this animal model. The size and charge of these 
two liposomes were similar and should exhibit similar longer circulation properties. 
Thus, the accumulation of Dir-RGD-TLCL should be at least similar to DiR-LCL 
because of passive accumulation of the liposomes at the tumor due to EPR effect. In 
contrast, the presence of RGD peptide on the surface of these targeted liposomes 
increased opsonization and macrophage uptake as shown by their increased accumulation 
in the liver and spleen. The total efficiency in the peritoneal cavity comprised of liver and 
spleen which are the major organs of clearance of liposomes was higher for DiR-RGD-
TLCL compared to DiR-LCL and DiR solution formulation (Figure 5-7). The 
accumulation of DiR-RGD-TLCL in the peritoneal cavity was significantly higher (p < 
0.001) than DiR-LCL at 1, 24, 48, and 72 h imaging time points. Their accumulation was 
also significantly higher (p < 0.001) than DiR solution formulation at all imaging time 
points studied. The DiR-LCL formulation also showed higher accumulation than DiR 
solution formulation at 8 h (p < 0.05), 24 h (p < 0.001), and 48 h (p < 0.01) imaging time 
points. The higher clearance of targeted liposomes resulted in lower blood levels as 
shown by the measurements from normal tissue which in turn lead to a reduced 
accumulation in the tumors. The results were similar to literature report measuring the 
concentration of radio labeled RGD conjugated liposomes in murine C26 colon 
carcinoma model [166]. The RGD conjugated liposomes showed lower blood levels, and 
an increased accumulation in spleen and liver compared to non conjugated liposomes. 
The expression of αvβ3 integrin receptors by the mononuclear cells in the spleen was 
suggested as a mechanism of splenic uptake of these liposomes by phagocytosis. The 
lower accumulation in the tumor could also be due to the limited effect on tumors with 
pre-established vasculature because integrins are not expressed in the interior parts of the 
tumor. 
 
The total efficiency of tumor tissue was compared to the total efficiency on normal 
tissue calculated from the flank as the region of interest. The tumor/normal tissue (T/N) 
ratio was calculated as a measure of tumor targeting index and is presented in Figure 5-8. 
The T/N ratio increased for all the DiR containing formulations to more than 20 within 8 
h of dosing and continued to increase for all the formulations. Even though DiR-LCL 
showed higher accumulation in the tumor compared to DiR-RGD-TLCL, and DiR 
solution formulation, there was no significant difference was observed in the T/N ratio of 
these DiR formulations. It can be explained based on the fact the total efficiency 
decreases in the normal tissue with time due to clearance. The decrease is greater for the 
formulations cleared rapidly from the circulation. Since T/N ratio takes the difference in 
total efficiency between tumor and normal tissue in to the calculation, the absolute 
difference at the extent of accumulation is not taken in to account. Since T/N ratio is a 
relative measure showing the extent of accumulation in the tumor versus normal tissue,  
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Figure 5-7.  Localization of DiR formulations in peritoneal cavity to represent uptake 
in liver and spleen 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 50 µL of normal 
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL 
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8, 
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was 
calculated in peritoneal cavity to represent the uptake in liver and spleen. The results 
indicate mean ± SEM of ROI measurements from five animals. 
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Figure 5-8.  Tumor/normal tissue ratio of DiR formulations calculated from NIRF 
imaging 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 50 µL of normal 
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL 
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8, 
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and 
emission wavelengths of 745 nm and 780 nm respectively. The tumor/normal tissue ratio 
was calculated from the ROI selected for tumor and flank tissue respectively. The results 
indicate mean ± SEM of ROI measurements from five animals. 
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it can only be used as a guide, and the absolute total efficiency needs to be considered for 
comparison between the formulations. 
 
 
5.2.4. Quantification of Paclitaxel from Plasma and Tumor Tissues to Determine 
Biodistribution of Paclitaxel-Loaded Liposomes 
 
The biodistribution was evaluated for paclitaxel micellar solution formulation, Pac-
LCL and Pac-RGD-TLCL in mouse xenografts bearing MDA-MB-231 breast cancer by 
quantifying paclitaxel in plasma and tumor. The size of the liposomal formulation was 
also varied to estimate the effect of size on plasma and tumor levels. The results are 
presented in Figure 5-9. Paclitaxel levels in plasma 24 h after dosing shows that there 
was no significant difference between paclitaxel solution formulation and the liposomal 
formulations of size ~ 160 nm. But, the liposomes of size ~ 80 nm showed significantly 
higher (p < 0.001) plasma levels compared to solution formulation and liposomes of size 
~ 160 nm. The tumor accumulation of ~ 160 nm liposomes was less than solution 
formulation at 24 hours post injection. But the Pac-RGD-TLCL showed significantly 
higher accumulation (p < 0.001) in the tumor compared to paclitaxel solution 
formulation, and Pac-LCL and Pac-RGD-TLCL of ~ 160 nm diameter. These results 
indicate that the effect of conjugation with RGD was not perceivable when the liposome 
size was ~ 160 nm. However, a significant effect of size was observed in plasma levels as 
well as tumor accumulation levels for paclitaxel from liposomes when the size was 
reduced to ~ 80 nm. The results were consistent with NIRF imaging results with similar 
blood levels and tumor accumulation for non-targeted and targeted liposomes at 24 hours 
post injection. 
 
 
5.2.5. Antitumor Efficacy of Tumor Vasculature and Tumor Cell Targeted 
Liposomes 
 
The antitumor efficacy of paclitaxel formulations was evaluated in mouse xenografts 
bearing MDA-MB-231 breast cancer in the axillary region. Tumor vasculature targeted 
RGD conjugated liposomes did not show better accumulation than non-targeted 
liposomes in the biodistribution studies. So, another group of animals was included in the 
antitumor efficacy study to compare the efficacy of these tumor vasculature targeted 
liposomes with tumor cell targeted liposomes. Since TfR1 receptors are expressed by the 
tumor cells, targeting with transferrin attached to the surface of paclitaxel-loaded 
liposomes is expected to improve the efficacy of the treatment by receptor mediated 
endocytosis of the tumor cells. Figure 5-10 shows the effect of different formulations on 
tumor volumes measured twice weekly for six weeks.  The statistical analysis was 
performed using two-way ANOVA with data up to 39 days post tumor inoculation 
because all the animals in normal saline control group reached euthanasia criteria of 
tumor size greater than 2 cm in diameter, and were sacrificed. Bonferroni post test 
comparisons between treatment groups showed that all the paclitaxel treatment groups 
significantly (p < 0.001) reduced tumor volume at 39 days post tumor inoculation 
compared to normal saline control group. The tumor cell targeted Pac-Tf-TLCL showed   
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Figure 5-9.  Biodistribution of paclitaxel formulations in plasma (A), and tumor (B) of 
mouse xenografts bearing MDA-MB-231 breast cancer 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 7.5 mg/kg of 
paclitaxel in solution formulation or Pac-LCL, 160 nm or Pac-RGD-TLCL, 160 nm or 
Pac-RGD-TLCL, 80 nm. Blood samples were collected after 24 hours of dosing. The 
animals were sacrificed and tumor tissues were collected. The concentration of paclitaxel 
in plasma and tumor tissues was determined by the RPHPLC. The results indicate mean ± 
standard deviation of samples from three animals. In A, *** is p < 0.001 for Pac-RGD-
TLCL (~ 80 nm) versus all other formulations. In B, ** is  p < 0.01 for Pac-Solution 
formulation versus Pac-LCL and Pac-RGD-TLCL of size ~ 160 nm, and  *** is p < 0.001 
for Pac-RGD-TLCL (~ 80 nm) versus all the other formulations.  
A 
B 
*** 
*** 
**
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Figure 5-10.  Antitumor efficacy of paclitaxel formulations in mouse xenografts bearing 
MDA-MB-231 breast cancer 
 
 
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in 
the axillary region of female athymic nude mice. The animals received 100 µL of normal 
saline as control (■) or 7.5 mg/kg of paclitaxel in solution formulation (▲) or Pac-LCL 
(●), or Pac-RGD-TLCL (♦) or Pac-Tf-TLCL (▼) on 8, 11, and 14  days post tumor 
inoculation (indicated by arrows). The tumor diameters were measured twice weekly and 
the tumor volume was calculated. The results indicate mean ± SEM of results calculated 
from five animals. 
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highest efficacy in tumor regression and was significantly (p < 0.001) higher than 
paclitaxel solution formulation, Pac-LCL, and Pac-RGD-TLCL. In contrast, the tumor 
vasculature targeted Pac-RGD-TLCL did not show a significant reduction in tumor 
volume compared to paclitaxel solution formulation, and Pac-LCL. The observations in 
the antitumor efficacy study for Pac-RGD-TLCL was similar to the observations from the 
biodistribution studies with NIRF imaging and quantification of paclitaxel from cRGD 
conjugated liposomes. The tumor vasculature targeting with cRGD should have increased 
the localization followed by uptake of paclitaxel by receptor mediated endocytosis. But 
the overall efficacy was similar to non-targeted liposomes. The possible reasons for this 
could be due to higher clearance of cRGD conjugated liposomes by an additional 
mechanism of phagocytosis followed by splenic uptake due to their binding to αvβ3 
integrin receptors expressed by the mononuclear cells in the spleen. So the total number  
of liposomes available for binding to the αvβ3 integrin receptors expressed in the tumor 
vasculature is reduced. Apart from that, well established tumors express αvβ3 integrin 
receptors only on the subset of vessels associated with tumor margin [174]. So, apoptosis 
is induced only to those tumor cells near that margin. Even though, the αvβ3 integrin 
receptors expressed on the tumor vasculature are readily accessible by the liposomes, the 
expression of these receptors is limited only to neovasculature and plays a major limiting 
factor in treating well established tumors. Nevertheless, Pac-RGD-TLCL would prove to 
be an effective strategy for treating metastatic tumors and primary tumors at very early 
stages of development. In contrast to tumor vasculature targeted liposomes, the tumor cell 
targeted Pac-Tf-TLCL was very effective in minimizing the tumor growth rate of breast 
cancer in mouse xenografts. The density of TfR1 on the surface of cells is correlated with 
the extent of cell growth and division, and consequently, the tumor cells express more 
TfR1 than normal cells. In contrast to tumor vasculature targeted liposomes, the targeting 
approach with transferrin to target tumor cells takes advantage of the active process of Fe 
transport to deliver paclitaxel to the tumor cells. Even though the rate limiting step is the 
accumulation of these liposomes in the tumor sites by passive accumulation due to EPR 
effect, the receptor mediated endocytosis by the cancer cells through transferrin is more 
efficient and hence improved efficacy is observed. 
 
 
5.3. SUMMARY AND CONCLUSIONS 
 
The biodistribution of cRGD conjugated paclitaxel-loaded liposomes was evaluated 
in mouse xenografts bearing MDA-MB-231 breast cancer by non-invasive NIRF imaging 
method. The accumulation of DiR-RGD-TLCL in the tumor was comparable to non-
targeted LCL. It was less than DiR-LCL at 48 h time point of imaging. The possible 
reason is the clearance of these targeted liposomes by splenic uptake due to expression of 
integrin receptors by mononuclear cells in spleen. Higher fluorescence intensity was 
observed in the abdominal region of the animals in the liposomal formulation groups 
suggesting the involvement of liver and spleen in clearance. The paclitaxel quantification 
from liposomal formulations also showed a similar trend with paclitaxel-loaded cRGD 
conjugated liposomes and non-targeted liposomes showing comparable accumulation in 
the tumors. The effect of size of the liposomes was evident with smaller sized liposomes 
of size ~ 80 nm showing higher blood levels, and tumor tissue levels compared to 
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liposomes of approximately double the size. These smaller liposomes also showed 
significantly higher blood levels and tumor tissue levels compared to paclitaxel solution 
formulation. The antitumor efficacy study in breast cancer mouse xenograft model 
showed that tumor cell targeted transferrin conjugated paclitaxel-loaded liposomes have 
higher efficacy in minimizing the tumor growth compared to tumor vasculature targeted 
cRGD conjugated paclitaxel-loaded liposomes. The Pac-Tf-TLCL showed higher 
efficacy than paclitaxel solution formulation suggesting the treatment with this 
formulation is superior to the currently approved therapy using Taxol®. Tumor 
vasculature targeting did not produce an appreciable effect compared to non-targeted 
liposomes possibly due to limited expression of integrin receptors in the core of well 
established tumors and due to splenic uptake of the liposomes via integrin receptors 
expressed by mononuclear cells. Even with the enhanced uptake by the spleen, the cRGD 
conjugated liposomes produced comparable effect produced by non-targeted liposomes, 
and paclitaxel solution formulation suggesting that these liposomes have better 
therapeutic potential in cases of metastasis and primary tumors with fast developing 
vasculature wherein the expression of αvβ3 integrin receptors is amplified.   
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CHAPTER 6. LYOPHILIZATION OF PACLITAXEL-LOADED LIPOSOMES 
TO IMPROVE LONG TERM STABILITY 
 
 
Paclitaxel is one of the most effective chemotherapeutic agents used in the treatment 
of solid tumors. It is a natural product obtained from the bark of Pacific Yew tree Taxus 
brevifolia [8, 9].  Paclitaxel, classified under Class IV of Biopharmaceutic Classification 
System (BCS) proposed by Amidon, has poor solubility and permeability [271, 272]. Due 
to its poor aqueous solubility, Taxol® (Bristol-Myers Squibb Company, Princeton, NJ), 
one of the marketed formulation of paclitaxel was formulated with Cremophor®EL and 
ethanol. Although the formulation is diluted before use, the concentration of 
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral 
administration, and require pretreatment with antihistamines and corticosteroids [15]. In 
addition, the use of free paclitaxel can affect normal tissues and result in systemic 
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, newer drug 
delivery systems are sought so that paclitaxel can be delivered locally to the tumor sites 
without affecting normal tissues. Liposomes are biocompatible carriers with ability to 
incorporate both lipophilic and hydrophilic drugs [23]. Encapsulating drugs within 
vesicles has the potential advantage of higher drug carrying capacity compared to 
attaching them to single polymer chain [250]. Preparation of liposomes of paclitaxel can 
alter the pharmacokinetic and pharmacodynamic properties of the free drug and result in 
reduced toxicity and enhanced efficacy of the treatment [251].  
 
Stability of the liposomes in dispersion during storage is a major concern in the 
development of liposomal formulations. Phospholipids from the liposomes can undergo 
hydrolysis and/or oxidation and result in physical degradation when stored as aqueous 
dispersions. As a result, the encapsulated drug tends to leak from the vesicles. Apart from 
leakage, the liposomes can aggregate or fuse together resulting in an increase in particle 
size distribution. The loss of encapsulated drug, and increase in vesicle size during 
storage can affect long-term stability of the product and hinder the drug development 
process. The stability of liposomes can be improved by freezing, lyophilization, spray 
drying, and supercritical fluid technology [29-31]. Lyophilization is one of the preferred 
method to improve long-term stability of liposomes especially those containing 
thermosensitive drugs [32]. It can prevent hydrolysis of phospholipids, and physical 
degradation during storage of the liposomes [34]. By removing water from the liposomal 
dispersion by lyophilization, the structural and permeability properties can be retained 
[33]. Interaction of water with hydrophilic phosphate head groups of phospholipids plays 
a key role in the formation of liposomes and hence, removal of water presents more 
challenges. In addition, the lyophilization process itself can induce physical changes such 
as loss of the encapsulated agent, and an increase in vesicle size [34]. Therefore, careful 
selection and optimization of the formulation and process is necessary to improve the 
long-term stability of paclitaxel-loaded liposomes. 
 
The ability of several carbohydrates to protect liposomes during lyophilization is 
described by ‘water replacement’ hypothesis [208-210] and ‘vitrification’ hypothesis 
[211-213].  This capability to protect liposomes during dehydration originated from the 
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fact that organisms such as brine shrimp cysts and some species of nematodes survive 
dehydration which is related to their capacity to produce nonreducing disaccharide 
trehalose [214, 215, 221]. These anhydrobiotic organisms survive for several years in dry 
state and return to normal metabolic activities on rehydration. Madden et al used this 
analogy to protect the integrity of liposomes with trehalose and other sugars [33]. Next to 
trehalose sucrose is widely used as a lyoprotectant in the development of lyophilized 
liposomal formulations [249, 260, 273]. It is a non-crystallizing solute and remains in the 
amorphous state during the lyophilization process. In this research work, we evaluated 
the effect of sucrose as a lyoprotectant in the development of paclitaxel-loaded long-
circulating liposomes (Pac-LCL). The effect of lipid-sugar ratio, and internal-external 
ratio with sucrose was evaluated for Pac-LCL. The optimized composition was used for 
the lyophilization of cRGD or transferrin conjugated targeted long-circulating liposomes. 
The shelf-life of these formulations was evaluated for three months. 
 
 
6.1. MATERIALS AND METHODS 
 
 
6.1.1. Materials 
 
Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The 
phospholipids used in this work were all of research grade. Egg phosphatidylcholine 
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from 
Northern Lipids (Burnbay, BC, Canada).  1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) (maleimide DSPE-
PEG2000) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(biotinyl poly(ethylene 
glycol)2000) (biotinyl DSPE-PEG2000)  were obtained from Avanti Polar Lipids 
(Alabaster, AL). Cyclo (Arg-Gly-Asp-D-Phe-Cys) peptide (cRGD) was obtained from 
Peptides International (Louisville, KY). Biotin labeled human transferrin (Tf), 
cholesterol, α-tocopherol, and sucrose were purchased from Sigma (St. Louis, MO). 
Streptavidin was obtained from PROzyme (Hayward, CA). HPLC grade water, 
acetonitrile, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC 
grade chloroform was purchased from Acros Organics (Morris Plains, NJ). All other 
chemicals and reagents were of analytical grade and used without further purification or 
characterization. 
 
 
6.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL) 
 
The Pac-LCL was be prepared by the lipid film hydration-extrusion method using 
EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by dissolving 
paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1 chloroform-methanol. The 
solution obtained was evaporated in a round bottom flask using rotary evaporator under 
reduced pressure at 45°C for 4-6 h. The dry film was hydrated with 50 mM HEPES 
buffer pH 6.5 at 65°C for 45-60 minutes. The multilamellar vesicles (MLVs) thus 
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obtained were sized by extrusion through stacked polycarbonate membrane filters of 
varying pore diameters under high pressure to obtain small unilamellar vesicles (SUVs). 
The SUVs were characterized for particle size distribution (PSD), zeta potential, and total 
and entrapped paclitaxel content. The liposomes were stored at 5 ± 3ºC until further use. 
 
 
6.1.3. Determination of Tgʹ 
 
The glass transition of maximally freeze concentrated amorphous phase (Tg′) of 
mixture of liposomes and sucrose was determined by differential scanning calorimetry 
(DSC) using a Q2000 differential scanning calorimeter equipped with refrigerated 
cooling system (TA Instruments, New Castle, DE). About 10-20 µL of the liposome 
mixture prior to lyophilization was placed in T-Zero aluminum pans and hermetically 
sealed.  An empty pan prepared in a similar manner was used as reference. The samples 
were equilibrated at 25°C and then cooled at 5°C/min to -70°C.  After equilibration, the 
samples were heated at the rate of 10°C/min to 25°C.  
 
 
6.1.4. Lyophilization of Pac-LCL 
 
The Pac-LCL was mixed with equal volume of sucrose solution at different lipid-
sugar ratios. The lyophilization cycle was designed based on the glass transition 
temperature of maximally freeze-concentrated amorphous phase (Tg′), determined by 
DSC. Lyophilization was carried out using a lab scale Virtis Genesis 25ES lyophilizer 
(The Virtis Company, Gardiner, NY). The primary drying temperature was selected 
based on Tg′ and the mixture was lyophilized in 2 cc glass amber vials.  The moisture 
content of the dry cake was monitored to ensure end point of secondary drying. The 
vesicle size, zeta potential, and total and entrapped paclitaxel content were monitored in 
samples reconstituted with HPLC grade water.  The vials were stored at 5 ± 3°C until 
further use. The gel to liquid crystalline transition temperature (Tm) of the lipid bilayer 
mixture in the lyophilized formulations was determined by DSC. About 10 mg of the 
lyophilized cake was placed in the aluminum pans. The samples were equilibrated at 
25°C and then heated at the rate of 10°C/min to 75°C, and thermograms were recorded. 
To evaluate the effect of internal-external sucrose ratios, the liposomes were prepared 
with different amounts of sucrose added at the hydration step. The resulting liposomes 
were mixed with sucrose solutions containing different amounts of external sucrose and 
then lyophilized.  
 
 
6.1.5. Characterization of Liposomal Formulations 
 
The PSD (Z-avg) of the liposomes was determined using dynamic light scattering 
using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped with 4.5 
mW diode laser as a source of light operating at 670 nm. Particle scattered photons were 
detected at an angle of 173°. The samples were suitably diluted with HPLC grade water 
for the determination of Z-avg. Three independent measurements were performed for 
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each sample. Zeta potential was determined from electrophoretic mobility using samples 
suitably diluted with HPLC grade water. The lyophilized formulations were reconstituted 
with HPLC grade water prior to measurement of the PSD and zeta potential. 
 
The loading efficiency of paclitaxel in the liposomes was determined by minicolumn 
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus, 
Holliston, MA) similar to the method described by Zhang et al [249] with modifications. 
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and 
were allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C 
for 4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to 
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the 
column. The column saturation with placebo liposomes was repeated for a total of three 
times. The gel columns were placed in fresh collection tubes for use with drug-loaded 
liposomes. The liposome samples were diluted with the dispersion medium of liposomes. 
About 100 µL of the diluted sample was added to the gel column, and centrifuged for 4 
minutes. The lyophilized liposomes were reconstituted with HPLC grade water prior to 
dilution. The eluate in the collection tube, containing only entrapped paclitaxel was 
analyzed by RPHPLC. Paclitaxel in the liposomes before passing through Sephadex G-25 
was quantified for the total drug content. The HPLC system comprised of Waters 600 
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector 
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was performed 
using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA).  
An isocratic elution was performed using acetonitrile-water in a ratio 55: 45 v/v at a flow 
rate of 1 mL/min, and detection wavelength of 230 nm. The liposomes were digested 
with absolute ethanol, and suitably diluted before injection. The entrapment efficiency 
was calculated using the formula, Entrapment efficiency = (Entrapped paclitaxel x 
100)/Total paclitaxel). 
 
The moisture content of the lyophilized cake was determined using an Orion AF8 
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was 
calibrated on each day of analysis with a known quantity of water.  About 75 mg of the 
dried sample was weighed accurately and added to the titration vessel. The titration was 
started after allowing one minute for extraction.  
 
 
6.1.6. Preparation and Lyophilization of Paclitaxel-Loaded cRGD Conjugated 
Targeted Long-Circulating Liposomes (Pac-RGD-TLCL) 
 
For the preparation of Pac-RGD-TLCL, a part (0.5 moles %) of DSPE-PEG2000 was 
replaced with maleimide DSPE-PEG2000 and the liposomes were prepared as described in 
section 6.1.2 to obtain SUVs with reactive maleimide functional groups. The maleimide-
Pac-LCL thus obtained was conjugated with cRGD peptide by incubation at 25°C for 12 
h. The reaction was quenched by the addition of 2-mercaptoethanol to block free 
maleimide. The unconjugated peptide and 2-mercaptoethanol remaining in the reaction 
mixture were removed from the liposomes by equilibrium dialysis through 10,000 
MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, Rockford, IL) 
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against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C overnight. The purified liposomes were 
mixed with sucrose solution and then lyophilized as described in 6.1.4. The liposomes 
were stored at 5 ± 3ºC until further use. 
 
 
6.1.7. Preparation and Lyophilization of Paclitaxel-Loaded Transferrin 
Conjugated Targeted Long-Circulating Liposomes (Pac-Tf-TLCL)  
 
For the preparation of Pac-Tf-TLCL, a part (0.01 moles %) of DSPE-PEG2000 was 
replaced with biotinylated DSPE-PEG2000 and the liposomes were prepared similar to 
6.1.2 using phosphate buffered saline pH 7.2 (PBS) instead of HEPES buffer. Transferrin 
was non-covalently conjugated to biotin on the distal end of the PEG spacers of the 
biotinylated SUVs using the procedure established in our laboratory [159]. Briefly, 
streptavidin was dissolved in PBS to prepare a 2 nM solution. To the streptavidin solution 
in a scintillation vial, biotinylated liposomes was added, and mixed. The reaction mixture 
was incubated at 25ºC for 30 min, and the free streptavidin was removed by ultrafiltration 
using Centricon 100 centrifugal filter device (100 KD MWCO, Millipore, Bedford, MA) 
at 5000 g for 30 min to obtain purified streptavidin conjugated long-circulating liposomes 
(SALCL). Biotin labeled human transferrin was dissolved in PBS (2 nM) and added to 
the SALCL, incubated at 25ºC for 30 min, and the free transferrin was removed by 
ultrafiltration. The purified liposomes were mixed with sucrose solution and then 
lyophilized as described in 6.1.4. The liposomes were stored at 5 ± 3ºC until further use. 
 
 
6.1.8. Stability Evaluation of Lyophilized Formulations of Pac-LCL, Pac-RGD-
TLCL, and Pac-Tf-TLCL 
 
Stability of lyophilized formulations of Pac-LCL, Pac-RGD-TLCL, and Pac-Tf-
TLCL was evaluated for three months. The formulations in 2 cc amber glass vials were 
stored at 5 ± 3ºC for three months, and 25ºC for one month. Samples were withdrawn at 
specific intervals and analyzed for total and entrapped paclitaxel, entrapment efficiency, 
PSD, zeta potential, and moisture content.   
 
 
6.2. RESULTS AND DISCUSSION 
 
 
6.2.1. Effect of Sucrose on Paclitaxel Retention and PSD 
 
The stability of liposomes in dispersion form during storage is a major challenge in 
the development of liposomal formulations. Physical instability results in leakage of 
encapsulated drug, and fusion and/or aggregation with an increase in vesicle size. The 
hydrolysis or oxidation of the phospholipids during storage can be prevented by 
removing water from the liposomes by lyophilization. But, the interaction of water with 
phospholipids plays a key role in the formation of liposomes and its removal creates more 
challenges. Some carbohydrates interact by hydrogen bonding between their –OH group 
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and polar head groups of phospholipids, and protect the liposomes during lyophilization 
[208]. It was shown that hydrogen bonding alters the spacing of the polar head groups 
and thereby decreases van der Waals interactions in the hydrocarbon chains. The net 
effect is improved physical stability of the liposomes. The protection effect was also 
attributed to their ability to replace water molecules normally hydrogen-bonded to the 
polar head groups of lipids [33]. Developments in analytical techniques such as high 
resolution 1H-NMR (nuclear magnetic resonance), Electron spin resonance (ESR) spin 
labeling and DSC studies [220, 221] showed that the mechanism of lyoprotection 
depends on the ability of these saccharides to replace water molecules of hydration by 
forming hydrogen bond with the polar phospholipid group at the same binding sites as 
water. In addition, water crystallizes during the freezing process to form ice crystals. At 
this stage, the vesicles and remaining solute are in a highly concentrated state which can 
induce fusion and aggregation. Inclusion of lyoprotectant can form an amorphous matrix 
around the vesicles and protect the vesicles from fusion and prevent rupture of the 
vesicles due to crystallization of ice. Koster et al showed that vitrification of sugars 
occurs in the intermembrane region, and the resulting glassy state mechanically hinders 
conformational changes of lipid bilayers [212, 227].  
 
Trehalose is the most widely used lyoprotectant in the stabilization of liposomes [208, 
217, 274]. In our preliminary evaluation of trehalose and sucrose as the lyoprotectants for 
liposomes (data not shown), we observed a better control on vesicle size with sucrose 
compared to trehalose. Our observations are in agreement with the results obtained by 
other investigators in the development of paclitaxel-loaded liposomes [249, 273]. In 
addition, Sundaramurthi and Suryanarayanan have demonstrated that trehalose has the 
tendency to undergo crystallization during lyophilization [275].  They suggested that 
partial crystallization occurs with annealing, and can be induced by other crystallizing 
solutes in the formulation such as buffer components. Even if nucleation is induced 
during lyophilization, crystal growth can occur during storage in the presence of residual 
moisture. Since crystallization during lyophilization can affect the integrity of the 
liposomes, we evaluated sucrose, a non-crystallizing solute as a lyoprotectant in the 
development of lyophilized formulation of Pac-LCL.  
 
The lyophilization cycle was designed based on the Tgʹ determined by DSC. The 
heating profiles of mixtures of liposomes containing different concentrations of sucrose 
are shown in Figure 6-1. The Tgʹ of these mixtures containing 50-450 mM of sucrose 
was between -34 to -39ºC. The Tgʹ values decreased with an increase in sucrose 
concentrations up to 100 mM. Further increase in sucrose caused a reverse effect with an 
increase in the transition temperature. For lyophilization cycle, the liposome-sucrose 
mixtures were frozen to -45ºC and held at that temperature for 5 hours. The primary 
drying was started at -40ºC. The product temperature, shelf temperature, and condenser 
temperature were monitored to determine the end point of primary drying. Then the 
temperature was slowly ramped up 10ºC at a time to 20ºC for the secondary drying. The 
end of secondary drying was monitored my measuring the moisture content of the 
lyophilized cake. The physical appearance of the cake, and ease of reconstitution with 
water were monitored as in-process quality control parameters. 
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Figure 6-1.  Effect of sucrose concentration on Tgʹ 
 
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar 
ratios. The samples were hermetically sealed in aluminum pans, and cooled at the rate of 
5°C/min to -70°C. After equilibration at -70°C, the samples were heated at the rate of 
10°C/min to 25°C. The heating profile is shown in the figure. Heat flow is shown on an 
arbitrary scale. 
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The pre-lyophilized liposomes were reconstituted for the determination of paclitaxel 
retention and PSD. Figure 6-2 shows the effect of sucrose concentration on paclitaxel 
retention in the Pac-LCL. Before lyophilization, the amount of free drug was low and the 
percent paclitaxel retained in the liposomes was approximately 90%. When the liposomes 
were lyophilized without sucrose, leakage of paclitaxel was observed with an increase in 
the amount of free drug in the reconstituted dispersion by more than five-fold, and a 
sharp decline in percent paclitaxel retained in the liposomes. The formation of ice crystals 
during lyophilization might have caused rupture to the bilayer and resulted in loss of 
integrity of these liposomes. Secondly, the removal of water molecules which are 
necessary for maintaining the structure of the liposomes without replacing them with 
lyoprotectants might have altered the arrangement of phospholipids in the bilayer 
resulting in loss of integrity. The loss of integrity was restored with increasing 
concentrations of sucrose as lyoprotectant in the formulation. The maximum effect of 
lyoprotection was observed at 250 mM of sucrose corresponding to a lipid-sugar ratio of 
1:5. The free drug content in the reconstituted liposomal dispersion was almost equal to 
that observed before lyophilization suggesting the leakage of paclitaxel was completely 
prevented at that concentration. Further changes in lipid-sugar ratio did not show any 
appreciable effect on paclitaxel retention in the liposomes. These results suggest that 
sucrose at the lipid-sugar ratios equal to or below 1:5 efficiently replaced water 
molecules hydrogen bonded to the phospholipids of the bilayer and helped to maintain 
the integrity of paclitaxel-loaded liposomes during lyophilization.  
 
The gel to liquid crystalline transition temperature also plays a key role in 
maintaining the integrity of the liposomes during dehydration and rehydration [217]. The 
phospholipids in the rehydrated form remain in liquid crystalline state. If the 
phospholipids in the dehydrated state remain in gel phase at room temperature, the 
conversion from gel to liquid crystalline state occurs. The liposomes are prone to leak 
encapsulated contents during this transition. Lyoprotectants reduce the Tm of the 
phospholipids in the bilayer on lyophilization. If such reduction brings the Tm below 
room temperature, the dehydrated liposomes stay at liquid crystalline temperature and 
rehydration will not result in the transition, and thus leakage of the encapsulated drug can 
be avoided. The effect of sucrose on Tm of the phospholipids of the bilayer of Pac-LCL is 
shown in Figure 6-3. The DSC thermograms obtained from the lyophilized samples 
shows that there is a decrease in the Tm of the phospholipids with an increase in the 
concentration of sucrose. But, the Tm of the formulations containing 250 mM sucrose was 
above room temperature suggesting that the phospholipids in the bilayer of Pac-LCL at 
room temperature will remain in the gel state and a transition during rehydration is 
inevitable. It is interesting to note that paclitaxel is a lipophilic drug and for 
thermodynamic reasons will stay within the lipophilic bilayers unless forced/precipitated 
out of the liposomes. On the other hand, the transition temperature will play a key role on 
the retention of hydrophilic drugs in the liposomes because these drugs can easily leak 
out of the liposomes if the integrity of the bilayer is compromised during the transition. 
Nevertheless, the change in Tm indicates that there is a direct interaction between the 
phospholipid head groups and sucrose which is responsible for lyoprotection.  
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Figure 6-2.  Effect of sucrose concentration on the effect of paclitaxel retention in the 
liposomes during lyophilization 
 
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar 
ratios and then lyophilized. The paclitaxel retained in the liposomes was determined 
before and after lyophilization. The lyophilized formulations were reconstituted with 
HPLC grade water for the determination of paclitaxel retention. For the determination of 
paclitaxel retention, the liposomes were subjected to minicolumn centrifugation in 
Sephadex G-25 macro spin columns to separate free paclitaxel from total paclitaxel. The 
eluate containing entrapped paclitaxel was digested with ethanol, and quantified by 
RPHPLC method. Free paclitaxel was calculated by subtracting entrapped paclitaxel 
from the total paclitaxel content quantified from samples before gel filtration. The results 
indicate the mean ± standard deviation of three injections (▲ Paclitaxel retained in the 
liposomes; ■ Percent paclitaxel retained in the liposomes; ● Free paclitaxel in the 
dispersion). 
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Figure 6-3.  Effect of sucrose concentration on Tm of the lipids in the bilayer 
 
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar 
ratios and then lyophilized. About 10 mg of the lyophilized cake was placed in T-zero 
aluminum pans. The samples were equilibrated at 25°C and then heated at the rate of 
10°C/min to 75°C. The resulting thermograms are shown in the figure. Heat flow is 
shown on an arbitrary scale. 
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The effect of lyoprotectant sucrose on the PSD of reconstituted liposomal dispersions 
compared to their PSD before lyophilization is presented in Figure 6-4. The particle size 
increased to almost seven-fold for the liposomes lyophilized without lyoprotectant 
sucrose suggesting that fusion and aggregation of liposomes occurred during 
lyophilization. The PSD results showed higher variability and a polydispersity index 
(PDI) of 0.726 ± 0.275. The addition of sucrose in the formulation for lyophilization 
minimized this increase in size with increasing concentrations of sucrose. Similar to the 
observations with paclitaxel retention in the reconstituted liposomal dispersion, the 
maximum effect of lyoprotectant was observed at sucrose concentration of 250 mM 
corresponding to the lipid-sugar ratio of 1:5. The vesicle size after lyophilization was 
slightly higher than the liposomes prior to lyophilization. The particle size distribution 
was unimodal with a PDI of 0.250 ± 0.011. Further decrease in the lipid to sugar ratio did 
not produce any appreciable effect on the PSD. Similar to the effect on integrity of the 
liposomes to prevent leakage, sucrose worked as an efficient lyoprotectant to minimize 
fusion and aggregation of liposomes and thereby minimized the increase in size after 
lyophilization.  
 
The effect of lyoprotectant is maximum when it is present on both internal and 
external portions of the bilayer [33]. The sucrose concentration of 350 mM corresponding 
to a lipid-sugar ratio of 1:7 was selected for further evaluation of internal to external ratio 
of sucrose. When the total 350 mM of sucrose is divided in to 1:6 or 2:5 in the internal-
external part of the bilayer, there would be enough sucrose (at least 250 mM) available in 
the external portion of the bilayer of liposomes to provide maximum lyoprotectant effect. 
The effect of internal-external ratio of sucrose on the PSD of the reconstituted liposomal 
dispersions compared to their PSD before lyophilization is shown in Figure 6-5. 
Inclusion of sucrose in the internal portion of the bilayer provided additional protection to 
the Pac-LCL during lyophilization as evidenced by the decrease in size of the 
reconstituted liposomal dispersions with an increase in internal sucrose. The internal to 
external-external sucrose ratio was not decreased further because the minimum required 
amount of external sucrose of 250 mM cannot be obtained with a total sucrose 
concentration of 350 mM. In addition, literature reports support the use of only a small 
fraction of lyoprotectant in the internal portion of the bilayer since the use of higher 
amounts of internal lyoprotectant has no effect on apparent stability of the liposomes 
[226, 232]. The internal-external sucrose ratio of 2:5 was selected as optimum with a total 
sucrose concentration of 350 mM corresponding to a lipid-sugar ratio of 1:7 was selected 
as optimum for further development. 
 
 
6.2.2. Development of Lyophilized Targeted Liposomes 
 
The optimized composition for lyophilization was used for the preparation of 
lyophilized targeted liposomes. The optimum sucrose concentration of 350 mM with an 
internal-external ratio of 2:5 provided adequate protection for Pac-RGD-TLCL, and Pac- 
Tf-TLCL during lyophilization. The presence of either cRGD or transferrin on the 
surface of the liposomes did not affect the drug retention or size during lyophilization. 
Similar to Pac-LCL, a slight but insignificant increase in vesicle size was observed with 
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Figure 6-4.  Effect of sucrose concentration on PSD of paclitaxel-loaded liposomes 
during lyophilization 
 
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar 
ratios and then lyophilized. The PSD of the liposomes was determined using dynamic 
light scattering. The lyophilized formulations were reconstituted with HPLC grade water 
for the determination of PSD. The results indicate mean ± standard deviation of three 
independent measurements (■ PSD before lyophilization; ▲ PSD after lyophilization 
determined from reconstituted samples). 
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Figure 6-5.  Effect of internal-external ratio of sucrose on PSD during lyophilization 
 
Notes. The liposomes were prepared with different internal sucrose concentrations 
added at the hydration step and then mixed with sucrose solution to produce different 
internal-external sucrose ratios. The PSD of the liposomes was determined using dynamic 
light scattering. The lyophilized formulations were reconstituted with HPLC grade water 
for the determination of PSD. The results indicate mean ± standard deviation of three 
independent measurements (■ PSD before lyophilization; ▲ PSD after lyophilization 
determined from reconstituted samples). 
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the reconstituted samples of targeted liposomes compared to their size before 
lyophilization. The paclitaxel retention was unaffected at the sucrose ratio used in the 
preparation of lyophilized Pac-RGD-TLCL and Pac-Tf-TLCL. The moisture content of 
the lyophilized cake was less than 1% w/v.  
 
 
6.2.3. Stability of Lyophilized Pac-LCL, Pac-RGD-TLCL, and Pac-Tf-TLCL 
 
The stability of the lyophilized formulations of Pac-LCL, Pac-RGD-TLCL, and Pac-
Tf-TLCL were evaluated in 2 cc amber vials at 5 ± 3°C for three months and 25°C for 1 
month. The stability data for lyophilized Pac-LCL is presented in Figure 6-6. The 
moisture content of the lyophilized cake was maintained below 1% w/v through the 
testing period. The paclitaxel retained in the liposomes and percent retained were within 
acceptable limit of 10% of initial at both the temperature conditions. The particle size and 
zeta potential were not affected at 5 ± 3°C, but an appreciable increase in size was 
observed at 25ºC suggesting that these liposomes undergo fusion or aggregation at room 
temperature. Nevertheless, the Pac-LCL maintained its size, charge, and integrity through 
the evaluation period when stored at refrigerated conditions. The stability data for Pac-
RGD-TLCL and Pac-Tf-TLCL is presented in Figure 6-7 and Figure 6-8 respectively. 
These targeted liposomes also exhibited a similar behavior in the stability as Pac-LCL. 
These targeted liposomes maintained integrity at 5 ± 3ºC as well as 25ºC. An increase in 
size of approximately 20 - 40 nm was observed with both the targeted liposomes within 
one month of storage at 25ºC but there was no significant change in size or charge at 
refrigerated conditions. The stability data suggests that Pac-LCL, Pac-RGD-TLCL, and 
Pac-Tf-TLCL lyophilized formulation must be stored at 5 ± 3ºC for a better shelf-life 
without any compromise on particle size distribution 
 
 
6.3. SUMMARY AND CONCLUSIONS 
 
The liposomal formulations containing paclitaxel were lyophilized to improve long-
term stability during storage. The Pac-LCL lyophilized without any lyoprotectant showed 
a loss of integrity resulting in high concentration of free paclitaxel in the dispersion. 
Sucrose was used as a lyoprotectant to stabilize the liposomes during lyophilization. The 
optimum concentration of sucrose to minimize paclitaxel leakage was found to be 250 
mM corresponding to a lipid-sucrose ratio of 1:5. Further increase in the concentration of 
sucrose in the formulation did not produce any appreciable effect on paclitaxel retention. 
A similar effect as in paclitaxel retention was observed with particle size distribution of 
liposomes lyophilized in presence of different concentrations of sucrose. When the 
liposomes were lyophilized without sucrose the particle size increased to above 700 nm. 
Increasing concentrations of sucrose minimized this increase in size. A sucrose 
concentration of 250 mM provided adequate protection to the liposomes during 
lyophilization and minimized fusion and aggregation.  To evaluate the internal-external 
ratio of sucrose, 350 mM of sucrose was used and internal-external ratios of 0:1, 1:6, and 
2:5 were studied. The additional protection to the inner portion of the bilayer further 
minimized the particle size increase after lyophilization. Since only a small fraction of 
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Figure 6-6.  Stability of lyophilized Pac-LCL formulation 
 
Notes. The Pac-LCL was stored at 5 ± 3ºC (solid symbols) and 25°C (open symbols) 
in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted with 
HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For the 
determination of paclitaxel retention, the samples were subjected to minicolumn 
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from 
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and 
quantified by RPHPLC method. The results indicate the mean ± standard deviation for 
three injections (▲ Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in 
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard 
deviation of three independent measurements (● PSD; ♦ Zeta potential). 
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Figure 6-7.  Stability of lyophilized Pac-RGD-TLCL 
 
Notes. The Pac-RGD-TLCL was stored at 5 ± 3ºC (solid symbols) and 25°C (open 
symbols) in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted 
with HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For 
the determination of paclitaxel retention, the samples were subjected to minicolumn 
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from 
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and 
quantified by RPHPLC method. The results indicate the mean ± standard deviation for 
three injections (▲Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in 
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard 
deviation of three independent measurements (● PSD; ♦ Zeta potential). 
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Figure 6-8.  Stability of lyophilized Pac-Tf-TLCL 
 
Notes. The Pac-Tf-TLCL stored at 5 ± 3ºC (solid symbols) and 25°C (open symbols) 
in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted with 
HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For the 
determination of paclitaxel retention, the samples were subjected to minicolumn 
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from 
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and 
quantified by RPHPLC method. The results indicate the mean ± standard deviation for 
three injections (▲Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in 
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard 
deviation of three independent measurements (● PSD; ♦ Zeta potential). 
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internal sucrose is necessary for the lyoprotection the internal-external ratio of 2:5 was 
selected as optimum. The composition for lyophilization was optimized for Pac-LCL and 
the optimum composition was used in the lyophilization of Pac-RGD-TLCL, and Pac-Tf-
TLCL. The presence of targeting ligands on the surface of these targeted liposomes did 
not affect the integrity, size, and charge and were similar to Pac-LCL. The stability data 
showed that these liposomes were stable in refrigerated condition for three months. The 
particle size increased by 20-40 nm in the samples stored at 25ºC suggesting that these 
liposomes undergo fusion and aggregation at room temperature. The freeze dried cake 
maintained its appearance and the moisture content was within acceptable limits through 
the testing period. The paclitaxel retention, particle size, and zeta potential were 
maintained within acceptable limits for three months in refrigerated conditions. A stable 
lyophilized formulation was developed for paclitaxel-loaded long-circulating liposomes 
and targeted long-circulating liposomes. 
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CHAPTER 7. SUMMARY AND CONCLUSIONS 
 
 
Breast cancer is a serious health care concern affecting nearly 200,000 women a year 
in the United States.  Paclitaxel is one of the most effective drugs used in the treatment of 
breast cancer but it has drawbacks of serious adverse effects due to formulation 
components or due to exposure of normal tissues to free drug. Therefore, an effective 
drug delivery system that can deliver paclitaxel locally at the tumor sites following 
intravenous administration without affecting normal tissues was sought. Liposomes are 
attractive choice for this purpose because they are biocompatible in nature, and can 
accommodate drugs of hydrophilic or lipophilic nature. In addition, the flexibility in 
design allows surface modifications to improve in vivo circulation times, and for 
targeting. Passive targeting approach with liposomes can take advantage of the leaky 
nature of the tumors for selective accumulation. Combination of passive targeting 
approach with an active targeting approach with selective targeting ligands to improve 
the cellular uptake of the liposomes at the tumor sites can have a significant impact on 
overall effectiveness of the therapy.  The objective of this dissertation work was to 
develop and evaluate paclitaxel-loaded targeted long-circulating liposomal formulations 
for drug delivery to breast cancer. In addition to targeted therapy, attempts were made to 
develop ultrasound active liposomes that can be visualized by ultrasound and 
disintegrated with high intensity ultrasound pulses. Ultrasound destruction mediated 
release, and improved vascular permeability is also expected to improve the effectiveness 
of the therapy. 
 
A prototype formulation of cRGD conjugated echogenic liposomes was developed to 
target αvβ3 integrin receptors over expressed in actively proliferating cells of the tumor 
vasculature. Perfluoropropane, a lipophilic gas commonly used in ultrasound contrast 
agents was filled into the bilayer of liposomes by freeze drying gas entrapment method in 
presence of mannitol. Mannitol undergoes crystallization during the warming phase of 
lyophilization and induces rupture of the bilayer through which gas penetrates the bilayer 
of liposomes. This process results in an increase in size of the liposomes to ~800 nm 
which makes it unsuitable for drug delivery applications. So, attempts were made to 
control the size of these liposomes to 150-200 nm by controlling the crystallization of 
mannitol. The use of non-crystallizing solute sucrose at a mannitol-sucrose ratio of 4:3 
minimized the crystallization of mannitol and thereby minimized the increase in size of 
these echogenic liposomes during lyophilization. Although, surfactant poloxamer 188 did 
not show any effect on crystallization, its use at concentrations above 0.05% w/v 
minimized the increase in size after lyophilization due to monolayer coating and steric 
effects on the surface. The echogenic formulations containing mannitol alone showed 
more than two-fold higher echogenicity compared the formulations containing mannitol 
and sucrose. The attachment of cRGD to the surface of the liposomes through PEG 
spacer did not affect size, charge or echogenicity of the formulation. The optimized 
formulation with a size of ~ 150 nm, and a zeta potential of ~ -30 mV was used as a 
platform for the development of paclitaxel-loaded echogenic liposomes. 
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Paclitaxel loading in the bilayer of liposomes and retention of the encapsulated drug 
in the bilayer is important to achieve long term stability of the liposomes. The liposomal 
formulation used in the preparation of prototype formulation was optimized to increase 
paclitaxel loading. Cholesterol content showed a significant negative influence on 
paclitaxel loading with highest loading achieved at 5 moles %. Saturated lipid content 
also showed a negative effect on paclitaxel loading. A HSPC-EPC ratio of 1:5 was 
selected as an optimum ratio. Total lipid concentration showed proportionate increase in 
loading with an increasing lipid concentration. A total lipid concentration of 100 mM was 
used in the optimized formulation. Drug-lipid ratio also showed a proportionate increase 
in loading with an increase in the amount of paclitaxel. But, paclitaxel precipitated out of 
formulations with higher amounts of paclitaxel. Short-term stability studies with different 
ratios showed that the drug-lipid ratio of 1:60 was optimum for adequate physical 
stability of these long-circulating liposomes. The optimized formulation with paclitaxel 
loading of ~ 1.2 mg/mL and a size of 100 ± 20 nm maintained its integrity, size and 
charge at 5 ± 3ºC for three months. 
 
The optimized paclitaxel-loaded long-circulating liposomes was used for the 
preparation of echogenic liposomes. When these liposomes were lyophilized in presence 
of mannitol-sucrose ratio of 4:3, and a poloxamer concentration of 0.15% w/v, optimized 
composition from the prototype formulation, the size of the liposomes increased by more 
than four-fold suggesting further optimization is necessary. So attempts were made to 
minimize the increase in size with different lipid-sugar ratios with sucrose alone in 
presence of poloxamer. A decrease in lipid-sugar ratio minimized the increase in size up 
to the ratio 1:7, and further decrease did not show any influence. The inclusion of sucrose 
in the internal portion of the bilayer at an internal-external ratio of 1:6 helped minimizing 
the increase in size due to lyoprotection of the internal portion of the bilayer. Number of 
cycles used in the preparation of liposomes showed an influence on the PDI of the 
liposomes after lyophilization. The change in PDI after lyophilization was lower in 
liposomes prepared with one extrusion cycle. Mannitol was introduced in the formulation 
at the concentration of 50, 100, and 150 mM to evaluate its influence on size and 
echogenicity of these liposomes. As expected, an increase in mannitol concentration 
caused an increase in size and PDI. The in vitro echogenicity evaluation showed that all 
the formulations containing mannitol showed ~ 50-fold increase in MGSV compared to 
background. The formulation that contained sucrose alone also showed ~ 20-fold increase 
in MGSV. Although mannitol containing formulations showed higher echogenicity, 
mannitol was excluded from the formulations to have better control on size and PDI. The 
cRGD peptide was conjugated to the surface of these liposomes through PEG spacers. 
These paclitaxel-loaded targeted echogenic liposomes of size 150-200 nm with a 
paclitaxel loading of ~ 500 µg/mL was stable at 5 ± 3ºC for three months. The ability to 
disintegrate these echogenic liposomes with ultrasound pulses was evaluated by an in 
vitro method using mouse tail vein infusion catheter immersed in water filled in a 
plexiglass tank. The decrease in contrast mean power at the ROI showed that these 
echogenic liposomes can be disintegrated with high intensity ultrasound pulses. These 
targeted echogenic liposomes containing paclitaxel has the potential for improving the 
outcome of therapy of breast cancer and other solid tumors. Attempts were made to 
establish an in vivo animal model for the evaluation of these paclitaxel-loaded echogenic 
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liposomes. Difficulties were experienced in visualizing these echogenic liposomes in the 
mouse xenograft model, which require further investigation. So, the gas-filled long-
circulating liposomes were not used further for the in vivo experiments. 
 
The biodistribution of cRGD conjugated liposomes was evaluated in mouse 
xenografts bearing MDA-MB-231 breast cancer by NIRF imaging with liposomes 
containing a fluorescent dye DiR. The results showed that the accumulation of DiR-
RGD-TLCL was lower than DiR-LCL, and slightly higher but not significantly different 
than DiR solution formulation. The total efficiency for the ROI measurements in the 
peritoneal cavity of the animals treated with DiR-RGD-TLCL was significantly higher 
compared to non targeted liposomes suggesting these targeted liposomes are cleared 
rapidly by the RES comprised of Kupffer cells of the liver and fixed macrophages of the 
spleen. The higher accumulation in the spleen was due to the expression of αvβ3 integrin 
receptors by the mononuclear cells of spleen. Quantification of paclitaxel in the tumor 
tissues after 24 hours of intravenous administration showed a comparable accumulation 
of Pac-RGD-TLCL and Pac-LCL for a size ~ 160 nm. But, the accumulation was less 
than that of the solution formulation. A decrease in size to ~ 80 nm showed a 
significantly higher blood levels and tumor accumulation emphasizing the importance of 
the size of these liposomes in tumor accumulation of paclitaxel. The antitumor efficacy of 
these tumor vasculature targeted liposomes was compared with tumor cell targeted 
liposomes using transferrin directed against TfR1 receptors over expressed by the tumor 
cells. The results showed that all the paclitaxel containing formulations were effective in 
reducing the percent increase in tumor size compared to normal saline control at 39 days 
post tumor inoculation. The efficacy was comparable for Pac-RGD-TLCL, Pac-LCL, and 
paclitaxel solution formulation with tumor volumes of ~ 60-70% of the control treatment. 
In contrast, the tumor cell targeted Pac-Tf-TLCL showed a significantly higher antitumor 
activity compared to all other treatments with the tumor volumes of  ~ 30% of the control 
treatment on 39 days post tumor inoculation. The tumor vasculature targeting did not 
produce an appreciable effect compared to non targeted liposomes possibly due to limited 
expression of αvβ3 integrin receptors in the vasculature of well established tumors, and 
due to higher clearance of these liposomes by binding of cRGD to these receptors 
expressed by mononuclear cells of the spleen. Nevertheless, tumor vasculature targeting 
has a potential for improving therapeutic efficacy in breast cancer with metastasis, and 
primary tumors with fast developing vasculature. In this animal model studied, tumor cell 
targeting produced a higher antitumor efficacy than tumor vasculature targeting because 
this strategy utilized the active process involved in Fe transport for targeting. Since TfR1 
is over expressed by proliferating tumor cells, receptor mediated endocytosis of Pac-Tf-
TLCL by these cells was enhanced, which in turn improved the efficacy of the treatment.  
 
The physical instability of the liposomal dispersions during storage is a major concern 
in liposomal formulation development. Removal of water from the dispersion by 
lyophilization can improve the long term stability, and thereby instabilities caused by 
hydrolysis or oxidation can be prevented. But, removal of water which is responsible for 
maintaining the structure of the liposomes presents more challenges and requires careful 
optimization of the formulation and process. The liposomes lyophilized without 
lyoprotectant showed more than five-fold increase in free drug, and more than seven-fold 
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increase in size. So, the Pac-LCL was lyophilized using a non-crystallizing solute sucrose 
as a lyoprotectant. The leakage of paclitaxel in the lyophilized samples was minimized 
with increasing concentrations of sucrose and the minimum concentration required was 
found to be 250 mM corresponding to a lipid-sugar ratio of 1:5. Similarly, the increase in 
size during lyophilization was minimized by sucrose at lipid-sugar ratios of 1:5 or lower. 
Inclusion of sucrose at an intravesicular-extravesicular ratio of 2:5 provided better 
protection to the internal portion of the bilayer and minimized the increase in particle 
size. The reconstituted pre-lyophilized Pac-LCL was 100 ± 20 nm in diameter with ~ 
90% paclitaxel retention. The optimized composition was used for the preparation of 
lyophilized Pac-RGD-TLCL, and Pac-Tf-TLCL. The lyophilized targeted liposomal 
formulations possessed similar characteristics as that of Pac-LCL. The stability 
evaluation showed that all these formulations were stable for three months at 5 ± 3ºC. 
 
In conclusion, targeted drug delivery with paclitaxel-loaded long-circulating 
liposomes improved the antitumor efficacy of breast cancer in a mouse xenograft model. 
Tumor cell targeted transferrin conjugated liposomes were more effective compared to 
tumor vasculature targeted cRGD conjugated liposomes. Although the effect of tumor 
vasculature targeted liposomes was comparable to non-targeted liposomes and paclitaxel 
solution, these cRGD conjugated liposomes have the potential for improving the 
therapeutic efficacy in tumor metastasis and primary tumors with fast developing 
vasculature. The stability of the paclitaxel-loaded liposomes in dispersion was improved 
by selecting an optimum composition. To further improve the long-term stability, these 
liposomes were lyophilized in presence of a non-crystallizing solute sucrose. The size, 
charge, and integrity of these liposomes were preserved for three months at refrigerated 
storage conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
LIST OF REFERENCES 
 
 
[1] D. Hanahan, R.A. Weinberg, The hallmarks of cancer. Cell 100(1) (2000) 57-70. 
[2] M. Heron, D.L. Hoyert, S.L. Murphy, J. Xu, K.D. Kochanek, B. Tejada-Vera, 
Deaths: final data for 2006. Natl Vital Stat Rep 57(14) (2009) 1-134. 
[3] M. Heron, Deaths: leading causes for 2006. Natl Vital Stat Rep 58(14) (2010) 1-
100. 
[4] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009. 
CA Cancer J Clin 59(4) (2009) 225-249. 
[5] S.H. Jang, M.G. Wientjes, D. Lu, J.L. Au, Drug delivery and transport to solid 
tumors. Pharm Res 20(9) (2003) 1337-1350. 
[6] R.K. Jain, Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science 307(5706) (2005) 58-62. 
[7] R.K. Jain, Delivery of molecular and cellular medicine to solid tumors. J Control 
Release 53(1-3) (1998) 49-67. 
[8] E.K. Rowinsky, R.C. Donehower, Paclitaxel (taxol). N Engl J Med 332(15) 
(1995) 1004-1014. 
[9] C.M. Spencer, D. Faulds, Paclitaxel. A review of its pharmacodynamic and 
pharmacokinetic properties and therapeutic potential in the treatment of cancer. 
Drugs 48(5) (1994) 794-847. 
[10] A. Goncalves, D. Braguer, G. Carles, N. Andre, C. Prevot, C. Briand, Caspase-8 
activation independent of CD95/CD95-L interaction during paclitaxel-induced 
apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol 60(11) 
(2000) 1579-1584. 
[11] M. Carre, G. Carles, N. Andre, S. Douillard, J. Ciccolini, C. Briand, D. Braguer, 
Involvement of microtubules and mitochondria in the antagonism of arsenic 
trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol 63(10) (2002) 
1831-1842. 
[12] N. Andre, M. Carre, G. Brasseur, B. Pourroy, H. Kovacic, C. Briand, D. Braguer, 
Paclitaxel targets mitochondria upstream of caspase activation in intact human 
neuroblastoma cells. FEBS Lett 532(1-2) (2002) 256-260. 
[13] G.W. Makin, B.M. Corfe, G.J. Griffiths, A. Thistlethwaite, J.A. Hickman, C. 
Dive, Damage-induced Bax N-terminal change, translocation to mitochondria and 
formation of Bax dimers/complexes occur regardless of cell fate. Embo J 20(22) 
(2001) 6306-6315. 
[14] S. Haldar, N. Jena, C.M. Croce, Inactivation of Bcl-2 by phosphorylation. Proc 
Natl Acad Sci USA 92(10) (1995) 4507-4511. 
[15] R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, 
J.R. Baker, Jr., D.A. Van Echo, D.D. Von Hoff, B. Leyland-Jones, 
Hypersensitivity reactions from taxol. J Clin Oncol 8(7) (1990) 1263-1268. 
[16] W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. 
Hawkins, J. O'Shaughnessy, Phase III trial of nanoparticle albumin-bound 
paclitaxel compared with polyethylated castor oil-based paclitaxel in women with 
breast cancer. J Clin Oncol 23(31) (2005) 7794-7803. 
150 
[17] N.I. Marupudi, J.E. Han, K.W. Li, V.M. Renard, B.M. Tyler, H. Brem, Paclitaxel: 
a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 
6(5) (2007) 609-621. 
[18] R.K. Jain, Transport phenomena in tumors. In: J. Wei, J. Anderson, M. Denn, J. 
Seinfeld, G. Stephanopoulos and J. Wei (Eds.), Advances in Chemical 
Engineering, Vol. 19, Academic Press Inc., San Diego, CA, 1994, pp. 129-200. 
[19] R.K. Jain, Barriers to drug delivery in solid tumors. Sci Am 271(1) (1994) 58-65. 
[20] J.K. Vasir, M.K. Reddy, V.D. Labhasetwar, Nanosystems in drug targeting: 
opportunities and challenges. Current Nanoscience 1 (2005) 47-64. 
[21] E. Ruoslahti, S.N. Bhatia, M.J. Sailor, Targeting of drugs and nanoparticles to 
tumors. J Cell Biol 188(6) (2010) 759-768. 
[22] M.E. Davis, Z.G. Chen, D.M. Shin, Nanoparticle therapeutics: an emerging 
treatment modality for cancer. Nat Rev Drug Discov 7(9) (2008) 771-782. 
[23] V.P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat 
Rev Drug Discov 4(2) (2005) 145-160. 
[24] D. Kirpotin, J.W. Park, K. Hong, S. Zalipsky, W.L. Li, P. Carter, C.C. Benz, D. 
Papahadjopoulos, Sterically stabilized anti-HER2 immunoliposomes: design and 
targeting to human breast cancer cells in vitro. Biochemistry 36(1) (1997) 66-75. 
[25] A. Gabizon, D. Goren, A.T. Horowitz, D. Tzemach, A. Lossos, T. Siegal, Long-
circulating liposomes for drug delivery in cancer therapy: a review of 
biodistribution studies in tumor-bearing animals. Adv Drug Del Rev 24(2-3) 
(1997) 337-344. 
[26] T. Yang, M.K. Choi, F.D. Cui, S.J. Lee, S.J. Chung, C.K. Shim, D.D. Kim, 
Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against 
human breast cancer cells. Pharm Res 24(12) (2007) 2402-2411. 
[27] N.Z. Wu, D. Da, T.L. Rudoll, D. Needham, A.R. Whorton, M.W. Dewhirst, 
Increased microvascular permeability contributes to preferential accumulation of 
stealth liposomes in tumor tissue. Cancer Res 53(16) (1993) 3765-3770. 
[28] T. Lian, R.J. Ho, Trends and developments in liposome drug delivery systems. J 
Pharm Sci 90(6) (2001) 667-680. 
[29] U.S. Kadimi, D.R. Balasubramanian, U.R. Ganni, M. Balaraman, V. 
Govindarajulu, In vitro studies on liposomal amphotericin B obtained by 
supercritical carbon dioxide-mediated process. Nanomedicine 3(4) (2007) 273-
280. 
[30] Y.L. Lo, J.C. Tsai, J.H. Kuo, Liposomes and disaccharides as carriers in spray-
dried powder formulations of superoxide dismutase. J Control Release 94(2-3) 
(2004) 259-272. 
[31] K. Mishima, Biodegradable particle formation for drug and gene delivery using 
supercritical fluid and dense gas. Adv Drug Deliv Rev 60(3) (2008) 411-432. 
[32] C. Chen, D. Han, C. Cai, X. Tang, An overview of liposome lyophilization and its 
future potential. J Control Release 142(3) (2010) 299-311. 
[33] T.D. Madden, M.B. Bally, M.J. Hope, P.R. Cullis, H.P. Schieren, A.S. Janoff, 
Protection of large unilamellar vesicles by trehalose during dehydration: retention 
of vesicle contents. Biochim Biophys Acta 817(1) (1985) 67-74. 
[34] E.C. van Winden, Freeze-drying of liposomes: theory and practice. Methods 
Enzymol 367 (2003) 99-110. 
151 
[35] S.L. Huang, R.C. MacDonald, Acoustically active liposomes for drug 
encapsulation and ultrasound-triggered release. Biochim Biophys Acta 1665(1-2) 
(2004) 134-141. 
[36] S.M. Stieger, C.F. Caskey, R.H. Adamson, S. Qin, F.R. Curry, E.R. Wisner, K.W. 
Ferrara, Enhancement of vascular permeability with low-frequency contrast-
enhanced ultrasound in the chorioallantoic membrane model. Radiology 243(1) 
(2007) 112-121. 
[37] E.C. Unger, T. Porter, W. Culp, R. Labell, T. Matsunaga, R. Zutshi, Therapeutic 
applications of lipid-coated microbubbles. Adv Drug Deliv Rev 56(9) (2004) 
1291-1314. 
[38] W.G. Pitt, G.A. Husseini, B.J. Staples, Ultrasonic drug delivery - a general 
review. Expert Opin Drug Deliv 1(1) (2004) 37-56. 
[39] A.L. Klibanov, Microbubble contrast agents: targeted ultrasound imaging and 
ultrasound-assisted drug-delivery applications. Invest Radiol 41(3) (2006) 354-
362. 
[40] A.D. Bangham, R.W. Horne, Negative staining of phospholipids and their 
structural modification by surface-active agents as observed in the electron 
microscope. J Mol Biol 8 (1964) 660-668. 
[41] A.D. Bangham, M.M. Standish, J.C. Watkins, Diffusion of univalent ions across 
the lamellae of swollen phospholipids. J Mol Biol 13(1) (1965) 238-252. 
[42] A.D. Bangham, M.M. Standish, G. Weissmann, The action of steroids and 
streptolysin S on the permeability of phospholipid structures to cations. J Mol 
Biol 13(1) (1965) 253-259. 
[43] A.D. Bangham, Liposomes: the Babraham connection. Chem Phys Lipids 64(1-3) 
(1993) 275-285. 
[44] G. Sessa, G. Weissmann, Phospholipid spherules (liposomes) as a model for 
biological membranes. J Lipid Res 9(3) (1968) 310-318. 
[45] G. Gregoriadis, P.D. Leathwood, B.E. Ryman, Enzyme entrapment in liposomes. 
FEBS Lett 14(2) (1971) 95-99. 
[46] G. Gregoriadis, B.E. Ryman, Liposomes as carriers of enzymes or drugs: a new 
approach to the treatment of storage diseases. Biochem J 124(5) (1971) 58P. 
[47] G. Gregoriadis, B.E. Ryman, Lysosomal localization of enzyme-containing 
liposomes injected into rats. Biochem J 128(4) (1972) 142P-143P. 
[48] G. Gregoriadis, B.E. Ryman, Lysosomal localization of fructofuranosidase 
containing liposomes injected into rats. Biochem J 129(1) (1972) 123-133. 
[49] G. Gregoriadis, Drug entrapment in liposomes. FEBS Lett 36(3) (1973) 292-296. 
[50] G. Gregoriadis, E.J. Wills, C.P. Swain, A.S. Tavill, Drug-carrier potential of 
liposomes in cancer chemotherapy. Lancet 1(7870) (1974) 1313-1316. 
[51] T. Kaasgaard, T.L. Andresen, Liposomal cancer therapy: exploiting tumor 
characteristics. Expert Opin Drug Deliv 7(2) (2010) 225-243. 
[52] V.P. Torchilin, Fluorescence microscopy to follow the targeting of liposomes and 
micelles to cells and their intracellular fate. Adv Drug Deliv Rev 57(1) (2005) 95-
109. 
[53] D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, D. Papahadjopoulos, 
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. 
Pharmacol Rev 51(4) (1999) 691-743. 
152 
[54] N. Maurer, D.B. Fenske, P.R. Cullis, Developments in liposomal drug delivery 
systems. Expert Opin Biol Ther 1(6) (2001) 923-947. 
[55] J. de Gier, J.G. Mandersloot, L.L. van Deenen, Lipid composition and 
permeability of liposomes. Biochim Biophys Acta 150(4) (1968) 666-675. 
[56] T.M. Koyama, C.R. Stevens, E.J. Borda, K.J. Grobe, D.A. Cleary, Characterizing 
the gel to liquid crystal transition in lipid-bilayer model systems. Chem. Educator 
4(1) (1999) 12-15. 
[57] J. Risbo, K. Jorgensen, M.M. Sperotto, O.G. Mouritsen, Phase behavior and 
permeability properties of phospholipid bilayers containing a short-chain 
phospholipid permeability enhancer. Biochim Biophys Acta 1329(1) (1997) 85-
96. 
[58] D.O. Shah, J.H. Schulman, Influence of calcium, cholesterol, and unsaturation on 
lecithin monolayers. J Lipid Res 8(3) (1967) 215-226. 
[59] B.D. Ladbrooke, R.M. Williams, D. Chapman, Studies on lecithin-cholesterol-
water interactions by differential scanning calorimetry and X-ray diffraction. 
Biochim Biophys Acta 150(3) (1968) 333-340. 
[60] D. Papahadjopoulos, J.C. Watkins, Phospholipid model membranes. II. 
Permeability properties of hydrated liquid crystals. Biochim Biophys Acta 135(4) 
(1967) 639-652. 
[61] J.d. Gier, C.W.M. Haest, J.G. Mandersloot, L.L.M.v. Deenen, Valinomycin-
induced permeation of 86Rb+ of liposomes with varying composition through the 
bilayers. Biochim Biophys Acta 211 (1970) 373-375. 
[62] R.A. Demel, K.R. Bruckdorfer, L.L. van Deenen, The effect of sterol structure on 
the permeability of lipomes to glucose, glycerol and Rb+. Biochim Biophys Acta 
255(1) (1972) 321-330. 
[63] R.A. Demel, B. De Kruyff, The function of sterols in membranes. Biochim 
Biophys Acta 457(2) (1976) 109-132. 
[64] C. Kirby, J. Clarke, G. Gregoriadis, Effect of the cholesterol content of small 
unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186(2) 
(1980) 591-598. 
[65] J. Senior, J.C. Crawley, G. Gregoriadis, Tissue distribution of liposomes 
exhibiting long half-lives in the circulation after intravenous injection. Biochim 
Biophys Acta 839(1) (1985) 1-8. 
[66] I. Abraham, A. Goundalkar, M. Mezei, Effect of liposomal surface charge on the 
pharmacokinetics of an encapsulated model compound. Biopharm Drug Dispos 
5(4) (1984) 387-398. 
[67] A.M. Abraham, A. Walubo, The effect of surface charge on the disposition of 
liposome-encapsulated gentamicin to the rat liver, brain, lungs and kidneys after 
intraperitoneal administration. Int J Antimicrob Agents 25(5) (2005) 392-397. 
[68] C.D. Black, G. Gregoriadis, Interaction of liposomes with blood plasma proteins. 
Biochem Soc Trans 4(2) (1976) 253-256. 
[69] D.J. Wilkins, P.A. Myers, Studies on the relationship between the electrophoretic 
properties of colloids and their blood clearance and organ distribution in the rat. 
Br J Exp Pathol 47(6) (1966) 568-576. 
153 
[70] F. Roerdink, N.M. Wassef, E.C. Richardson, C.R. Alving, Effects of negatively 
charged lipids on phagocytosis of liposomes opsonized by complement. Biochim 
Biophys Acta 734(1) (1983) 33-39. 
[71] T. Ogiso, T. Yamaguchi, M. Iwaki, T. Tanino, Y. Miyake, Effect of positively 
and negatively charged liposomes on skin permeation of drugs. J Drug Target 
9(1) (2001) 49-59. 
[72] D. Baczynska, K. Widerak, M. Ugorski, M. Langner, Surface charge and the 
association of liposomes with colon carcinoma cells. Z Naturforsch C 56(9-10) 
(2001) 872-877. 
[73] T.D. Heath, N.G. Lopez, D. Papahadjopoulos, The effects of liposome size and 
surface charge on liposome-mediated delivery of methotrexate-gamma-aspartate 
to cells in vitro. Biochim Biophys Acta 820(1) (1985) 74-84. 
[74] R.A. Schwendener, P.A. Lagocki, Y.E. Rahman, The effects of charge and size on 
the interaction of unilamellar liposomes with macrophages. Biochim Biophys 
Acta 772(1) (1984) 93-101. 
[75] W.G. Love, N. Amos, B.D. Williams, I.W. Kellaway, Effect of liposome surface 
charge on the stability of technetium (99mTc) radiolabelled liposomes. J 
Microencapsul 6(1) (1989) 105-113. 
[76] C.R. Miller, B. Bondurant, S.D. McLean, K.A. McGovern, D.F. O'Brien, 
Liposome-cell interactions in vitro: effect of liposome surface charge on the 
binding and endocytosis of conventional and sterically stabilized liposomes. 
Biochemistry 37(37) (1998) 12875-12883. 
[77] S. Krasnici, A. Werner, M.E. Eichhorn, M. Schmitt-Sody, S.A. Pahernik, B. 
Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, M. Dellian, Effect of the 
surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J 
Cancer 105(4) (2003) 561-567. 
[78] M. Schmitt-Sody, S. Krasnici, P.C. Manegold, B. Sauer, B. Schulze, M. Teifel, U. 
Michaelis, M. Dellian, Paclitaxel encapsulated in cationic liposomes: effect on 
growth and metastases of solid tumors in vivo. Chirurgisches Forum 2001 für 
experimentelle und klinische Forschung, Springer, Heidelberg, 2001, pp. 61–63. 
[79] H. Harashima, H. Kiwada, Liposomal targeting and drug delivery: kinetic 
consideration. Adv Drug Del Rev 19 (1996) 425-444. 
[80] T.M. Allen, C. Hansen, J. Rutledge, Liposomes with prolonged circulation times: 
factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys 
Acta 981(1) (1989) 27-35. 
[81] H. Harashima, K. Sakata, K. Funato, H. Kiwada, Enhanced hepatic uptake of 
liposomes through complement activation depending on the size of liposomes. 
Pharm Res 11(3) (1994) 402-406. 
[82] T.M. Allen, J.M. Everest, Effect of liposome size and drug release properties on 
pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Ther 226(2) 
(1983) 539-544. 
[83] Y.E. Rahman, E.A. Cerny, K.R. Patel, E.H. Lau, B.J. Wright, Differential uptake 
of liposomes varying in size and lipid composition by parenchymal and kupffer 
cells of mouse liver. Life Sci 31(19) (1982) 2061-2071. 
[84] R.M. Abra, C.A. Hunt, Liposome disposition in vivo. III. Dose and vesicle-size 
effects. Biochim Biophys Acta 666(3) (1981) 493-503. 
154 
[85] T.M. Allen, A. Chonn, Large unilamellar liposomes with low uptake into the 
reticuloendothelial system. FEBS Lett 223(1) (1987) 42-46. 
[86] A. Gabizon, D. Papahadjopoulos, Liposome formulations with prolonged 
circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci 
USA 85(18) (1988) 6949-6953. 
[87] A. Gabizon, D. Papahadjopoulos, The role of surface charge and hydrophilic 
groups on liposome clearance in vivo. Biochim Biophys Acta 1103(1) (1992) 94-
100. 
[88] G. Blume, G. Cevc, Liposomes for the sustained drug release in vivo. Biochim 
Biophys Acta 1029(1) (1990) 91-97. 
[89] A.L. Klibanov, K. Maruyama, V.P. Torchilin, L. Huang, Amphipathic 
polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS 
Lett 268(1) (1990) 235-237. 
[90] T.S. Levchenko, R. Rammohan, A.N. Lukyanov, K.R. Whiteman, V.P. Torchilin, 
Liposome clearance in mice: the effect of a separate and combined presence of 
surface charge and polymer coating. Int J Pharm 240(1-2) (2002) 95-102. 
[91] G.N. Chiu, M.B. Bally, L.D. Mayer, Selective protein interactions with 
phosphatidylserine containing liposomes alter the steric stabilization properties of 
poly(ethylene glycol). Biochim Biophys Acta 1510(1-2) (2001) 56-69. 
[92] H. Takeuchi, H. Yamamoto, T. Toyoda, H. Toyobuku, T. Hino, Y. Kawashima, 
Physical stability of size controlled small unilameller liposomes coated with a 
modified polyvinyl alcohol. Int J Pharm 164(1-2) (1998) 103-111. 
[93] K. Nakano, Y. Tozuka, H. Takeuchi, Effect of surface properties of liposomes 
coated with a modified polyvinyl alcohol (PVA-R) on the interaction with 
macrophage cells. Int J Pharm 354(1-2) (2008) 174-179. 
[94] T. Shehata, K. Ogawara, K. Higaki, T. Kimura, Prolongation of residence time of 
liposome by surface-modification with mixture of hydrophilic polymers. Int J 
Pharm 359(1-2) (2008) 272-279. 
[95] L.D. Mayer, M.B. Bally, M.J. Hope, P.R. Cullis, Techniques for encapsulating 
bioactive agents into liposomes. Chem Phys Lipids 40(2-4) (1986) 333-345. 
[96] C.M. Colley, B.E. Ryman, Liposomes as carriers in vivo for methotrexate. 
Biochem Soc Trans 3(1) (1975) 157-159. 
[97] L.D. Mayer, M.B. Bally, M.J. Hope, P.R. Cullis, Uptake of antineoplastic agents 
into large unilamellar vesicles in response to a membrane potential. Biochim 
Biophys Acta 816(2) (1985) 294-302. 
[98] F. Szoka, Jr., D. Papahadjopoulos, Procedure for preparation of liposomes with 
large internal aqueous space and high capture by reverse-phase evaporation. Proc 
Natl Acad Sci USA 75(9) (1978) 4194-4198. 
[99] E. Goormaghtigh, P. Chatelain, J. Caspers, J.M. Ruysschaert, Evidence of a 
specific complex between adriamycin and negatively-charged phospholipids. 
Biochim Biophys Acta 597(1) (1980) 1-14. 
[100] A. Gabizon, A. Dagan, D. Goren, Y. Barenholz, Z. Fuks, Liposomes as in vivo 
carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in 
mice. Cancer Res 42(11) (1982) 4734-4739. 
155 
[101] A. Rahman, G. White, N. More, P.S. Schein, Pharmacological, toxicological, and 
therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. 
Cancer Res 45(2) (1985) 796-803. 
[102] L.D. Mayer, M.B. Bally, P.R. Cullis, Uptake of adriamycin into large unilamellar 
vesicles in response to a pH gradient. Biochim Biophys Acta 857(1) (1986) 123-
126. 
[103] G. Haran, R. Cohen, L.K. Bar, Y. Barenholz, Transmembrane ammonium sulfate 
gradients in liposomes produce efficient and stable entrapment of amphipathic 
weak bases. Biochim Biophys Acta 1151(2) (1993) 201-215. 
[104] P.G. Tardi, R.C. Gallagher, S. Johnstone, N. Harasym, M. Webb, M.B. Bally, 
L.D. Mayer, Coencapsulation of irinotecan and floxuridine into low cholesterol-
containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 
1768(3) (2007) 678-687. 
[105] Y.F. Zhang, J.C. Wang, D.Y. Bian, X. Zhang, Q. Zhang, Targeted delivery of 
RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin 
for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74(3) 
(2010) 467-473. 
[106] X. Li, G.R. Ruan, W.L. Lu, H.Y. Hong, G.W. Liang, Y.T. Zhang, Y. Liu, C. 
Long, X. Ma, L. Yuan, J.C. Wang, X. Zhang, Q. Zhang, A novel stealth liposomal 
topotecan with amlodipine: apoptotic effect is associated with deletion of 
intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in 
leukemia. J Control Release 112(2) (2006) 186-198. 
[107] M.C. Garnett, Targeted drug conjugates: principles and progress. Adv Drug Deliv 
Rev 53(2) (2001) 171-216. 
[108] L.E. Gerlowski, R.K. Jain, Microvascular permeability of normal and neoplastic 
tissues. Microvasc Res 31(3) (1986) 288-305. 
[109] H.F. Dvorak, J.A. Nagy, J.T. Dvorak, A.M. Dvorak, Identification and 
characterization of the blood vessels of solid tumors that are leaky to circulating 
macromolecules. Am J Pathol 133(1) (1988) 95-109. 
[110] R.K. Jain, Transport of molecules across tumor vasculature. Cancer Metastasis 
Rev 6(4) (1987) 559-593. 
[111] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and 
the antitumor agent smancs. Cancer Res 46(12 Pt 1) (1986) 6387-6392. 
[112] H. Maeda, The enhanced permeability and retention (EPR) effect in tumor 
vasculature: the key role of tumor-selective macromolecular drug targeting. Adv 
Enzyme Regul 41 (2001) 189-207. 
[113] H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review. J Control Release 
65(1-2) (2000) 271-284. 
[114] F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. 
Jain, Vascular permeability in a human tumor xenograft: molecular size 
dependence and cutoff size. Cancer Res 55(17) (1995) 3752-3756. 
[115] S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, 
R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type 
and microenvironment. Proc Natl Acad Sci USA 95(8) (1998) 4607-4612. 
156 
[116] Y. Nishioka, H. Yoshino, Lymphatic targeting with nanoparticulate system. Adv 
Drug Deliv Rev 47(1) (2001) 55-64. 
[117] H. Hatakeyama, H. Akita, E. Ishida, K. Hashimoto, H. Kobayashi, T. Aoki, J. 
Yasuda, K. Obata, H. Kikuchi, T. Ishida, H. Kiwada, H. Harashima, Tumor 
targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. 
Int J Pharm 342(1-2) (2007) 194-200. 
[118] D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, 
J.D. Marks, C.C. Benz, J.W. Park, Antibody targeting of long-circulating lipidic 
nanoparticles does not increase tumor localization but does increase 
internalization in animal models. Cancer Res 66(13) (2006) 6732-6740. 
[119] M.H. Kranenborg, O.C. Boerman, J.C. Oosterwijk-Wakka, M.C. de Weijert, F.H. 
Corstens, E. Oosterwijk, Two-step radio-immunotargeting of renal-cell carcinoma 
xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific 
monoclonal antibodies. Int J Cancer 75(1) (1998) 74-80. 
[120] V.K. Jansons, P.L. Mallett, Targeted liposomes: a method for preparation and 
analysis. Anal Biochem 111(1) (1981) 54-59. 
[121] G. Gregoriadis, E.D. Neerunjun, Homing of liposomes to target cells. Biochem 
Biophys Res Commun 65(2) (1975) 537-544. 
[122] G. Gregoriadis, The carrier potential of liposomes in biology and medicine 
(second of two parts). N Engl J Med 295(14) (1976) 765-770. 
[123] G. Blume, G. Cevc, M.D. Crommelin, I.A. Bakker-Woudenberg, C. Kluft, G. 
Storm, Specific targeting with poly(ethylene glycol)-modified liposomes: 
coupling of homing devices to the ends of the polymeric chains combines 
effective target binding with long circulation times. Biochim Biophys Acta 
1149(1) (1993) 180-184. 
[124] T.M. Allen, E. Brandeis, C.B. Hansen, G.Y. Kao, S. Zalipsky, A new strategy for 
attachment of antibodies to sterically stabilized liposomes resulting in efficient 
targeting to cancer cells. Biochim Biophys Acta 1237(2) (1995) 99-108. 
[125] K. Maruyama, N. Takahashi, T. Tagawa, K. Nagaike, M. Iwatsuru, 
Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show 
prolonged circulation time and high extravasation into targeted solid tumors in 
vivo. FEBS Lett 413(1) (1997) 177-180. 
[126] J.W. Park, D.B. Kirpotin, K. Hong, R. Shalaby, Y. Shao, U.B. Nielsen, J.D. 
Marks, D. Papahadjopoulos, C.C. Benz, Tumor targeting using anti-her2 
immunoliposomes. J Control Release 74(1-3) (2001) 95-113. 
[127] J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, 
U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, C.C. Benz, Anti-HER2 
immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin 
Cancer Res 8(4) (2002) 1172-1181. 
[128] J.N. Moreira, T. Ishida, R. Gaspar, T.M. Allen, Use of the post-insertion 
technique to insert peptide ligands into pre-formed stealth liposomes with 
retention of binding activity and cytotoxicity. Pharm Res 19(3) (2002) 265-269. 
[129] S. Zalipsky, N. Mullah, J.A. Harding, J. Gittelman, L. Guo, S.A. DeFrees, 
Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide 
ligands appended to the termini of the polymer chains. Bioconjug Chem 8(2) 
(1997) 111-118. 
157 
[130] P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, G.Z. Zhu, 
Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed 
liposomes results in prolonged in vivo circulation time. FEBS Lett 386(2-3) 
(1996) 243-246. 
[131] T. Ishida, D.L. Iden, T.M. Allen, A combinatorial approach to producing 
sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 460(1) (1999) 
129-133. 
[132] Y. Lu, P.S. Low, Folate-mediated delivery of macromolecular anticancer 
therapeutic agents. Adv Drug Deliv Rev 54(5) (2002) 675-693. 
[133] B.A. Kamen, A. Capdevila, Receptor-mediated folate accumulation is regulated 
by the cellular folate content. Proc Natl Acad Sci USA 83(16) (1986) 5983-5987. 
[134] G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, M. Boiocchi, 
Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74(2) 
(1997) 193-198. 
[135] R.J. Lee, P.S. Low, Delivery of liposomes into cultured KB cells via folate 
receptor-mediated endocytosis. J Biol Chem 269(5) (1994) 3198-3204. 
[136] R.J. Lee, P.S. Low, Folate-mediated tumor cell targeting of liposome-entrapped 
doxorubicin in vitro. Biochim Biophys Acta 1233(2) (1995) 134-144. 
[137] D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, A. Gabizon, 
Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of 
multidrug-resistance efflux pump. Clin Cancer Res 6(5) (2000) 1949-1957. 
[138] D.R. Richardson, D.S. Kalinowski, S. Lau, P.J. Jansson, D.B. Lovejoy, Cancer 
cell iron metabolism and the development of potent iron chelators as anti-tumour 
agents. Biochim Biophys Acta 1790(7) (2009) 702-717. 
[139] D.S. Kalinowski, D.R. Richardson, The evolution of iron chelators for the 
treatment of iron overload disease and cancer. Pharmacol Rev 57(4) (2005) 547-
583. 
[140] D.R. Richardson, Mobilization of iron from neoplastic cells by some iron 
chelators is an energy-dependent process. Biochim Biophys Acta 1320(1) (1997) 
45-57. 
[141] T.R. Daniels, T. Delgado, J.A. Rodriguez, G. Helguera, M.L. Penichet, The 
transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the 
treatment of cancer. Clin Immunol 121(2) (2006) 144-158. 
[142] T.R. Daniels, T. Delgado, G. Helguera, M.L. Penichet, The transferrin receptor 
part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 
121(2) (2006) 159-176. 
[143] D.A. Eavarone, X. Yu, R.V. Bellamkonda, Targeted drug delivery to C6 glioma 
by transferrin-coupled liposomes. J Biomed Mater Res 51(1) (2000) 10-14. 
[144] S. Anabousi, M. Laue, C.M. Lehr, U. Bakowsky, C. Ehrhardt, Assessing 
transferrin modification of liposomes by atomic force microscopy and 
transmission electron microscopy. Eur J Pharm Biopharm 60(2) (2005) 295-303. 
[145] C. Fonseca, J.N. Moreira, C.J. Ciudad, M.C. Pedroso de Lima, S. Simoes, 
Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia 
cells. Eur J Pharm Biopharm 59(2) (2005) 359-366. 
 
158 
[146] T. Kakudo, S. Chaki, S. Futaki, I. Nakase, K. Akaji, T. Kawakami, K. Maruyama, 
H. Kamiya, H. Harashima, Transferrin-modified liposomes equipped with a pH-
sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 
43(19) (2004) 5618-5628. 
[147] O. Ishida, K. Maruyama, H. Tanahashi, M. Iwatsuru, K. Sasaki, M. Eriguchi, H. 
Yanagie, Liposomes bearing polyethyleneglycol-coupled transferrin with 
intracellular targeting property to the solid tumors in vivo. Pharm Res 18(7) 
(2001) 1042-1048. 
[148] X. Li, L. Ding, Y. Xu, Y. Wang, Q. Ping, Targeted delivery of doxorubicin using 
stealth liposomes modified with transferrin. Int J Pharm 373(1-2) (2009) 116-123. 
[149] H. Iinuma, K. Maruyama, K. Okinaga, K. Sasaki, T. Sekine, O. Ishida, N. 
Ogiwara, K. Johkura, Y. Yonemura, Intracellular targeting therapy of cisplatin-
encapsulated transferrin-polyethylene glycol liposome on peritoneal 
dissemination of gastric cancer. Int J Cancer 99(1) (2002) 130-137. 
[150] R. Suzuki, T. Takizawa, Y. Kuwata, M. Mutoh, N. Ishiguro, N. Utoguchi, A. 
Shinohara, M. Eriguchi, H. Yanagie, K. Maruyama, Effective anti-tumor activity 
of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346(1-2) 
(2008) 143-150. 
[151] K. Maruyama, O. Ishida, S. Kasaoka, T. Takizawa, N. Utoguchi, A. Shinohara, 
M. Chiba, H. Kobayashi, M. Eriguchi, H. Yanagie, Intracellular targeting of 
sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-
PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 
98(2) (2004) 195-207. 
[152] S. Masunaga, S. Kasaoka, K. Maruyama, D. Nigg, Y. Sakurai, K. Nagata, M. 
Suzuki, Y. Kinashi, A. Maruhashi, K. Ono, The potential of transferrin-pendant-
type polyethyleneglycol liposomes encapsulating decahydrodecaborate-(10)B 
(GB-10) as (10)B-carriers for boron neutron capture therapy. Int J Radiat Oncol 
Biol Phys 66(5) (2006) 1515-1522. 
[153] K.M. Hege, D.L. Daleke, T.A. Waldmann, K.K. Matthay, Comparison of anti-Tac 
and anti-transferrin receptor-conjugated liposomes for specific drug delivery to 
adult T-cell leukemia. Blood 74(6) (1989) 2043-2052. 
[154] T. Kobayashi, T. Ishida, Y. Okada, S. Ise, H. Harashima, H. Kiwada, Effect of 
transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated 
drug resistant tumor cells. Int J Pharm 329(1-2) (2007) 94-102. 
[155] M.L. Krieger, N. Eckstein, V. Schneider, M. Koch, H.D. Royer, U. Jaehde, G. 
Bendas, Overcoming cisplatin resistance of ovarian cancer cells by targeted 
liposomes in vitro. Int J Pharm 389(1-2) (2010) 10-17. 
[156] J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug 
resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and 
verapamil. J Pharm Pharm Sci 10(3) (2007) 350-357. 
[157] V. Soni, D.V. Kohli, S.K. Jain, Transferrin coupled liposomes as drug delivery 
carriers for brain targeting of 5-florouracil. J Drug Target 13(4) (2005) 245-250. 
[158] V. Soni, D.V. Kohli, S.K. Jain, Transferrin-conjugated liposomal system for 
improved delivery of 5-fluorouracil to brain. J Drug Target 16(1) (2008) 73-78. 
159 
[159] M.K. Divi, Development and evaluation of brain tumor targeted liposome 
delivery system for paclitaxel. [Dissertation], [Memphis], The University of 
Tennessee Health Science Center, (2007), 126 p. 
[160] T.W. Hambley, W.N. Hait, Is anticancer drug development heading in the right 
direction? Cancer Res 69(4) (2009) 1259-1262. 
[161] D. Hanahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell 86(3) (1996) 353-364. 
[162] J. Folkman, Addressing tumor blood vessels. Nat Biotechnol 15(6) (1997) 510. 
[163] W. Arap, R. Pasqualini, E. Ruoslahti, Cancer treatment by targeted drug delivery 
to tumor vasculature in a mouse model. Science 279(5349) (1998) 377-380. 
[164] R. Pasqualini, E. Koivunen, E. Ruoslahti, Alpha v integrins as receptors for tumor 
targeting by circulating ligands. Nat Biotechnol 15(6) (1997) 542-546. 
[165] A.P. Janssen, R.M. Schiffelers, T.L. ten Hagen, G.A. Koning, A.J. Schraa, R.J. 
Kok, G. Storm, G. Molema, Peptide-targeted PEG-liposomes in anti-angiogenic 
therapy. Int J Pharm 254(1) (2003) 55-58. 
[166] R.M. Schiffelers, G.A. Koning, T.L. ten Hagen, M.H. Fens, A.J. Schraa, A.P. 
Janssen, R.J. Kok, G. Molema, G. Storm, Anti-tumor efficacy of tumor 
vasculature-targeted liposomal doxorubicin. J Control Release 91(1-2) (2003) 
115-122. 
[167] P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, R.E. 
Kontermann, Novel RGD lipopeptides for the targeting of liposomes to integrin-
expressing endothelial and melanoma cells. Protein Eng Des Sel 17(5) (2004) 
433-441. 
[168] X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, Q. Zhang, 
Intracellular delivery of doxorubicin with RGD-modified sterically stabilized 
liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 
94(8) (2005) 1782-1793. 
[169] X.B. Xiong, Y. Huang, W.L. Lu, H. Zhang, X. Zhang, Q. Zhang, Enhanced 
intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro 
resulting in improved antitumor activity in vivo. Pharm Res 22(6) (2005) 933-939. 
[170] X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, Q. Zhang, 
Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin 
by sterically stabilized liposomes modified with a synthetic RGD mimetic. J 
Control Release 107(2) (2005) 262-275. 
[171] H. Zhao, J.C. Wang, Q.S. Sun, C.L. Luo, Q. Zhang, RGD-based strategies for 
improving antitumor activity of paclitaxel-loaded liposomes in nude mice 
xenografted with human ovarian cancer. J Drug Target 17(1) (2009) 10-18. 
[172] C.B. Pattillo, F. Sari-Sarraf, R. Nallamothu, B.M. Moore, G.C. Wood, M.F. 
Kiani, Targeting of the antivascular drug combretastatin to irradiated tumors 
results in tumor growth delay. Pharm Res 22(7) (2005) 1117-1120. 
[173] P.K. Dubey, V. Mishra, S. Jain, S. Mahor, S.P. Vyas, Liposomes modified with 
cyclic RGD peptide for tumor targeting. J Drug Target 12(5) (2004) 257-264. 
[174] E.A. Murphy, B.K. Majeti, L.A. Barnes, M. Makale, S.M. Weis, K. Lutu-Fuga, 
W. Wrasidlo, D.A. Cheresh, Nanoparticle-mediated drug delivery to tumor 
vasculature suppresses metastasis. Proc Natl Acad Sci USA 105(27) (2008) 9343-
9348. 
160 
[175] F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. 
Longhi, T.M. Allen, A. Corti, M. Ponzoni, Vascular damage and anti-angiogenic 
effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63(21) 
(2003) 7400-7409. 
[176] S.V. Garde, A.J. Forte, M. Ge, E.A. Lepekhin, C.J. Panchal, S.A. Rabbani, J.J. 
Wu, Binding and internalization of NGR-peptide-targeted liposomal doxorubicin 
(TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 
18(10) (2007) 1189-1200. 
[177] M. Loi, S. Marchio, P. Becherini, D. Di Paolo, M. Soster, F. Curnis, C. Brignole, 
G. Pagnan, P. Perri, I. Caffa, R. Longhi, B. Nico, F. Bussolino, C. Gambini, D. 
Ribatti, M. Cilli, W. Arap, R. Pasqualini, T.M. Allen, A. Corti, M. Ponzoni, F. 
Pastorino, Combined targeting of perivascular and endothelial tumor cells 
enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J 
Control Release 145(1) (2010) 66-73. 
[178] G.M. Kuesters, R.B. Campbell, Conjugation of bevacizumab to cationic 
liposomes enhances their tumor-targeting potential. Nanomedicine (Lond) 5(2) 
(2010) 181-192. 
[179] F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. 
Pagnan, F. Piccardi, M. Cilli, R. Longhi, D. Ribatti, A. Corti, T.M. Allen, M. 
Ponzoni, Targeting liposomal chemotherapy via both tumor cell-specific and 
tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 
66(20) (2006) 10073-10082. 
[180] J.M. Saul, A.V. Annapragada, R.V. Bellamkonda, A dual-ligand approach for 
enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 
114(3) (2006) 277-287. 
[181] X. Ying, H. Wen, W.L. Lu, J. Du, J. Guo, W. Tian, Y. Men, Y. Zhang, R.J. Li, 
T.Y. Yang, D.W. Shang, J.N. Lou, L.R. Zhang, Q. Zhang, Dual-targeting 
daunorubicin liposomes improve the therapeutic efficacy of brain glioma in 
animals. J Control Release 141(2) (2010) 183-192. 
[182] C.H. Chen, D.Z. Liu, H.W. Fang, H.J. Liang, T.S. Yang, S.Y. Lin, Evaluation of 
multi-target and single-target liposomal drugs for the treatment of gastric cancer. 
Biosci Biotechnol Biochem 72(6) (2008) 1586-1594. 
[183] V.P. Torchilin, Cell penetrating peptide-modified pharmaceutical nanocarriers for 
intracellular drug and gene delivery. Biopolymers 90(5) (2008) 604-610. 
[184] V.P. Torchilin, R. Rammohan, V. Weissig, T.S. Levchenko, TAT peptide on the 
surface of liposomes affords their efficient intracellular delivery even at low 
temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 
98(15) (2001) 8786-8791. 
[185] Y.L. Tseng, J.J. Liu, R.L. Hong, Translocation of liposomes into cancer cells by 
cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol 
Pharmacol 62(4) (2002) 864-872. 
[186] R.M. Sawant, J.P. Hurley, S. Salmaso, A. Kale, E. Tolcheva, T.S. Levchenko, 
V.P. Torchilin, "SMART" drug delivery systems: double-targeted pH-responsive 
pharmaceutical nanocarriers. Bioconjug Chem 17(4) (2006) 943-949. 
161 
[187] C. Marty, C. Meylan, H. Schott, K. Ballmer-Hofer, R.A. Schwendener, Enhanced 
heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-
modified liposomes. Cell Mol Life Sci 61(14) (2004) 1785-1794. 
[188] D.C. Drummond, M. Zignani, J. Leroux, Current status of pH-sensitive liposomes 
in drug delivery. Prog Lipid Res 39(5) (2000) 409-460. 
[189] H. Karanth, R.S. Murthy, pH-sensitive liposomes - principle and application in 
cancer therapy. J Pharm Pharmacol 59(4) (2007) 469-483. 
[190] I.Y. Kim, Y.S. Kang, D.S. Lee, H.J. Park, E.K. Choi, Y.K. Oh, H.J. Son, J.S. 
Kim, Antitumor activity of EGFR targeted pH-sensitive immunoliposomes 
encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 
140(1) (2009) 55-60. 
[191] T. Ishida, M.J. Kirchmeier, E.H. Moase, S. Zalipsky, T.M. Allen, Targeted 
delivery and triggered release of liposomal doxorubicin enhances cytotoxicity 
against human B lymphoma cells. Biochim Biophys Acta 1515(2) (2001) 144-
158. 
[192] N.K. Subbarao, R.A. Parente, F.C. Szoka, Jr., L. Nadasdi, K. Pongracz, pH-
dependent bilayer destabilization by an amphipathic peptide. Biochemistry 26(11) 
(1987) 2964-2972. 
[193] M.J. Turk, J.A. Reddy, J.A. Chmielewski, P.S. Low, Characterization of a novel 
pH-sensitive peptide that enhances drug release from folate-targeted liposomes at 
endosomal pHs. Biochim Biophys Acta 1559(1) (2002) 56-68. 
[194] P. Simard, J.C. Leroux, pH-sensitive immunoliposomes specific to the CD33 cell 
surface antigen of leukemic cells. Int J Pharm 381(2) (2009) 86-96. 
[195] G.A. Koning, A.M. Eggermont, L.H. Lindner, T.L. Ten Hagen, Hyperthermia and 
thermosensitive liposomes for improved delivery of chemotherapeutic drugs to 
solid tumors. Pharm Res 27(8) (2010) 1750-1754. 
[196] M.B. Yatvin, J.N. Weinstein, W.H. Dennis, R. Blumenthal, Design of liposomes 
for enhanced local release of drugs by hyperthermia. Science 202(4374) (1978) 
1290-1293. 
[197] M.H. Gaber, N.Z. Wu, K. Hong, S.K. Huang, M.W. Dewhirst, D. 
Papahadjopoulos, Thermosensitive liposomes: extravasation and release of 
contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 36(5) 
(1996) 1177-1187. 
[198] D. Needham, M.W. Dewhirst, The development and testing of a new temperature-
sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv 
Rev 53(3) (2001) 285-305. 
[199] D. Needham, G. Anyarambhatla, G. Kong, M.W. Dewhirst, A new temperature-
sensitive liposome for use with mild hyperthermia: characterization and testing in 
a human tumor xenograft model. Cancer Res 60(5) (2000) 1197-1201. 
[200] G. Kong, G. Anyarambhatla, W.P. Petros, R.D. Braun, O.M. Colvin, D. 
Needham, M.W. Dewhirst, Efficacy of liposomes and hyperthermia in a human 
tumor xenograft model: importance of triggered drug release. Cancer Res 60(24) 
(2000) 6950-6957. 
[201] R.J. Ho, B.T. Rouse, L. Huang, Target-sensitive immunoliposomes: preparation 
and characterization. Biochemistry 25(19) (1986) 5500-5506. 
162 
[202] R.J. Ho, B.T. Rouse, L. Huang, Interactions of target-sensitive immunoliposomes 
with herpes simplex virus. The foundation of a sensitive immunoliposome assay 
for the virus. J Biol Chem 262(29) (1987) 13979-13984. 
[203] R.J. Ho, B.T. Rouse, L. Huang, Target-sensitive immunoliposomes as an efficient 
drug carrier for antiviral activity. J Biol Chem 262(29) (1987) 13973-13978. 
[204] P. Pinnaduwage, L. Huang, Stable target-sensitive immunoliposomes. 
Biochemistry 31(11) (1992) 2850-2855. 
[205] H. Alkan-Onyuksel, S.M. Demos, G.M. Lanza, M.J. Vonesh, M.E. Klegerman, 
B.J. Kane, J. Kuszak, D.D. McPherson, Development of inherently echogenic 
liposomes as an ultrasonic contrast agent. J Pharm Sci 85(5) (1996) 486-490. 
[206] S. Huang, A.J. Hamilton, S.D. Tiukinhoy, A. Nagaraj, B.J. Kane, M. Klegerman, 
D.D. McPherson, R.C. MacDonald, Liposomes as ultrasound imaging contrast 
agents and as ultrasound-sensitive drug delivery agents. Cell Mol Biol Lett 7(2) 
(2002) 233-235. 
[207] J.A. Kopechek, T.M. Abruzzo, B. Wang, S.M. Chrzanowski, D.A. Smith, P.H. 
Kee, S. Huang, J.H. Collier, D.D. McPherson, C.K. Holland, Ultrasound-
mediated release of hydrophilic and lipophilic agents from echogenic liposomes. J 
Ultrasound Med 27(11) (2008) 1597-1606. 
[208] J.H. Crowe, L.M. Crowe, D. Chapman, Preservation of membranes in 
anhydrobiotic organisms: the role of trehalose. Science 223(4637) (1984) 701-
703. 
[209] J.H. Crowe, F.A. Hoekstra, K.H. Nguyen, L.M. Crowe, Is vitrification involved in 
depression of the phase transition temperature in dry phospholipids? Biochim 
Biophys Acta 1280(2) (1996) 187-196. 
[210] S. Ohtake, C. Schebor, J.J. de Pablo, Effects of trehalose on the phase behavior of 
DPPC-cholesterol unilamellar vesicles. Biochim Biophys Acta 1758(1) (2006) 
65-73. 
[211] J.L. Green, C.A. Angell, Phase relations and vitrification in saccharide-water 
solutions and the trehalose anomaly. J Phys Chem 93(8) (1989) 2880-2882. 
[212] K.L. Koster, M.S. Webb, G. Bryant, D.V. Lynch, Interactions between soluble 
sugars and POPC (1-palmitoyl-2-oleoylphosphatidylcholine) during dehydration: 
vitrification of sugars alters the phase behavior of the phospholipid. Biochim 
Biophys Acta 1193(1) (1994) 143-150. 
[213] K.L. Koster, Glass formation and desiccation tolerance in seeds. Plant Physiol 
96(1) (1991) 302-304. 
[214] J.S. Clegg, The origin of trehalose and its significance during the formation of 
encysted dormant embryos of artemia salina. Comp Biochem Physiol 14 (1965) 
135-143. 
[215] J.H. Crowe, K.A.C. Madin, Anhydrobiosis in nematodes: evaporative water loss 
and survival. J Exp Zool 193(3) (1975) 323-333. 
[216] J.H. Crowe, M.A. Whittam, D. Chapman, L.M. Crowe, Interactions of 
phospholipid monolayers with carbohydrates. Biochim Biophys Acta 769(1) 
(1984) 151-159. 
[217] L.M. Crowe, J.H. Crowe, A. Rudolph, C. Womersley, L. Appel, Preservation of 
freeze-dried liposomes by trehalose. Arch Biochem Biophys 242(1) (1985) 240-
247. 
163 
[218] J.H. Crowe, B.J. Spargo, L.M. Crowe, Preservation of dry liposomes does not 
require retention of residual water. Proc Natl Acad Sci USA 84(6) (1987) 1537-
1540. 
[219] C. Womersley, P.S. Uster, A.S. Rudolph, J.H. Crowe, Inhibition of dehydration-
induced fusion between liposomal membranes by carbohydrates as measured by 
fluorescence energy transfer. Cryobiology 23(3) (1986) 245-255. 
[220] G. Strauss, P. Schurtenberger, H. Hauser, The interaction of saccharides with lipid 
bilayer vesicles: stabilization during freeze-thawing and freeze-drying. Biochim 
Biophys Acta 858(1) (1986) 169-180. 
[221] H. Hauser, G. Strauss, Stabilization of small, unilamellar phospholipid vesicles by 
sucrose during freezing and dehydration. Adv Exp Med Biol 238 (1988) 71-80. 
[222] C.S. Pereira, P.H. Hunenberger, Interaction of the sugars trehalose, maltose and 
glucose with a phospholipid bilayer: a comparative molecular dynamics study. J 
Phys Chem B 110(31) (2006) 15572-15581. 
[223] C.S. Pereira, P.H. Hunenberger, Effect of trehalose on a phospholipid membrane 
under mechanical stress. Biophys J 95(8) (2008) 3525-3534. 
[224] A.V. Popova, D.K. Hincha, Effects of cholesterol on dry bilayers: interactions 
between phosphatidylcholine unsaturation and glycolipid or free sugar. Biophys J 
93(4) (2007) 1204-1214. 
[225] M. Doxastakis, A.K. Sum, J.J. de Pablo, Modulating membrane properties: the 
effect of trehalose and cholesterol on a phospholipid bilayer. J Phys Chem B 
109(50) (2005) 24173-24181. 
[226] J.H. Crowe, L.M. Crowe, Factors affecting the stability of dry liposomes. 
Biochim Biophys Acta 939(2) (1988) 327-334. 
[227] K.L. Koster, Y.P. Lei, M. Anderson, S. Martin, G. Bryant, Effects of vitrified and 
nonvitrified sugars on phosphatidylcholine fluid-to-gel phase transitions. Biophys 
J 78(4) (2000) 1932-1946. 
[228] E.C. van Winden, W. Zhang, D.J. Crommelin, Effect of freezing rate on the 
stability of liposomes during freeze-drying and rehydration. Pharm Res 14(9) 
(1997) 1151-1160. 
[229] E.C. van Winden, H. Talsma, D.J. Crommelin, Thermal analysis of freeze-dried 
liposome-carbohydrate mixtures with modulated temperature differential scanning 
calorimetry. J Pharm Sci 87(2) (1998) 231-237. 
[230] Y. Aso, S. Yoshioka, Effect of freezing rate on physical stability of lyophilized 
cationic liposomes. Chem Pharm Bull (Tokyo) 53(3) (2005) 301-304. 
[231] M. Friede, M.H. Van Regenmortel, F. Schuber, Lyophilized liposomes as shelf 
items for the preparation of immunogenic liposome-peptide conjugates. Anal 
Biochem 211(1) (1993) 117-122. 
[232] C. Chen, D. Han, Y. Zhang, Y. Yuan, X. Tang, The freeze-thawed and freeze-
dried stability of cytarabine-encapsulated multivesicular liposomes. Int J Pharm 
387(1-2) (2010) 147-153. 
[233] S.B. Barnett, G.R. ter Haar, M.C. Ziskin, W.L. Nyborg, K. Maeda, J. Bang, 
Current status of research on biophysical effects of ultrasound. Ultrasound Med 
Biol 20(3) (1994) 205-218. 
 
164 
[234] S.L. Huang, A.J. Hamilton, A. Nagaraj, S.D. Tiukinhoy, M.E. Klegerman, D.D. 
McPherson, R.C. Macdonald, Improving ultrasound reflectivity and stability of 
echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J 
Pharm Sci 90(12) (2001) 1917-1926. 
[235] K. Temming, R.M. Schiffelers, G. Molema, R.J. Kok, RGD-based strategies for 
selective delivery of therapeutics and imaging agents to the tumour vasculature. 
Drug Resist Updat 8(6) (2005) 381-402. 
[236] H.R. Desu, Targeted delivery of surface modified nanoparticles: modulation of 
inflammation for acute lung injury. [Dissertation], [Memphis], The University of 
Tennessee Health Science Center, (2009), 153 p. 
[237] N.A. Williams, T. Dean, Vial breakage by frozen mannitol solutions: correlation 
with thermal characteristics and effect of stereoisomerism, additives, and vial 
configuration. J Parenter Sci Technol 45(2) (1991) 94-100. 
[238] A.I. Kim, M.J. Akers, S.L. Nail, The physical state of mannitol after freeze-
drying: effects of mannitol concentration, freezing rate, and a noncrystallizing 
cosolute. J Pharm Sci 87(8) (1998) 931-935. 
[239] A. Pyne, R. Surana, R. Suryanarayanan, Crystallization of mannitol below Tg' 
during freeze-drying in binary and ternary aqueous systems. Pharm Res 19(6) 
(2002) 901-908. 
[240] C. Telang, L. Yu, R. Suryanarayanan, Effective inhibition of mannitol 
crystallization in frozen solutions by sodium chloride. Pharm Res 20(4) (2003) 
660-667. 
[241] R.K. Cavatur, N.M. Vemuri, A. Pyne, Z. Chrzan, D. Toledo-Velasquez, R. 
Suryanarayanan, Crystallization behavior of mannitol in frozen aqueous solutions. 
Pharm Res 19(6) (2002) 894-900. 
[242] F.J. Martin, D. Papahadjopoulos, Irreversible coupling of immunoglobulin 
fragments to preformed vesicles. An improved method for liposome targeting. J 
Biol Chem 257(1) (1982) 286-288. 
[243] C.B. Hansen, G.Y. Kao, E.H. Moase, S. Zalipsky, T.M. Allen, Attachment of 
antibodies to sterically stabilized liposomes: evaluation, comparison and 
optimization of coupling procedures. Biochim Biophys Acta 1239(2) (1995) 133-
144. 
[244] R. Nallamothu, G.C. Wood, C.B. Pattillo, R.C. Scott, M.F. Kiani, B.M. Moore, 
L.A. Thoma, A tumor vasculature targeted liposome delivery system for 
combretastatin A4: design, characterization, and in vitro evaluation. AAPS 
PharmSciTech 7(2) (2006) E32. 
[245] T. Kodama, N. Tomita, S. Horie, N. Sax, H. Iwasaki, R. Suzuki, K. Maruyama, S. 
Mori, F. Manabu, Morphological study of acoustic liposomes using transmission 
electron microscopy. J Electron Microsc (Tokyo) (2009). 
[246] K.E. Hitchcock, D.N. Caudell, J.T. Sutton, M.E. Klegerman, D. Vela, G.J. Pyne-
Geithman, T. Abruzzo, P.E. Cyr, Y.J. Geng, D.D. McPherson, C.K. Holland, 
Ultrasound-enhanced delivery of targeted echogenic liposomes in a novel ex vivo 
mouse aorta model. J Control Release 144(3) (2010) 288-295. 
[247] D.H. Kim, M.J. Costello, P.B. Duncan, D. Needham, Mechanical properties and 
microstructure of polycrystalline phospholipid monolayer shells: novel solid 
microparticles. Langmuir 19(20) (2003) 8455-8466. 
165 
[248] G. Pu, M.L. Longo, M.A. Borden, Effect of microstructure on molecular oxygen 
permeation through condensed phospholipid monolayers. J Am Chem Soc 
127(18) (2005) 6524-6525. 
[249] J.A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, I. Ahmad, 
Development and characterization of a novel Cremophor EL free liposome-based 
paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59(1) (2005) 177-187. 
[250] R. Langer, Drug delivery and targeting. Nature 392(6679 Suppl) (1998) 5-10. 
[251] R.M. Straubinger, A. Sharma, M. Murray, E. Mayhew, Novel Taxol formulations: 
Taxol-containing liposomes. J Natl Cancer Inst Monogr(15) (1993) 69-78. 
[252] A. Sharma, R.M. Straubinger, Novel Taxol formulations: preparation and 
characterization of Taxol-containing liposomes. Pharm Res 11(6) (1994) 889-896. 
[253] A. Sharma, E. Mayhew, R.M. Straubinger, Antitumor effect of Taxol-containing 
liposomes in a Taxol-resistant murine tumor model. Cancer Res 53(24) (1993) 
5877-5881. 
[254] S.V. Balasubramanian, R.M. Straubinger, Taxol-lipid interactions: Taxol-
dependent effects on the physical properties of model membranes. Biochemistry 
33(30) (1994) 8941-8947. 
[255] C. Bernsdorff, R. Reszka, R. Winter, Interaction of the anticancer agent Taxol 
(paclitaxel) with phospholipid bilayers. J Biomed Mater Res 46(2) (1999) 141-
149. 
[256] L.P. Cavalcanti, O. Konovalov, H. Haas, X-ray diffraction from paclitaxel-loaded 
zwitterionic and cationic model membranes. Chem Phys Lipids 150(1) (2007) 58-
65. 
[257] R.M. Straubinger, S.V. Balasubramanian, Preparation and characterization of 
taxane-containing liposomes. Methods Enzymol 391 (2005) 97-117. 
[258] P. Crosasso, M. Ceruti, P. Brusa, S. Arpicco, F. Dosio, L. Cattel, Preparation, 
characterization and properties of sterically stabilized paclitaxel-containing 
liposomes. J Control Release 63(1-2) (2000) 19-30. 
[259] J. Wu, Q. Liu, R.J. Lee, A folate receptor-targeted liposomal formulation for 
paclitaxel. Int J Pharm 316(1-2) (2006) 148-153. 
[260] T. Yang, F.D. Cui, M.K. Choi, J.W. Cho, S.J. Chung, C.K. Shim, D.D. Kim, 
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and 
in vivo evaluation. Int J Pharm 338(1-2) (2007) 317-326. 
[261] T. Yang, M.K. Choi, F.D. Cui, J.S. Kim, S.J. Chung, C.K. Shim, D.D. Kim, 
Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J 
Control Release 120(3) (2007) 169-177. 
[262] D.B. Khismatullin, Resonance frequency of microbubbles: effect of viscosity. J 
Acoust Soc Am 116(3) (2004) 1463-1473. 
[263] H. Zheng, O. Mukdadi, R. Shandas, Theoretical predictions of harmonic 
generation from submicron ultrasound contrast agents for nonlinear biomedical 
ultrasound imaging. Phys Med Biol 51(3) (2006) 557-573. 
[264] K.W. Ferrara, Driving delivery vehicles with ultrasound. Adv Drug Deliv Rev 
60(10) (2008) 1097-1102. 
 
 
166 
[265] P.A. Dayton, S. Zhao, S.H. Bloch, P. Schumann, K. Penrose, T.O. Matsunaga, R. 
Zutshi, A. Doinikov, K.W. Ferrara, Application of ultrasound to selectively 
localize nanodroplets for targeted imaging and therapy. Mol Imaging 5(3) (2006) 
160-174. 
[266] K.C. Crowder, M.S. Hughes, J.N. Marsh, A.M. Barbieri, R.W. Fuhrhop, G.M. 
Lanza, S.A. Wickline, Sonic activation of molecularly-targeted nanoparticles 
accelerates transmembrane lipid delivery to cancer cells through contact-mediated 
mechanisms: implications for enhanced local drug delivery. Ultrasound Med Biol 
31(12) (2005) 1693-1700. 
[267] K. Park, J.H. Kim, Y.S. Nam, S. Lee, H.Y. Nam, K. Kim, J.H. Park, I.S. Kim, K. 
Choi, S.Y. Kim, I.C. Kwon, Effect of polymer molecular weight on the tumor 
targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control 
Release 122(3) (2007) 305-314. 
[268] H.Y. Hwang, I.S. Kim, I.C. Kwon, Y.H. Kim, Tumor targetability and antitumor 
effect of docetaxel-loaded hydrophobically modified glycol chitosan 
nanoparticles. J Control Release 128(1) (2008) 23-31. 
[269] J. Klohs, A. Wunder, K. Licha, Near-infrared fluorescent probes for imaging 
vascular pathophysiology. Basic Res Cardiol 103(2) (2008) 144-151. 
[270] J.V. Frangioni, In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 
7(5) (2003) 626-634. 
[271] G.L. Amidon, H. Lennernas, V.P. Shah, J.R. Crison, A theoretical basis for a 
biopharmaceutic drug classification: the correlation of in vitro drug product 
dissolution and in vivo bioavailability. Pharm Res 12(3) (1995) 413-420. 
[272] M.V. Varma, R. Panchagnula, Enhanced oral paclitaxel absorption with vitamin 
E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J 
Pharm Sci 25(4-5) (2005) 445-453. 
[273] S. Koudelka, P. Turanek-Knotigova, J. Masek, Z. Korvasova, M. Skrabalova, J. 
Plockova, E. Bartheldyova, J. Turanek, Liposomes with high encapsulation 
capacity for paclitaxel: preparation, characterization and in vivo anticancer effect. 
J Pharm Sci 99(5) (2010) 2309-2319. 
[274] J.H. Crowe, L.M. Crowe, A.E. Oliver, N. Tsvetkova, W. Wolkers, F. Tablin, The 
trehalose myth revisited: introduction to a symposium on stabilization of cells in 
the dry state. Cryobiology 43(2) (2001) 89-105. 
[275] P. Sundaramurthi, R. Suryanarayanan, Trehalose crystallization during freeze-
drying: implications on lyoprotection. J Phys Chem Lett 1 (2010) 510-514. 
 
 
 
 
 
 
 
 
 
 
 
167 
VITA 
 
 
Vinayagam Kannan was born in Vellore, Tamil Nadu, India in 1972. He received his 
Bachelor of Pharmacy degree from the Tamil Nadu Dr. MGR Medical University, 
Chennai, Tamil Nadu, India and his Master of Science degree in Pharmaceutics from 
National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, 
Punjab, India. He worked as a Research Associate in New Drug Discovery Research 
(NDDR) division of Ranbaxy Research Laboratories, Gurgaon, Haryana, India for about 
two years. He enrolled for the Ph.D. program in Pharmaceutical Sciences at The 
University of Tennessee Health Science Center (UTHSC), Memphis in the year 2005 and 
joined the Parenteral Medications Laboratories (PML) with Dr. George C. Wood as 
major advisor. 
 
He is the member of American Association of Pharmaceutical Scientists (AAPS) and 
Parenteral Drug Association (PDA). He was inducted into The Rho Chi Society in the 
year 2009 for his academic accomplishments. He also received Best Graduate Teaching 
Assistant Award in Pharmaceutics for the academic year 2007-2008. He has presented 
the research work in various international meetings. He was the recipient of PDA’s 
graduate research symposium and pre-doctoral fellowship in the year 2008. After 
graduation, he plans to pursue his career in formulation research and development. 
